id,title,grade,gradeVer,gender,ageRange/0,ageRange/1,text,servFreq,riskName,general,tool/0,tool/1,tool/2,riskText,rationale,tool/3,tool/4
162,Asymptomatic Bacteriuria: Screening -- Pregnant Women,A,1,female,11,49,"The USPSTF recommends screening for asymptomatic bacteriuria with urine culture for pregnant women at 12 to 16 weeks' gestation or at the first prenatal visit, if later.","All pregnant women should provide a clean-catch urine specimen for a screening culture at 12 to 16 weeks' gestation or at the first prenatal visit, if later. The optimal frequency of subsequent urine testing during pregnancy is uncertain.

",Pregnant,90,105,None,0,None,None,None,None
207,Cervical Cancer: Screening -- Women 21 to 65 (Pap Smear) or 30-65 (in combo with HPV testing),A,1,female,21,65,"This recommendation statement applies to women who have a cervix, regardless of sexual history. This recommendation statement does not apply to women who have received a diagnosis of a high-grade precancerous cervical lesion or cervical cancer, women with in utero exposure to diethylstilbestrol, or women who are immunocompromised (such as those who are HIV positive).The USPSTF recommends screening for cervical cancer in women age 21 to 65 years with cytology (Pap smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years.","Screening women age 21 to 65 years every 3 years with cytology provides a reasonable balance between benefits and harms. Among women age 30 to 65 years, HPV testing combined with cytology (co-testing) every 5 years offers a comparable balance of benefits and harms and is therefore a reasonable alternative for women in this age group who would prefer to extend the screening interval.Screening with cytology more often than every 3 years confers little additional benefit, with large increases in harms, including additional procedures and assessment and treatment of transient lesions.",Age,113,51,153,150,None,None,None,None
309,Colorectal Cancer: Screening --Adults aged 50 to 75 years,A,1,men and women,50,75,The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years.The risks and benefits of different screening methods vary. See the&nbsp,Clinical Considerations section&nbsp,Age,166,309,None,0,"For the vast majority of adults, the most important risk factor for colorectal cancer is older age. Most cases of colorectal cancer occur among adults older than 50 years; the median age at diagnosis is 68 years.3A positive family history (excluding known inherited familial syndromes) is thought to be linked to about 20% of cases of colorectal cancer.1&nbsp;About 3% to 10% of the population has a first-degree relative with colorectal cancer.7&nbsp;The USPSTF did not specifically review the evidence on screening in populations at increased risk; however, other professional organizations recommend that patients with a family history of colorectal cancer (a first-degree relative with early-onset colorectal cancer or multiple first-degree relatives with the disease) be screened more frequently starting at a younger age, and with colonoscopy.8Male sex and black race are also associated with higher colorectal cancer incidence and mortality. Black adults have the highest incidence and mortality rates compared with other racial/ethnic subgroups.3&nbsp;The reasons for these disparities are not entirely clear. Studies have documented inequalities in screening, diagnostic follow-up, and treatment; they also suggest that equal treatment generally seems to produce equal outcomes.9-11&nbsp;Accordingly, this recommendation applies to all racial/ethnic groups, with the clear acknowledgement that efforts are needed to ensure that at-risk populations receive recommended screening, follow-up, and treatment.",,,
323,Folic Acid for the Prevention of Neural Tube Defects: Preventive Medication --Women who are planning or capable of pregnancy,A,1,female,11,49,The USPSTF recommends that all women who are planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 &micro,g) of folic acid.,Other,176,287,None,0,"Women who have a personal or family history of a pregnancy affected by a neural tube defect are at increased risk of having an affected pregnancy. However, most cases occur in the absence of any personal or family history",None,None,None
234,HIV: Screening - Adolescents and Adults,A,1,men and women,15,65,The USPSTF recommends that clinicians screen for HIV infection in adolescents and adults aged 15 to 65 years. Younger adolescents and older adults who are at increased risk should also be screened.,"The evidence is insufficient to determine optimum time intervals for HIV screening. One reasonable approach would be one-time screening of adolescent and adult patients to identify persons who are already HIV-positive, with repeated screening of those who are known to be at risk for HIV infection, those who are actively engaged in risky behaviors, and those who live or receive medical care in a high-prevalence setting. According to the CDC, a high-prevalence setting is a geographic location or community with an HIV seroprevalence of at least 1%. These settings include sexually transmitted disease (STD) clinics, correctional facilities, homeless shelters, tuberculosis clinics, clinics serving men who have sex with men, and adolescent health clinics with a high prevalence of STDs. Patient populations that would more likely benefit from more frequent testing include those who are known to be at higher risk for HIV infection, those who are actively engaged in risky behaviors, and those who live in a high-prevalence setting. Given the paucity of available evidence for specific screening intervals, a reasonable approach may be to rescreen groups at very high risk (see Assessment of Risk) for new HIV infection at least annually and individuals at increased risk at somewhat longer intervals (for example, 3 to 5 years). Routine rescreening may not be necessary for individuals who have not been at increased risk since they were found to be HIV-negative. Women screened during a previous pregnancy should be rescreened in subsequent pregnancies.",None,126,185,184,0,None,"Importance
An estimated 1.2 million persons in the United States are currently living with HIV infection, and the annual incidence of the disease is approximately 50,000 cases. Since the first cases of AIDS were reported in 1981, more than 1.1 million persons have been diagnosed and nearly 595,000 have died from the condition. Approximately 20% to 25% of individuals living with HIV infection are unaware of their positive status.
Detection
The USPSTF found convincing evidence that conventional and rapid HIV antibody tests are highly accurate in diagnosing HIV infection.
Benefits of Detection and Early Intervention
The USPSTF found convincing evidence that identification and treatment of HIV infection is associated with a markedly reduced risk for progression to AIDS, AIDS-related events, and death in individuals with immunologically advanced disease (defined as a CD4 count &lt;0.200 &times; 109 cells/L). Adequate evidence shows that initiating combined antiretroviral therapy (ART) earlier (that is, at CD4 counts between 0.200 and 0.500 &times; 109cells/L)&mdash;when individuals are more likely to be asymptomatic and detected by screening rather than clinical presentation&mdash;is also associated with reduced risk for AIDS-related events or death. The USPSTF found convincing evidence that the use of ART is associated with a substantially decreased risk for transmission from HIV-positive persons to uninfected heterosexual partners. Convincing evidence also shows that identification and treatment of HIV-positive pregnant women dramatically reduces rates of mother-to-child transmission. The overall benefits of screening for HIV infection in adolescents, adults, and pregnant women are substantial.
Harms of Detection and Early Intervention
The USPSTF found convincing evidence that individual antiretroviral drugs, drug classes, and combinations are all associated with short-term adverse events; however, many of these events are transient or self-limited, and effective alternatives can often be found. Although the long-term use of certain antiretroviral drugs may be associated with increased risk for cardiovascular and other adverse events, the magnitude of risk seems to be small. The overall harms of screening for and treatment of HIV infection in adolescents, adults, and pregnant women are small.
USPSTF Assessment
The USPSTF concludes with high certainty that the net benefit of screening for HIV infection in adolescents, adults, and pregnant women is substantial.",None,None
235,HIV: Screening - Pregnant Women,A,1,female,11,64,"The USPSTF recommends that clinicians screen all pregnant women for HIV, including those who present in labor who are untested and whose HIV status is unknown.","The evidence is insufficient to determine optimum time intervals for HIV screening. One reasonable approach would be one-time screening of adolescent and adult patients to identify persons who are already HIV-positive, with repeated screening of those who are known to be at risk for HIV infection, those who are actively engaged in risky behaviors, and those who live or receive medical care in a high-prevalence setting. According to the CDC, a high-prevalence setting is a geographic location or community with an HIV seroprevalence of at least 1%. These settings include sexually transmitted disease (STD) clinics, correctional facilities, homeless shelters, tuberculosis clinics, clinics serving men who have sex with men, and adolescent health clinics with a high prevalence of STDs. Patient populations that would more likely benefit from more frequent testing include those who are known to be at higher risk for HIV infection, those who are actively engaged in risky behaviors, and those who live in a high-prevalence setting. Given the paucity of available evidence for specific screening intervals, a reasonable approach may be to rescreen groups at very high risk (see Assessment of Risk) for new HIV infection at least annually and individuals at increased risk at somewhat longer intervals (for example, 3 to 5 years). Routine rescreening may not be necessary for individuals who have not been at increased risk since they were found to be HIV-negative. Women screened during a previous pregnancy should be rescreened in subsequent pregnancies.",Pregnant,126,185,184,0,None,"Importance
An estimated 1.2 million persons in the United States are currently living with HIV infection, and the annual incidence of the disease is approximately 50,000 cases. Since the first cases of AIDS were reported in 1981, more than 1.1 million persons have been diagnosed and nearly 595,000 have died from the condition. Approximately 20% to 25% of individuals living with HIV infection are unaware of their positive status.
Detection
The USPSTF found convincing evidence that conventional and rapid HIV antibody tests are highly accurate in diagnosing HIV infection.
Benefits of Detection and Early Intervention
The USPSTF found convincing evidence that identification and treatment of HIV infection is associated with a markedly reduced risk for progression to AIDS, AIDS-related events, and death in individuals with immunologically advanced disease (defined as a CD4 count &lt;0.200 &times; 109 cells/L). Adequate evidence shows that initiating combined antiretroviral therapy (ART) earlier (that is, at CD4 counts between 0.200 and 0.500 &times; 109cells/L)&mdash;when individuals are more likely to be asymptomatic and detected by screening rather than clinical presentation&mdash;is also associated with reduced risk for AIDS-related events or death. The USPSTF found convincing evidence that the use of ART is associated with a substantially decreased risk for transmission from HIV-positive persons to uninfected heterosexual partners. Convincing evidence also shows that identification and treatment of HIV-positive pregnant women dramatically reduces rates of mother-to-child transmission. The overall benefits of screening for HIV infection in adolescents, adults, and pregnant women are substantial.
Harms of Detection and Early Intervention
The USPSTF found convincing evidence that individual antiretroviral drugs, drug classes, and combinations are all associated with short-term adverse events; however, many of these events are transient or self-limited, and effective alternatives can often be found. Although the long-term use of certain antiretroviral drugs may be associated with increased risk for cardiovascular and other adverse events, the magnitude of risk seems to be small. The overall harms of screening for and treatment of HIV infection in adolescents, adults, and pregnant women are small.
USPSTF Assessment
The USPSTF concludes with high certainty that the net benefit of screening for HIV infection in adolescents, adults, and pregnant women is substantial.",None,None
187,Hepatitis B Virus: Screening -- Pregnant Women,A,1,female,11,49,"The USPSTF recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit
",Screen pregnant women at thier first prenatal visit. ,Pregnant,103,121,None,0,None,None,None,None
281,High Blood Pressure: Screening and Home Monitoring -- Adults,A,1,men and women,18,100,The USPSTF recommends screening for high blood pressure in adults aged 18 years or older. The USPSTF recommends obtaining measurements outside of the clinical setting for diagnostic confirmation before starting treatment.,The USPSTF recommends annual screening for adults aged 40 years or older and for those who are at increased risk for high blood pressure.,Age,152,245,None,0,"The USPSTF recommends annual screening for adults aged 40 years or older and for those who are at increased risk for high blood pressure. Persons at increased risk include those who have high-normal blood pressure (130 to 139/85 to 89 mm Hg), those who are overweight or obese, and African Americans. Adults aged 18 to 39 years with normal blood pressure (&lt;130/85 mm Hg) who do not have other risk factors should be rescreened every 3 to 5 years.&nbsp;The USPSTF recommends rescreening with properly measured office blood pressure and, if blood pressure is elevated, confirming the diagnosis of hypertension with ABPM.",None,None,None
205,Ocular Prophylaxis for Gonococcal Ophthalmia Neonatorum: Preventive Medication for All Newborns,A,1,men and women,0,1,"The USPSTF recommends prophylactic ocular topical medication for all newborns for the prevention of gonococcal ophthalmia neonatorum. 
&nbsp;",Prophylaxis should be provided within 24 hours after birth.,Age,111,149,100,0,None,None,None,None
79,"Rh(D) Blood Typing: Screening -- Pregnant Women, First Pregnancy Related Visit",A,0,female,11,49,The USPSTF strongly recommends Rh (D) blood typing and antibody testing for all pregnant women during their first visit for pregnancy-related care. ,First prenatal visit.,Pregnant,38,None,None,0,None,"The USPSTF found good evidence that Rh (D) blood typing, anti-Rh (D) antibody testing, and intervention with Rh (D) immunoglobulin, as appropriate, prevents maternal sensitization and improves outcomes for newborns. The benefits substantially outweigh any potential harms.
",None,None
185,Syphilis: Screening - Pregnant Women ,A,1,female,11,49,"The USPSTF recommends that clinicians screen all pregnant women for syphilis infection. 
","All pregnant women should be tested at their first prenatal visit. For women in high-risk groups, many organizations recommend repeat serologic testing in the third trimester and at delivery. Most states mandate that all pregnant women be screened at some point during pregnancy, and many mandate screening at the time of delivery.",Pregnant,101,131,None,0,None,None,None,None
311,"Syphilis: Screening --Asymptomatic, nonpregnant adults and adolescents who are at increased risk for syphilis infection",A,1,men and women,11,100,The USPSTF recommends screening for syphilis infection in persons who are at increased risk for infection.,The optimal screening frequency for persons who are at increased risk for syphilis infection is not well established. Men who have sex with men or persons living with HIV may benefit from more frequent screening. Initial studies suggest that detection of syphilis infection in MSM or persons living with HIV improves when screening is performed every 3 months compared with annually.7,Sexually Active,169,281,280,0,"Based on 2014 surveillance data,1&nbsp;men who have sex with men (MSM) and men and women living with HIV have the highest risk for syphilis infection. &nbsp;When deciding which other persons to screen for syphilis, clinicians should be aware of the prevalence of infection in the communities they serve, as well as other sociodemographic factors that may be associated with increased risk of syphilis infection. Factors associated with increased prevalence that clinicians should consider include history of incarceration, history of commercial sex work, certain racial/ethnic groups, and being a male younger than 29 years, as well as regional variations that are well described. Refer to clinical considerations of the recommendation statement.",None,None,None
283,Tobacco Smoking Cessation: Behavioral and Pharmacotherapy Interventions -- Adults who are not pregnant,A,1,men and women,18,100,"The USPSTF recommends that clinicians ask all adults about tobacco use, advise them to stop using tobacco, and provide behavioral interventions and U.S. Food and Drug Administration (FDA)&ndash;approved pharmacotherapy for cessation to adults who use tobacco.",See Clinical Considerations.,Tobacco user,153,248,247,0,"According to the 2012&ndash;2013 National Adult Tobacco Survey, smoking prevalence is higher in the following groups: men; adults aged 25 to 44 years; persons with a race or ethnicity category of &ldquo;other, non-Hispanic&rdquo;; persons with a GED (vs. graduate-level education); persons with an annual household income of less than $20,000; and persons who are lesbian, gay, bisexual, or transgender.&nbsp;Higher rates of smoking have been found in persons with mental health conditions.",None,249,None
284,Tobacco Smoking Cessation:Behavioral Interventions -- Pregnant Women,A,1,female,11,64,"The USPSTF recommends that clinicians ask all pregnant women about tobacco use, advise them to stop using tobacco, and provide behavioral interventions for cessation to pregnant women who use tobacco.",See Clinical Considerations.,Tobacco user,153,248,247,246,"According to the 2012&ndash;2013 National Adult Tobacco Survey, smoking prevalence is higher in the following groups: men; adults aged 25 to 44 years; persons with a race or ethnicity category of &ldquo;other, non-Hispanic&rdquo;; persons with a GED (vs. graduate-level education); persons with an annual household income of less than $20,000; and persons who are lesbian, gay, bisexual, or transgender.&nbsp;Higher rates of smoking have been found in persons with mental health conditions.",None,249,None
269,Abdominal Aortic Aneurysm: Screening -- Men Ages 65 to 75 Years Who Have Ever Smoked.,B,1,male,65,75,The U.S. Preventive Services Task Force (USPSTF) recommends one-time screening for abdominal aortic aneurysm (AAA) with ultrasonography in men ages 65 to 75 years who have ever smoked.,"Evidence is adequate to support one-time screening in men who have ever smoked. All of the population-based RCTs of AAA screening used a one-time screening approach, and several fair- to good-quality prospective cohort studies show that AAA-associated mortality over 5 to 12 years is low (0.0% to 2.4%) in men with initially normal results on ultrasonography.",Tobacco user,145,231,232,0,"Consuming 100 or more cigarettes is commonly used in epidemiologic literature to define an &ldquo;ever-smoker.&rdquo; However, the randomized trials of screening for AAA did not gather specific data about participants' smoking histories. Occasional tobacco use for a short time in the past (for example, occasional &ldquo;social&rdquo; smoking as an adolescent or young adult) is unlikely to have a pronounced biological effect, and the odds ratio (OR) of developing a large (&ge;5.0 cm) AAA is actually less than 1.0 for prior smokers who have quit for at least 10 years. However, observational studies have found that even a relatively modest smoking history (for example, smoking a half-pack or less per day for fewer than 10 years) does increase the likelihood of developing a large AAA.","Importance
Abdominal aortic aneurysms are typically defined by an aortic diameter of 3.0 cm or larger. Population-based studies in adults older than 50 years have found that the prevalence of AAA is 3.9% to 7.2% in men and 1.0% to 1.3% in women. It is important to consider potential screening strategies for AAA because most AAAs are asymptomatic until they rupture. Although the risk for rupture varies greatly by aneurysm size, the associated risk for death is as high as 75% to 90%.
Detection
Evidence is adequate that ultrasonography is a safe and accurate screening test for AAA.
Benefits of Detection and Early Treatment
Men Ages 65 to 75 Years Who Have Ever Smoked
Four large, population-based, randomized, controlled trials (RCTs) show that invitation to one-time screening for AAA is associated with reduced AAA-specific mortality in men. This benefit begins 3 years after testing and persists up to 15 years. In addition, risk reduction for AAA rupture and emergency surgery persists up to 10 to 13 years. In the two highest-quality trials, the relative reduction in AAA-specific mortality after 13 years was 42% to 66%. In the largest trial, where prevalence of AAA was approximately 5% in the screened group, screening was associated with an absolute risk reduction in AAA death of 1.4 per 1,000 men.&nbsp; Abdominal aortic aneurysms are most prevalent in men who have ever smoked, occurring in approximately 6% to 7% of this population. This prevalence increases the importance of screening in these men because it maximizes the absolute benefit that could be achieved (that is, it improves the likelihood that men in this group will benefit from screening). Convincing evidence shows that one-time screening for AAA with ultrasonography results in a moderate benefit in men ages 65 to 75 years who have ever smoked.
Men Ages 65 to 75 Years Who Have Never Smoked
Screening men overall reduces AAA-specific death, rupture, and emergency surgery. However, the lower prevalence of AAA in men who have never smoked (approximately 2%) substantially reduces the absolute benefit (that is, it greatly lowers the probability that men in this group will benefit from screening). Adequate evidence shows that one-time screening for AAA with ultrasonography results in a small benefit in men ages 65 to 75 years who have never smoked.
Women Ages 65 to 75 Years Who Have Ever Smoked
Only one RCT on screening for AAA included women. It detected no difference in the rate of AAA rupture, AAA-specific mortality, or all-cause mortality between women invited for screening and the control group. However, the trial was ultimately underpowered to detect differences in health outcomes by sex; as such, the results do not rule out the possibility of a small benefit of screening in this population. Women age 70 years who have ever smoked have a relatively low prevalence of AAA (approximately 0.8% overall and about 2% for current smokers). Evidence is inadequate to conclude whether one-time screening for AAA with ultrasonography is beneficial in women ages 65 to 75 years who have ever smoked.
Women Who Have Never Smoked
The prevalence of AAA in women who have never smoked is low (0.03% to 0.60% in women ages 50 to 79 years). The evidence also shows no apparent benefit of screening for AAA in women. The USPSTF therefore concludes that adequate evidence shows that the absolute benefit of one-time screening for AAA with ultrasonography in women who have never smoked can effectively be bounded at none or almost none.
Harms of Detection and Early Treatment
In the available trials, groups invited to screening were approximately twice as likely as control groups to have any AAA surgery within 3 to 5 years, predominantly driven by an increase in elective surgeries. More than 90% of AAAs identified by screening were below the 5.5-cm threshold for immediate repair. Detecting smaller AAAs generally leads to long-term (potentially lifelong) surveillance. A person's risk for death related to elective surgery for AAA is lower than that for death related to emergency surgery for AAA rupture. However, the increase in the overall rates of detection and surgery in the screening groups still potentially represents a harm. A proportion of AAAs will never rupture because they do not advance to conditions for the rupture to appear or because a person dies of a competing cause. The exact extent of overdiagnosis and overtreatment is difficult to estimate. One study from Massachusetts General Hospital reviewed 24,000 consecutive autopsies between 1952 and 1975 and found that 75% of the 473 patients who died with an undetected or unoperated AAA had a cause of death not related to the AAA (41% of AAAs were &gt;5.1 cm in diameter). Given that even elective treatment of AAA is associated with some risk for perioperative mortality, overtreatment is an important issue to consider when deciding whether to screen for this condition. One study reported that women had a higher risk for death related to AAA surgery than men; death rates of women and men were approximately 7% versus 5% for open repair and 2% versus 1% for endovascular repair, respectively. Evidence is limited and conflicting about the effect of screening for AAA on quality of life or psychological status (for example, anxiety). Convincing evidence shows that the harms associated with one-time screening for AAA with ultrasonography are at least small in all populations and potentially higher in women because of their higher risk for operative mortality.
USPSTF Assessment
The USPSTF concludes with high certainty that screening for AAA with ultrasonography in men ages 65 to 75 years who have ever smoked has a moderate net benefit. The USPSTF concludes with moderate certainty that screening for AAA with ultrasonography in men ages 65 to 75 years who have never smoked has a small net benefit. The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of screening for AAA in women ages 65 to 75 years who have ever smoked. The USPSTF concludes with moderate certainty that the harms of screening for AAA outweigh any potential benefits in women who have never smoked.",None,None
236,Alcohol Misuse: Screening and Behavioral Counseling Interventions in Primary Care -- Adults,B,1,men and women,18,100,The USPSTF recommends that clinicians screen adults aged 18 years or older for alcohol misuse and provide persons engaged in risky or hazardous drinking with brief behavioral counseling interventions to reduce alcohol misuse.&nbsp,None,None,127,186,187,0,None,None,"Importance
The USPSTF uses the term &ldquo;alcohol misuse&rdquo; to define a spectrum of behaviors, including risky or hazardous alcohol use (for example, harmful alcohol use and alcohol abuse or dependence). Risky or hazardous alcohol use means drinking more than the recommended daily, weekly, or per-occasion amounts resulting in increased risk for health consequences. For example, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the U.S. Department of Agriculture define &ldquo;risky use&rdquo; as consuming more than 4 drinks on any day or 14 drinks per week for men, or more than 3 drinks on any day or 7 drinks per week for women (as well as any level of consumption under certain circumstances). &ldquo;Harmful alcohol use&rdquo; (defined by the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision) is a pattern of drinking that causes damage to physical or mental health. &ldquo;Alcohol abuse&rdquo; (defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) is drinking that leads an individual to recurrently fail in major home, work, or school responsibilities; use alcohol in physically hazardous situations (such as while operating heavy machinery); or have alcohol-related legal or social problems. &ldquo;Alcohol dependence&rdquo; (or alcoholism) (defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) includes physical cravings and withdrawal symptoms, frequent consumption of alcohol in larger amounts than intended over longer periods, and a need for markedly increased amounts of alcohol to achieve intoxication.An estimated 30% of the U.S. population is affected by alcohol misuse, and most of these persons engage in risky use. More than 85,000 deaths per year are attributable to alcohol misuse; it is the estimated third leading cause of preventable deaths in the United States.
Detection
The USPSTF found adequate evidence that numerous screening instruments can detect alcohol misuse in adults with acceptable sensitivity and specificity.
Benefits of Detection and Behavioral Counseling Interventions
The USPSTF found adequate evidence that brief behavioral counseling interventions are effective in reducing heavy drinking episodes in adults engaging in risky or hazardous drinking. These interventions also reduce weekly alcohol consumption rates and increase adherence to recommended drinking limits. Direct evidence about the effectiveness of brief behavioral counseling interventions in pregnant women engaging in alcohol use is more limited. However, studies in the general adult population show that such interventions reduce alcohol consumption and increase adherence to recommended drinking limits among women of childbearing age.The USPSTF found insufficient evidence on the effect of screening for alcohol misuse and brief behavioral counseling interventions on outcomes in adolescents.
Harms of Detection and Behavioral Counseling Interventions
There are minimal data to assess the magnitude of harms of screening for alcohol misuse or of consequent brief behavioral counseling interventions in any population. However, no studies have identified direct evidence of harms. Thus, given the noninvasive nature of the screening process and behavioral counseling interventions, the related harms are probably small to none.
USPSTF Assessment
The USPSTF concludes with moderate certainty that there is a moderate net benefit to screening for alcohol misuse and brief behavioral counseling interventions in the primary care setting for adults aged 18 years or older. The evidence on screening for alcohol misuse and brief behavioral counseling interventions in the primary care setting for adolescents is insufficient, and the balance of benefits and harms cannot be determined.",None
276,Aspirin Use for the Prevention of Morbidity and Mortality from Preeclampsia: Preventive Medication--Pregnant Women who are at High Risk for Preeclampsia,B,1,female,15,49,The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia.,Use of low-dose aspirin was initiated between 12 and 28 weeks of gestation. Evidence did not suggest additional benefit when use of aspirin was started earlier (12 to 16 weeks) rather than later (&ge,Pregnant,148,148,237,238,None,None,"Importance
Preeclampsia is one of the most serious health problems affecting pregnant women. It is a complication in 2% to 8% of pregnancies worldwide and contributes to both maternal and infant morbidity and mortality. Preeclampsia also accounts for 15% of preterm births in the United States. The disorder is defined by the onset of hypertension (blood pressure &ge;140/90 mm Hg) and proteinuria (&ge;0.3 g of protein in the urine within a 24-hour period) during the second half of pregnancy (&gt;20 weeks). In the absence of proteinuria, preeclampsia is classified as hypertension with any of the following: thrombocytopenia, impaired liver function, renal insufficiency, pulmonary edema, or cerebral or visual disturbances.
Recognition of Risk Status
Important risk factors for preeclampsia include history of preeclampsia (including early-onset preeclampsia), intrauterine growth restriction (IUGR), or preterm birth; placental abruption or fetal death; maternal comorbid conditions (including type 1 or 2 pregestational diabetes, chronic hypertension, renal disease, and autoimmune diseases); and multifetal gestation.Predictive models that combine risk factors to identify women at risk for preeclampsia, such as serum biomarkers, uterine artery Doppler ultrasonography, and clinical history and measures, are in development. None have yet shown sufficient accuracy for clinical use.
Benefits of Preventive Medication
The USPSTF found adequate evidence of a reduction in risk for preeclampsia, preterm birth, and IUGR in women at increased risk for preeclampsia who received low-dose aspirin, thus demonstrating substantial benefit. Low-dose aspirin (range, 60 to 150 mg/d) reduced the risk for preeclampsia by 24% in clinical trials and reduced the risk for preterm birth by 14% and IUGR by 20%.
Harms of Preventive Medication
The USPSTF found adequate evidence that low-dose aspirin as preventive medication does not increase the risk for placental abruption, postpartum hemorrhage, or fetal intracranial bleeding. In a meta-analysis of randomized, controlled trials (RCTs) and observational studies of women at low/average or increased risk for preeclampsia, there was no significantly increased risk for these adverse events. In addition, there was no difference in the risk for placental abruption by aspirin dosage.The USPSTF also found adequate evidence that low-dose aspirin as preventive medication in women at increased risk for preeclampsia does not increase the risk for perinatal mortality. Evidence on long-term outcomes in offspring exposed in utero to low-dose aspirin is limited, but no developmental harms were identified by 18 months of age in the one study reviewed.The USPSTF concludes that the harms of low-dose aspirin in pregnancy are no greater than small.
USPSTF Assessment
The USPSTF concludes with moderate certainty that there is a substantial net benefit of daily low-dose aspirin use to reduce the risk for preeclampsia, preterm birth, and IUGR in women at high risk for preeclampsia.",None
303,Aspirin Use to Prevent CVD and CRC: Preventive Medication Adults aged 50 to 59 years with a &ge,B,1,men and women,1,50,59,"The USPSTF recommends initiating low-dose aspirin use for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) in adults aged 50 to 59 years who have a 10% or greater 10-year CVD risk, are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years.",Other,163,163,274,275,None,"Risk assessment for CVD should include ascertainment of the following risk factors: age, sex, race/ethnicity, total cholesterol level, high-density lipoprotein cholesterol level, systolic blood pressure, hypertension treatment, diabetes, and smoking. An online version of the ACC/AHA risk calculator can be found at http://tools.acc.org/ASCVD-Risk-Estimator/.Risk factors for gastrointestinal (GI) bleeding with aspirin use include higher dose and longer duration of use, history of GI ulcers or upper GI pain, bleeding disorders, renal failure, severe liver disease, and thrombocytopenia. Other factors that increase risk for GI or intracranial bleeding with low-dose aspirin use include concurrent anticoagulation or nonsteroidal anti-inflammatory drug (NSAID) use, uncontrolled hypertension, male sex, and older age.4,&nbsp;5This recommendation applies to adults who are at increased CVD risk and at average risk for CRC. Persons who are at increased CVD risk and are known to be at increased risk for CRC (for example, persons with a family or personal history of CRC or familial adenomatous polyposis)6 should consult their health care provider.",None,None
252,"BRCA-Related Cancer: Risk Assessment, Genetic Counseling, &amp; Genetic Testing -- Women at Increased Risk",B,1,female,18,100,"The USPSTF recommends that primary care providers screen women who have family members with breast, ovarian, tubal, or peritoneal cancer with 1 of several screening tools designed to identify a family history that may be associated with an increased risk for potentially harmful mutations in breast cancer susceptibility genes (BRCA1 or BRCA2). Women with positive screening results should receive genetic counseling and, if indicated after counseling, BRCA testing.","Consideration of screening for potentially harmful BRCA mutations should begin once women have reached the age of consent (18 years). Primary care providers should periodically assess all patients for changes in family history (for example, comprehensive review at least every 5 to 10 years).",None,134,202,203,0,"Mutations in the BRCA genes cluster in families, exhibiting an autosomal dominant pattern of transmission in maternal or paternal lineage. During standard elicitation of family history information from patients, primary care providers should ask about specific types of cancer, primary cancer sites, which family members were affected, relatives with multiple types of primary cancer, and the age at diagnosis and sex of affected family members.For women who have at least 1 family member with breast, ovarian, or other types of BRCA-related cancer, primary care providers may use 1 of several brief familial risk stratification tools to determine the need for in-depth genetic counseling. Although several risk tools are available, the tools evaluated by the USPSTF include the Ontario Family History Assessment Tool (Table 1), Manchester Scoring System (Table 2), Referral Screening Tool (Table 3), Pedigree Assessment Tool (Table 4), and FHS-7 (Table 5). The Referral Screening Tool (available at www.breastcancergenescreen.org) and FHS-7 are the simplest and quickest to administer. All of these tools seem to be clinically useful predictors of which women should be referred for genetic counseling due to increased risk for potentially harmful BRCA mutations (most sensitivity estimates were &gt;85%), although some models have been evaluated in only 1 study. To determine which patients would benefit from BRCA risk assessment, primary care providers should not use general breast cancer risk assessment models (for example, the National Cancer Institute Breast Cancer Risk Assessment Tool, which is based on the Gail model) because they are not designed to determine which women should receive genetic counseling or BRCA testing. In general, these tools elicit information about factors that are associated with increased likelihood of BRCA mutations. Family history factors associated with increased likelihood of potentially harmful BRCA mutations include breast cancer diagnosis before age 50 years, bilateral breast cancer, presence of breast and ovarian cancer, presence of breast cancer in 1 or more male family members, multiple cases of breast cancer in the family, 1 or more family members with 2 primary types of BRCA-related cancer, and Ashkenazi Jewish ethnicity. The USPSTF recognizes that each risk assessment tool has limitations and found insufficient comparative evidence to recommend one tool over another. The USPSTF also found insufficient evidence to support a specific risk threshold for referral for testing.","Importance
The cancer types related to potentially harmful mutations of the BRCA genes are predominantly breast, ovarian, and fallopian tube cancer, although other types are also associated. In the general population, 12.3% of women will develop breast cancer during their lifetime and 2.74% will die of the disease, whereas 1.4% of women will develop ovarian cancer and 1.0% will die of the disease. A woman's risk for breast cancer increases to 45% to 65% by age 70 years if there are clinically significant mutations in either BRCA gene. Mutations in the BRCA1 gene increase ovarian cancer risk to 39% by age 70 years, and BRCA2 mutations increase ovarian cancer risk to 10% to 17% by age 70 years. In the general population, these mutations occur in an estimated 1 in 300 to 500 women (0.2% to 0.3%). In a meta-analysis conducted for the USPSTF, the combined prevalence of BRCA1 and BRCA2mutations was 2.1% in a general population of Ashkenazi Jewish women.
Detection of Potentially Harmful BRCA Mutations
Genetic risk assessment and BRCA mutation testing is generally a multistep process involving identification of individuals who may be at increased risk for potentially harmful mutations, followed by genetic counseling from suitably trained health care providers and genetic testing of selected high-risk individuals when indicated. Several familial risk stratification tools are clinically useful for selecting patients who should be offered genetic counseling to further determine their candidacy for possible BRCA mutation testing.
Benefits of Testing for Potentially Harmful Mutations
For women whose family history is associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2 genes, adequate evidence suggests that the benefits of testing for potentially harmful BRCA mutations are moderate. For women whose family history is not associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2genes, there is adequate evidence that the benefits of testing for potentially harmful BRCA mutations are few to none.
Harms of Detection of Potentially Harmful BRCA Mutations and Early Intervention and Treatment
Adequate evidence suggests that the overall harms of detection of and early intervention for potentially harmful BRCA mutations are small to moderate.
USPSTF Assessment
For women whose family history is associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2 genes, there is moderate certainty that the net benefit of testing for potentially harmful BRCA mutations and early intervention is moderate. For women whose family history is not associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2 genes, there is moderate certainty that the net benefit of testing for potentially harmful BRCA mutations and early intervention ranges from minimal to potentially harmful.",None,None
250,Breast Cancer: Preventive Medications -- Women At Increased Risk,B,1,female,35,100,"The USPSTF recommends that clinicians engage in shared, informed decision making with women who are at increased risk for breast cancer about medications to reduce their risk. For women who are at increased risk for breast cancer and at low risk for adverse medication effects, clinicians should offer to prescribe risk-reducing medications, such as tamoxifen or raloxifene.",None,Other,133,200,201,0,"Assessment of Breast Cancer Risk
If a family history of breast cancer or a personal history of breast biopsy is found during the usual patient assessment, clinicians may consider further evaluation using a breast cancer risk assessment tool. Risk assessment tools specifically for family history of breast cancer are available elsewhere (www.uspreventiveservicestaskforce.org). The National Cancer Institute has developed a Breast Cancer Risk Assessment Tool (available at www.cancer.gov/bcrisktool) that is based on the Gail model and estimates the 5-year incidence of invasive breast cancer in women on the basis of characteristics entered into a risk calculator. This tool helps identify women who may be at increased risk for the disease. Other risk assessment models have been developed by the Breast Cancer Surveillance Consortium (BCSC), Rosner and Colditz, Chlebowski, Tyrer and Cuzick, and others. Examples of risk factors elicited by risk assessment tools include patient age, race or ethnicity, age at menarche, age at first live childbirth, personal history of DCIS or LCIS, number of first-degree relatives with breast cancer, personal history of breast biopsy, body mass index, menopause status or age, breast density, estrogen and progestin use, smoking, alcohol use, physical activity, and diet. These models are not recommended for use in women with a personal history of breast cancer, a history of radiation treatment to the chest, or a possible family history of mutations in the BRCA1 or BRCA2 genes. Only a small fraction of women are at increased risk for breast cancer. Most who are at increased risk will not develop the disease, and most cases will arise in women who are not identified as being at increased risk. Risk assessment should be repeated when there is a significant change in breast cancer risk factors. There is no single cutoff for defining increased risk. Most clinical trials defined increased risk as a 5-year risk for invasive breast cancer of 1.66% or greater, as determined by the BCPT (Breast Cancer Prevention Trial). At this cutoff, however, many women would not have a net benefit from risk-reducing medications. Freedman and colleagues developed risk tables that incorporate the BCPT estimate of a woman's breast cancer risk as well as her age, race or ethnicity, and presence of uterus. On the basis of the Freedman risk&ndash;benefit tables for women aged 50 years or older (Figures 2 to 5), the USPSTF concludes that many women with an estimated 5-year breast cancer risk of 3% or greater are likely to have more benefit than harm from using tamoxifen or raloxifene, although the balance depends on age, race or ethnicity, the medication used, and whether the patient has a uterus.
Assessment of Risk for Adverse Effects
In general, women taking medications for breast cancer risk reduction are less likely to experience a VTE if they are younger and have no other predisposition to thromboembolic events. Women with a personal or family history of venous thromboembolism are at higher risk for these adverse effects. Women without a uterus are not at risk for tamoxifen-related endometrial cancer. Women with a uterus should have a baseline gynecologic examination prior to starting tamoxifen, with regular followup after the end of treatment.","Importance
Breast cancer is the most common nonskin cancer in women. An estimated 232,340 new cases will be diagnosed in 2013, and 39,620 women will die of the disease. In the United States, mortality rates are highest among African American women. Screening for breast cancer may allow for early detection but does not prevent the development of the disease.Tamoxifen and raloxifene are selective estrogen receptor modulators that have been shown in randomized, controlled trials to reduce the risk for estrogen receptor (ER)&ndash;positive breast cancer. They have been approved by the U.S. Food and Drug Administration (FDA) for this indication.
Assessment of Breast Cancer Risk Status
Important risk factors for breast cancer include increasing age, family history of breast or ovarian cancer (especially among first-degree relatives and onset before age 50 years), history of atypical hyperplasia or other nonmalignant high-risk breast lesions, previous breast biopsy, and extremely dense breast tissue. A history of these or other risk factors (see the Clinical Considerations) may prompt clinicians to conduct a formal breast cancer risk assessment.Available risk assessment models can accurately estimate the number of breast cancer cases that may arise in certain study populations, but their ability to accurately predict which women will (and will not) develop the disease is modest. Only a small fraction of women are at increased risk for breast cancer; moreover, only a subset of those women will derive benefit from risk-reducing medications.Information about the validity, feasibility, and effect of using risk assessment models to identify appropriate candidates for risk-reducing medications in primary care settings is limited.
Potential Benefits of Medications for Breast Cancer Risk Reduction
The USPSTF found adequate evidence that treatment with tamoxifen or raloxifene can significantly reduce the relative risk (RR) for invasive ER-positive breast cancer in postmenopausal women who are at increased risk for breast cancer. A systematic review of clinical trials found that tamoxifen and raloxifene reduced the incidence of invasive breast cancer by 7 to 9 events per 1000 women over 5 years and that tamoxifen reduced breast cancer incidence more than raloxifene (Table). Tamoxifen also reduces the incidence of invasive breast cancer in premenopausal women who are at increased risk for the disease. Women who are at increased risk for breast cancer are more likely to benefit from risk-reducing medications. In general, women with an estimated 5-year risk of 3% or greater are, on the basis of model estimates (Figures 2 to 5), more likely to benefit from tamoxifen or raloxifene. The USPSTF found that the benefits of tamoxifen and raloxifene for breast cancer risk reduction are no greater than small in women who are not at increased risk for the disease.In addition to breast cancer risk reduction, the USPSTF found adequate evidence that tamoxifen and raloxifene reduce the risk for nonvertebral or vertebral fractures, respectively, in postmenopausal women.
Potential Harms of Medications for Breast Cancer Risk Reduction
The USPSTF found adequate evidence that tamoxifen and raloxifene increase risk for venous thromboembolic events (VTEs) by 4 to 7 events per 1000 women over 5 years and that tamoxifen increases risk more than raloxifene (Table). The USPSTF found that potential harms from thromboembolic events are small to moderate, with increased potential for harms in older women.The USPSTF also found adequate evidence that tamoxifen but not raloxifene increases risk for endometrial cancer (4 more cases per 1000 women). Potential harms from tamoxifen-related endometrial cancer are small to moderate and depend on hysterectomy status and age. The potential risks for tamoxifen-related harms are higher in women older than 50 years and in women with a uterus. Tamoxifen may also increase the incidence of cataracts.Vasomotor symptoms (hot flashes) are a common adverse effect of both medications that is not typically classified as serious, but these symptoms may affect a patient's quality of life and willingness to use or adhere to these medications.
USPSTF Assessment
The USPSTF concludes with moderate certainty that there is a moderate net benefit from use of tamoxifen and raloxifene to reduce the incidence of invasive breast cancer in women who are at increased risk for the disease. The USPSTF concludes with moderate certainty that the potential harms of tamoxifen and raloxifene outweigh the potential benefits for breast cancer risk reduction in women who are not at increased risk for the disease.",None,None
294,Breast Cancer:Screening with Mammography Women aged 50 to 74 years,B,1,female,50,74,"The USPSTF recommends biennial screening mammography for women aged 50 to 74 years.*The Department of Health and Human Services, in implementing the Affordable Care Act under the standard it sets out in revised Section 2713(a)(5) of the Public Health Service Act, utilizes the 2002 recommendation on breast cancer screening of the USPSTF. &nbsp;In 2015, Congress enacted separate legislation as part of the Comprehensive Omnibus Funding law that ensured this provision remains in effect. This recommendation states: The USPSTF recommends screening mammography, with or without clinical breast examination (CBE), every 1-2 years for women aged 40 and older (B recommendation). &nbsp;We provide this information here to help primary care providers understand the implications this may have on co-payments and coverage related to screening patients for breast cancer.",The USPSTF Recommends biennial (every 2 years)&nbsp,Age,159,159,263,0,None,"Advancing age is the most important risk factor for breast cancer in most women, but epidemiologic data from the BCSC suggest that having a first-degree relative with breast cancer is associated with an approximately 2-fold increased risk for breast cancer in women aged 40 to 49 years.2, 9 Further, the CISNET models suggest that for women with about a 2-fold increased risk for breast cancer, starting annual digital screening at age 40 years results in a similar harm-to-benefit ratio (based on number of false-positive results or overdiagnosed cases per 1000 breast cancer deaths avoided) as beginning biennial digital screening at age 50 years in average-risk women.7, 8 This approach has not been formally tested in a clinical trial; therefore, there is no direct evidence that it would result in net benefit similar to that of women aged 50 to 74 years. However, given the increased burden of disease and potential likelihood of benefit, women aged 40 to 49 years who have a known first-degree relative (parent, child, or sibling) with breast cancer may consider initiating screening earlier than age 50 years. Many other risk factors have been associated with breast cancer in epidemiologic studies, but most of these relationships are weak or inconsistent and would not likely influence how women value the tradeoffs of the potential benefits and harms of screening. Risk calculators, such as the National Cancer Institute&rsquo;s Breast Cancer Risk Assessment Tool (available at www.cancer.gov/BCRISKTOOL<a href=""http://www.uspreventiveservicestaskforce.org/Page/Name/exit-disclaimer"" title=""This link goes offsite.
Click to read the external link disclaimer"" class=""extLink"">This link goes offsite. Click to read the external link disclaimer), have good calibration between predicted and actual outcomes in groups of women but are not accurate at predicting an individual woman&rsquo;s risk for breast cancer.10",None,None
315,"Breastfeeding: Primary Care Preventions --Pregnant women, new mothers, and their children",B,1,female,11,49,The USPSTF recommends providing interventions during pregnancy and after birth to support breastfeeding.,During pregnancy and after birth,None,173,None,None,0,"This recommendation applies to pregnant women, new mothers, and their infants and children. Interventions to support breastfeeding may also involve a woman's partner, other family members, and friends. This recommendation does not apply in circumstances where there are contraindications to breastfeeding (e.g., certain maternal medical conditions or infant metabolic disorders, such as galactosemia). The USPSTF did not review evidence on interventions directed at breastfeeding of preterm infants.",None,None,None
277,Chlamydia: Screening -- Sexually Active Women,B,1,female,11,100,The USPSTF recommends screening for chlamydia in sexually active women age 24 years and younger and in older women who are at increased risk for infection.,"In the absence of studies on screening intervals, a reasonable approach would be to screen patients whose sexual history reveals new or persistent risk factors since the last negative test result.",Sexually Active,149,239,240,0,"Age is a strong predictor of risk for chlamydial and gonococcal infections, with the highest infection rates occurring in women aged 20 to 24 years, followed by females aged 15 to 19 years. Chlamydial infections are 10 times more prevalent than gonococcal infections in young adult women. Among men, infection rates are highest in those aged 20 to 24 years. Other risk factors for infection include having a new sex partner, more than 1 sex partner, a sex partner with concurrent partners, or a sex partner who has an STI; inconsistent condom use among persons who are not in mutually monogamous relationships; previous or coexisting STI; and exchanging sex for money or drugs. Prevalence is also higher among incarcerated populations, military recruits, and patients receiving care at public STI clinics. There are also racial and ethnic differences in STI prevalence. In 2012, black and Hispanic persons had higher rates of infection than white persons. Clinicians should consider the communities they serve and may want to consult local public health authorities for guidance on identifying groups that are at increased risk.",None,None,None
266,Dental Caries: Fluoride Varnish -- Infants and Children,B,1,men and women,0,5,The USPSTF recommends that primary care clinicians apply fluoride varnish to the primary teeth of all infants and children starting at the age of primary tooth eruption.,"No study directly assessed the appropriate ages at which to start and stop the application of fluoride varnish. Available trials of fluoride varnish enrolled children ages 3 to 5 years; however, given the mechanism of action of this intervention, benefits are very likely to accrue starting at the time of primary tooth eruption. Limited evidence found no clear effect on caries increment between performing a single fluoride varnish once every 6 months versus once a year or between a single application every 6 months versus multiple applications once a year or every 6 months.",None,142,228,224,0,"Some organizations have advocated restricting fluoride varnish use to children at &ldquo;increased risk.&rdquo; Although several caries risk assessment tools exist, none have been validated in the primary care setting, nor do existing studies demonstrate that these tools, when used by primary care clinicians, can accurately and consistently differentiate between children who will develop dental caries and those who will not. A risk-based approach to fluoride varnish application will miss opportunities to provide an effective dental caries preventive intervention to children who could benefit from it, particularly because currently, in the United States, infants and preschool-aged children are more likely to have regular visits with nondental primary care clinicians than dental care providers.","Importance
Dental caries is the most common chronic disease in children in the United States. According to the 1999&ndash;2004 National Health and Nutrition Examination Survey (NHANES), approximately 42% of children ages 2 to 11 years have dental caries in their primary teeth. After decreasing from the early 1970s to the mid-1990s, the prevalence of dental caries in children has been increasing, particularly in young children ages 2 to 5 years.
Recognition of Risk Status
Risk assessment tools generally evaluate risk based on factors such as demographic risk, personal and family oral health history, dietary habits, fluoride exposure, and oral hygiene practices. Information from a clinical evaluation has also been proposed, as well as qualitative or quantitative measure of oral bacterial load. The USPSTF found no studies that evaluated the accuracy of risk assessment instruments for future dental caries in the primary care setting.
Benefits of Preventive Interventions and Early Detection
Preventive Interventions
The USPSTF found adequate evidence that oral fluoride supplementation, also known as dietary fluoride supplementation, in children who have low levels of fluoride in their water and application of fluoride varnish to the primary teeth of all children can each provide moderate benefit in preventing dental caries.The USPSTF found insufficient evidence on the benefits of provider education of parents regarding oral hygiene practices to prevent dental caries in their children.
Screening
The USPSTF found no studies addressing the direct effect of routine oral screening examinations performed by primary care clinicians on improved clinical outcomes in children younger than age 5 years.
Harms of Preventive Interventions and Early Detection
Preventive Interventions
The USPSTF found adequate evidence of a link between early childhood exposure to systemic fluoride and enamel fluorosis, a visible change in the appearance of the enamel due to altered mineralization. Fluorosis can range from mild (small white spots or streaks) to severe (discoloration, pitting, or rough enamel), depending on the overall systemic fluoride exposure level over time.No studies specifically reported on the risk for fluorosis with fluoride varnish; however, compared with other topical fluoride interventions, systematic exposure to fluoride is low after varnish application. It is important to consider a child's overall systemic exposure to fluoride from multiple sources (e.g., water fluoridation, toothpaste, supplements, and/or varnish), but in the United States, enamel fluorosis presents as mild cosmetic changes in &gt;99% of cases.The USPSTF concludes that there is limited evidence about the harms associated with fluoride varnish or other preventive interventions for dental caries, but that these risks are likely small.
Screening
The USPSTF found no studies addressing the magnitude of harms of screening children from birth to age 5 years for dental caries or future risk for dental caries in the primary care setting.
USPSTF Assessment
The USPSTF concludes with moderate certainty that there is a moderate net benefit of preventing future dental caries with oral fluoride supplementation at recommended doses in children older than age 6 months who reside in communities with inadequate water fluoride.The USPSTF concludes with moderate certainty that there is a moderate net benefit of preventing future dental caries with fluoride varnish application in all children starting at the age of eruption of primary teeth to age 5 years.The USPSTF concludes that the evidence on performing routine oral screening examinations for dental caries in children from birth to age 5 years is insufficient, and the balance of benefits and harms of screening cannot be determined.",None,None
265,Dental Caries: Oral Fluoride Supplementation -- Children Age 6 Months to 5 Years,B,1,men and women,0,5,The USPSTF recommends that primary care clinicians prescribe oral fluoride supplementation starting at age 6 months for children whose water supply is deficient in fluoride.&nbsp,None,None,142,142,228,224,None,"All children are at potential risk for dental caries; those whose primary water supply is deficient in fluoride (defined as containing &lt;0.6 ppm F) are at particular risk. While there are no validated multivariate screening tools to determine which children are at higher risk for dental caries, there are a number of individual factors that elevate risk. Higher prevalence and severity of dental caries are found among minority and economically disadvantaged children. Other risk factors for caries in children include frequent sugar exposure, inappropriate bottle feeding, developmental defects of the tooth enamel, dry mouth, and a history of previous caries. Maternal and family factors can also increase children's risk. These factors include poor oral hygiene, low socioeconomic status, recent maternal caries, sibling caries, and frequent snacking. Additional factors associated with dental caries in young children include lack of access to dental care; inadequate preventive measures, such as failure to use fluoride-containing toothpastes; and lack of parental knowledge about oral health.","Importance
Dental caries is the most common chronic disease in children in the United States. According to the 1999&ndash;2004 National Health and Nutrition Examination Survey (NHANES), approximately 42% of children ages 2 to 11 years have dental caries in their primary teeth. After decreasing from the early 1970s to the mid-1990s, the prevalence of dental caries in children has been increasing, particularly in young children ages 2 to 5 years.
Recognition of Risk Status
Risk assessment tools generally evaluate risk based on factors such as demographic risk, personal and family oral health history, dietary habits, fluoride exposure, and oral hygiene practices. Information from a clinical evaluation has also been proposed, as well as qualitative or quantitative measure of oral bacterial load. The USPSTF found no studies that evaluated the accuracy of risk assessment instruments for future dental caries in the primary care setting.
Benefits of Preventive Interventions and Early Detection
Preventive Interventions
The USPSTF found adequate evidence that oral fluoride supplementation, also known as dietary fluoride supplementation, in children who have low levels of fluoride in their water and application of fluoride varnish to the primary teeth of all children can each provide moderate benefit in preventing dental caries. The USPSTF found insufficient evidence on the benefits of provider education of parents regarding oral hygiene practices to prevent dental caries in their children.
Screening
The USPSTF found no studies addressing the direct effect of routine oral screening examinations performed by primary care clinicians on improved clinical outcomes in children younger than age 5 years.
Harms of Preventive Interventions and Early Detection
Preventive Interventions
The USPSTF found adequate evidence of a link between early childhood exposure to systemic fluoride and enamel fluorosis, a visible change in the appearance of the enamel due to altered mineralization. Fluorosis can range from mild (small white spots or streaks) to severe (discoloration, pitting, or rough enamel), depending on the overall systemic fluoride exposure level over time.No studies specifically reported on the risk for fluorosis with fluoride varnish; however, compared with other topical fluoride interventions, systematic exposure to fluoride is low after varnish application. It is important to consider a child's overall systemic exposure to fluoride from multiple sources (e.g., water fluoridation, toothpaste, supplements, and/or varnish), but in the United States, enamel fluorosis presents as mild cosmetic changes in &gt;99% of cases. The USPSTF concludes that there is limited evidence about the harms associated with fluoride varnish or other preventive interventions for dental caries, but that these risks are likely small.
Screening
The USPSTF found no studies addressing the magnitude of harms of screening children from birth to age 5 years for dental caries or future risk for dental caries in the primary care setting.
USPSTF Assessment
The USPSTF concludes with moderate certainty that there is a moderate net benefit of preventing future dental caries with oral fluoride supplementation at recommended doses in children older than age 6 months who reside in communities with inadequate water fluoride. The USPSTF concludes with moderate certainty that there is a moderate net benefit of preventing future dental caries with fluoride varnish application in all children starting at the age of eruption of primary teeth to age 5 years. The USPSTF concludes that the evidence on performing routine oral screening examinations for dental caries in children from birth to age 5 years is insufficient, and the balance of benefits and harms of screening cannot be determined.",None
300,Depression: Screening -- Adolescents aged 12 to 18 years,B,1,men and women,12,18,"The USPSTF recommends screening for major depressive disorder (MDD) in adolescents aged 12 to 18 years. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.",None,Other,161,268,267,0,"The USPSTF recommends screening for MDD in all adolescents but notes that several risk factors might help identify patients who are at higher risk. The causes of MDD are not fully known and likely involve a combination of genetic, biological, and environmental factors. Risk factors for MDD in children and adolescents include female sex; older age; family (especially maternal) history of depression; prior episode of depression; other mental health or behavioral problems; chronic medical illness; overweight and obesity; and, in some studies, Hispanic race/ethnicity. Other psychosocial risk factors include childhood abuse or neglect, exposure to traumatic events (including natural disasters), loss of a loved one or romantic relationship, family conflict, uncertainty about sexual orientation, low socioeconomic status, and poor academic performance.",None,None,None
299,"Depression: Screening -- General adult population, including pregnant and postpartum women",B,1,men and women,18,100,"The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up.","There is little evidence regarding the optimal timing for screening. The optimum interval for screening for depression is also unknown; more evidence for all populations is needed to identify ideal screening intervals. A pragmatic approach in the absence of data might include screening all adults who have not been screened previously and using clinical judgment in consideration of risk factors, comorbid conditions, and life events to determine if additional screening of high-risk patients is warranted.",Other,160,264,265,0,"The USPSTF recommends screening in all adults regardless of risk factors. However, a number of factors are associated with an increased risk of depression. Among general adult populations, prevalence rates vary by sex, age, race/ethnicity, education, marital status, geographic location, and employment status. Women, young and middle-aged adults, and nonwhite persons have higher rates of depression than their counterparts, as do persons who are undereducated, previously married, or unemployed. Other groups who are at increased risk of developing depression include persons with chronic illnesses (eg, cancer or cardiovascular disease), other mental health disorders (including substance misuse), or a family history of psychiatric disorders. Among older adults, risk factors for depression include disability and poor health status related to medical illness, complicated grief, chronic sleep disturbance, loneliness, and a history of depression. However, the presence or absence of risk factors alone cannot distinguish patients with depression from those without depression. Risk factors for depression during pregnancy and postpartum include poor self-esteem, child-care stress, prenatal anxiety, life stress, decreased social support, single/unpartnered relationship status, history of depression, difficult infant temperament, previous postpartum depression, lower socioeconomic status, and unintended pregnancy.",None,None,None
293,Diabetes Mellitus (Type 2) and Abnormal Blood Glucose: Screening -- Adults aged 40 to 70 years who are overweight or obese,B,1,men and women,40,70,The USPSTF recommends screening for abnormal blood glucose as part of cardiovascular risk assessment in adults aged 40 to 70 years who are overweight or obese. Clinicians should offer or refer patients with abnormal blood glucose to intensive behavioral counseling interventions to promote a healthful diet and physical activity.,Evidence on the optimal rescreening interval for adults with an initial normal glucose test result is limited.&nbsp,Other,158,158,262,0,None,"Persons who have a family history of diabetes, have a history of gestational diabetes or polycystic ovarian syndrome, or are members of certain racial/ethnic groups (that is, African Americans, American Indians or Alaskan Natives, Asian Americans, Hispanics or Latinos, or Native Hawaiians or Pacific Islanders) may be at increased risk for diabetes at a younger age or at a lower body mass index. Clinicians should consider screening earlier in persons with 1 or more of these characteristics.",None,None
343,Falls Prevention in Community-Dwelling Older Adults: Interventions --Adults 65 or older,B,1,men and women,65,100,The USPSTF recommends exercise interventions to prevent falls in community-dwelling adults 65 years or older who are at increased risk for falls.,None,Other,191,309,310,0,At increased risk for falls.,None,None,None
257,Gestational Diabeetes Mellitus:Screening -- Pregnant Women After 24 Weeks of Gestation,B,1,female,15,49,The USPSTF recommends screening for gestational diabetes mellitus (GDM) in asymptomatic pregnant women after 24 weeks of gestation.,None,Pregnant,138,212,213,0,"Several factors increase a woman's risk for developing GDM, including obesity, increased maternal age, history of GDM, family history of diabetes, and belonging to an ethnic group that has increased risk for developing type 2 diabetes mellitus (Hispanic, Native American, South or East Asian, African American, or Pacific Island descent). Factors associated with a lower risk for developing GDM include age younger than 25 to 30 years, white race, a body mass index (BMI) of 25 kg/m2 or less, no family history (that is, in a first-degree relative) of diabetes, and no history of glucose intolerance or adverse pregnancy outcomes related to GDM.","Importance
Gestational diabetes mellitus is glucose intolerance discovered during pregnancy. The prevalence of GDM in the United States is 1% to 25%, depending on patient demographics and diagnostic thresholds. Pregnant women with gestational diabetes are at increased risk for maternal and fetal complications, including preeclampsia, fetal macrosomia (which can cause shoulder dystocia and birth injury), and neonatal hypoglycemia. Women with GDM are also at increased risk for developing type 2 diabetes mellitus; approximately 15% to 60% of women develop type 2 diabetes within 5 to 15 years of delivery. Screening for GDM generally occurs after the 24th week of pregnancy. Screening before 24 weeks may identify women with glucose intolerance earlier in pregnancy.
Detection
The USPSTF found adequate evidence that primary care providers can accurately detect GDM in asymptomatic pregnant women after 24 weeks of gestation. The most commonly used screening test in the United States is the 50-g oral glucose challenge test (OGCT).Other methods of screening include the fasting plasma glucose test and screening based on risk factors. However, there is limited evidence on these alternative screening approaches. The USPSTF found inadequate evidence to compare the effectiveness of different screening tests or thresholds for a positive screen result.
Benefits of Detection and Early Treatment
The USPSTF found adequate evidence that treatment of screen-detected GDM with dietary modifications, glucose monitoring, and insulin (if needed) can significantly reduce the risk of preeclampsia, fetal macrosomia, and shoulder dystocia. When these outcomes are considered collectively, there is a moderate net benefit for both mother and infant. The benefit of treatment on long-term metabolic outcomes in women who are treated for GDM compared with those who are not treated is uncertain.The USPSTF found inadequate evidence to determine whether there are benefits to screening for GDM in women before 24 weeks of gestation.
Harms of Detection and Early Treatment
Overall, the USPSTF found adequate evidence that the magnitude of the harms of screening and treatment is small to none. Randomized, controlled trials (RCTs) demonstrated an increase in the number of prenatal visits in screen-detected women who were treated for GDM compared with screen-detected women who were not treated. There was conflicting evidence on the risk for an increase in the induction of labor associated with treatment. No significant differences were reported for cesarean delivery or neonatal intensive care unit admissions between women who were treated and women who were not treated for GDM in the overall pooled meta-analysis. Trials also demonstrated no significant differences in the incidence of small-for-gestational-age infants or episodes of neonatal hypoglycemia, but the trials were not adequately powered to detect meaningful differences in these outcomes.
USPSTF Assessment
The USPSTF concludes with moderate certainty that there is a moderate net benefit to screening for gestational diabetes after 24 weeks of gestation to reduce maternal and fetal complications (the collective outcomes of preeclampsia, macrosomia, and shoulder dystocia). The USPSTF concludes that the evidence on screening for gestational diabetes before 24 weeks of gestation is insufficient, and the balance of benefits and harms of screening cannot be determined.",None,None
278,Gonorrhea: Screening -- Sexually Active Women,B,1,female,11,100,The USPSTF recommends screening for gonorrhea in sexually active women age 24 years and younger and in older women who are at increased risk for infection.,"In the absence of studies on screening intervals, a reasonable approach would be to screen patients whose sexual history reveals new or persistent risk factors since the last negative test result.",Sexually Active,149,239,240,0,"Age is a strong predictor of risk for chlamydial and gonococcal infections, with the highest infection rates occurring in women aged 20 to 24 years, followed by females aged 15 to 19 years. Chlamydial infections are 10 times more prevalent than gonococcal infections in young adult women. Among men, infection rates are highest in those aged 20 to 24 years. Other risk factors for infection include having a new sex partner, more than 1 sex partner, a sex partner with concurrent partners, or a sex partner who has an STI; inconsistent condom use among persons who are not in mutually monogamous relationships; previous or coexisting STI; and exchanging sex for money or drugs. Prevalence is also higher among incarcerated populations, military recruits, and patients receiving care at public STI clinics. There are also racial and ethnic differences in STI prevalence. In 2012, black and Hispanic persons had higher rates of infection than white persons. Clinicians should consider the communities they serve and may want to consult local public health authorities for guidance on identifying groups that are at increased risk.",None,None,None
275,Healthful Diet and Physical Activity for CVD Disease Prevention: Counseling -- Adults with CVD Risk Factors,B,1,men and women,18,100,The USPSTF recommends offering or referring adults who are overweight or obese and have additional cardiovascular disease (CVD) risk factors to intensive behavioral counseling interventions to promote a healthful diet and physical activity for CVD prevention.,"Most studies evaluated interventions that combined counseling on a healthful diet and physical activity and were intensive, with multiple contacts (which may have included individual or group counseling sessions) over extended periods. Interventions involved an average of 5 to 16 contacts over 9 to 12 months depending on their intensity. Most of the sessions were in-person, and many included additional telephone contacts.",None,147,235,236,0,"This recommendation applies to adults aged 18 years or older in primary care settings who are overweight or obese and have known CVD risk factors (hypertension, dyslipidemia, impaired fasting glucose, or the metabolic syndrome). In the studies reviewed by the USPSTF, the vast majority of participants had a BMI greater than 25 kg/m2.","Importance
Cardiovascular disease, primarily in the forms of heart disease and stroke, is a leading cause of death in the United States. Obesity is associated with increased CVD mortality. Adults who adhere to national guidelines for a healthful diet&nbsp;and physical activity&nbsp;have lower cardiovascular morbidity and mortality than those who do not. All persons, regardless of CVD risk status, can accrue the health benefits of improved nutrition, healthy eating behaviors, and increased physical activity.
Benefits of Behavioral Counseling Interventions
The USPSTF found adequate evidence that intensive behavioral counseling interventions have moderate benefits for CVD risk in overweight or obese adults who are at increased risk for CVD, including decreases in blood pressure, lipid and fasting glucose levels, and body mass index (BMI) and increases in levels of physical activity. The reduction in glucose levels was large enough to decrease the incidence of a diabetes diagnosis. The USPSTF found inadequate direct evidence that intensive behavioral counseling interventions lead to decreases in mortality or CVD rates.
Harms of Behavioral Counseling Interventions
The USPSTF found adequate evidence that the harms of behavioral counseling interventions are small to none. None of the dietary intervention studies explicitly reported adverse events. Studies of physical activity interventions reported mostly minor adverse events, and intense physical activity was rarely associated with cardiovascular events.
USPSTF Assessment
The USPSTF concludes with moderate certainty that intensive behavioral counseling interventions to promote a healthful diet and physical activity have a moderate net benefit in overweight or obese adults who are at increased risk for CVD.",None,None
268,Hepatitis B: Screening -- Nonpregnant Adolescents and Adults At High Risk,B,1,men and women,12,100,The USPSTF recommends screening for hepatitis B virus (HBV) infection in persons at high risk for infection.&nbsp,None,Other,161,144,229,230,None,"A major risk factor for HBV infection is country of origin. The risk for HBV infection varies substantially by country of origin in foreign-born persons in the United States. Persons born in countries with a prevalence of HBV infection of 2% or greater account for 47% to 95% of those with chronic HBV infection in the United States (Table 1). Another important risk factor for HBV infection is lack of vaccination in infancy in U.S.-born persons with parents from a country or region with high prevalence (&ge;8%), such as sub-Saharan Africa, central and southeast Asia, and China (Figure). Because HBV infection prevalence may gradually change over time, it is important to note that some countries and regions with prevalence rates between 5-7% are considered to be highly endemic areas.&nbsp;The CDC also recommends screening in persons receiving hemodialysis or cytotoxic or immunosuppressive therapy (for example, chemotherapy for malignant diseases and immunosuppression related to organ transplantation and for rheumatologic and gastroenterologic disorders). Some persons with combinations of risk factors who are not members of one of these risk factor groups may also be at increased risk for HBV infection. However, reliable information about combinations of risk factors is not available. Clinicians should exercise their judgment in deciding whether these persons are at sufficiently high risk to warrant screening. For example, screening is probably appropriate in settings that treat a large proportion of persons at increased risk, such as clinics for sexually transmitted infections; HIV testing and treatment centers; health care settings that provide services for injection drug users or men who have sex with men; correctional facilities; and institutions that serve populations from countries with a high prevalence of infection, including community health centers. The prevalence of HBV infection is low in the general U.S. population, and most infected persons do not develop complications. Therefore, screening is not recommended in those who are not at increased risk. The USPSTF notes that high rates of HBV infection have been found in cities and other areas with high numbers of immigrants or migrant persons from Asia or the Pacific Islands or their adult children. Providers should consider the population they serve when making screening decisions.","Importance
Approximately 700,000 to 2.2 million persons in the United States have chronic HBV infection. In the United States, persons considered at high risk for HBV infection include those from countries with a high prevalence of HBV infection, HIV-positive persons, injection drug users, household contacts of persons with HBV infection, and men who have sex with men.The natural history of chronic HBV infection varies but can include the potential long-term sequelae of cirrhosis, hepatic decompensation, and hepatocellular carcinoma. An estimated 15% to 25% of persons with chronic HBV infection die of cirrhosis or hepatocellular carcinoma. Those with chronic infection also serve as a reservoir for person-to-person transmission of HBV infection. Screening for HBV infection could identify chronically infected persons who may benefit from treatment or other interventions, such as surveillance for hepatocellular carcinoma.
Detection
Identification of chronic HBV infection based on serologic markers is considered accurate. Immunoassays for detecting hepatitis B surface antigen (HBsAg) have a reported sensitivity and specificity of greater than 98%.
Benefits of Detection and Early Intervention
The USPSTF found no randomized, controlled trials that provide direct evidence of the health benefits (that is, reduction in morbidity, mortality, and disease transmission) of screening for HBV infection in asymptomatic, nonpregnant adolescents and adults.&nbsp;The USPSTF found adequate evidence that HBV vaccination is effective at decreasing disease acquisition.&nbsp; The USPSTF found convincing evidence that antiviral treatment in patients with chronic HBV infection is effective at improving intermediate outcomes (that is, virologic or histologic improvement or clearance of hepatitis B e antigen [HBeAg]) and adequate evidence that antiviral regimens improve health outcomes (such as reduced risk for hepatocellular carcinoma). The evidence showed an association between improvement in intermediate outcomes after antiviral therapy and improvement in clinical outcomes, but outcomes were heterogeneous and the studies had methodological limitations. The USPSTF found inadequate evidence that education or behavior change counseling reduces disease transmission. The prevalence of HBV infection differs among various populations. As a result, the magnitude of benefit of screening varies according to risk group. The USPSTF concludes that screening is of moderate benefit for populations at high risk for HBV infection, given the accuracy of the screening test and the effectiveness of antiviral treatment.
Harms of Detection and Early Intervention
The USPSTF found inadequate evidence on the harms of screening for HBV infection. Although evidence to determine the magnitude of harms of screening is limited, the USPSTF considers these harms to be small to none.The USPSTF found adequate evidence that antiviral therapy regimens are associated with a higher risk for withdrawal due to adverse events than placebo. However, trials found no difference in the risk for serious adverse events or the number of participants who had any adverse event. In addition, most antiviral adverse events are self-limited with discontinuation of therapy. The USPSTF found adequate evidence that the magnitude of harms of treatment is small to none.
USPSTF Assessment
The USPSTF concludes with moderate certainty that screening for HBV infection in adults at high risk for infection has moderate net benefit.",None
239,Hepatitis C Virus Infection: Screening--Adults at High Risk and Adults born between 1945 and 1965,B,1,men and women,18,100,The USPSTF recommends screening for hepatitis C virus (HCV) infection in persons at high risk for infection. The USPSTF also recommends offering 1-time screening for HCV infection to adults born between 1945 and 1965.&nbsp,None,Other,129,191,190,0,None,"The most important risk factor for HCV infection is past or current injection drug use. Another established risk factor for HCV infection is receipt of a blood transfusion before 1992. Because of the implementation of screening programs for donated blood, blood transfusions are no longer an important source of HCV infection. In contrast, 60% of new HCV infections occur in persons who report injection drug use within the past 6 months. Additional risk factors include long-term hemodialysis, being born to an HCV-infected mother, incarceration, intranasal drug use, getting an unregulated tattoo, and other percutaneous exposures (such as in health care workers or from having surgery before the implementation of universal precautions).&nbsp; Evidence on tattoos and other percutaneous exposures as risk factors for HCV infection is limited. The relative importance of these additional risk factors may differ on the basis of geographic location and other factors. Large population-based studies report an independent association between high-risk sexual behaviors (multiple sex partners, unprotected sex, or sex with an HCV-infected person or injection drug user) and HCV infection. However, HCV seems to be inefficiently transmitted through sexual contact, and observed associations may have been confounded by other high-risk behaviors. In 1998, the highest prevalence rates of the anti-HCV antibody occurred in persons with significant direct percutaneous exposures, such as injection drug users and persons with hemophilia (60% to 90%); persons with less significant percutaneous exposures involving smaller amounts of blood, such as patients receiving hemodialysis (10% to 30%), had more moderate prevalence rates. Persons engaging in high-risk sexual behaviors (1% to 10%); recipients of blood transfusions (6%); and persons with infrequent percutaneous exposures, such as health care workers (1% to 2%), had the lowest prevalence rates. Among patients with abnormal results on liver function tests (measurement of aspartate aminotransferase, alanine aminotransferase, or bilirubin) who were tested for reasons other than HCV screening, finding the cause of the abnormality often includes testing for HCV infection and is considered case finding rather than screening; therefore, it is outside the scope of this recommendation. In 2010, the overall incidence rate of acute HCV infection was 0.3 cases per 100,000 persons and varied by race or ethnicity. The incidence rate for acute hepatitis C was lowest among persons of Asian or Pacific Islander descent and highest among American Indians and Alaskan natives. Blacks had the highest mortality rates from HCV, at 6.5 to 7.8 deaths per 100,000 persons, according to data from 2004 to 2008.","Importance
Hepatitis C virus is the most common chronic bloodborne pathogen in the United States and a leading cause of complications from chronic liver disease. The prevalence of the anti-HCV antibody in the United States is approximately 1.6% in noninstitutionalized persons. According to data from 1999 to 2008, about three fourths of patients in the United States living with HCV infection were born between 1945 and 1965, with a peak prevalence of 4.3% in persons aged 40 to 49 years from 1999 to 2002. The most important risk factor for HCV infection is past or current injection drug use, with most studies reporting a prevalence of 50% or more. The incidence of HCV infection was more than 200,000 cases per year in the 1980s but decreased to 25,000 cases per year by 2001. According to the Centers for Disease Control and Prevention (CDC), there were an estimated 16,000 new cases of HCV infection in 2009 and an estimated 15,000 deaths in 2007. Hepatitis C&ndash;related end-stage liver disease is the most common indication for liver transplants among U.S. adults, accounting for more than 30% of cases. Studies suggest that about one half of the recently observed 3-fold increase in incidence of hepatocellular carcinoma is related to acquisition of HCV infection 2 to 4 decades earlier.
Detection
The USPSTF found adequate evidence that anti&ndash;HCV antibody testing followed by confirmatory polymerase chain reaction testing accurately detects chronic HCV infection.In screening strategies targeting persons with risk factors for HCV infection (such as past or present injection drug use, sex with an injection drug user, or blood transfusion before 1992), anti&ndash;HCV antibody testing is associated with high sensitivity (&gt;90%) and small numbers needed to screen to identify 1 case of HCV infection (&lt;20 persons). Anti&ndash;HCV antibody testing remains highly accurate in low-prevalence populations, although the numbers needed to screen to detect 1 case of HCV infection are higher.The USPSTF also found adequate evidence that various noninvasive tests have good to very good diagnostic accuracy in diagnosing fibrosis or cirrhosis.
Benefits of Detection and Early Intervention
The USPSTF found no direct evidence on the benefit of screening for HCV infection in asymptomatic adults in reducing morbidity and mortality. However, the USPSTF found adequate evidence that antiviral regimens result in sustained virologic response (SVR) and improved clinical outcomes.The USPSTF found inadequate evidence that counseling or immunization of patients with HCV infection against other infections improves health outcomes, reduces transmission of HCV, or changes high-risk behaviors. The USPSTF found inadequate evidence that knowledge of positive status for HCV infection reduces high-risk behaviors. The USPSTF also found inadequate evidence that labor management and breastfeeding strategies in HCV-positive women are effective at reducing risk for mother-to-child transmission.Given the accuracy of the screening test and the availability of effective interventions for HCV infection, the USPSTF concludes that screening is of moderate benefit for populations at high risk for infection. The USPSTF concludes that 1-time screening in all adults in the United States born between 1945 and 1965 is also of moderate benefit.
Harms of Detection and Early Intervention
The USPSTF found limited evidence on the harms of screening for HCV. Potential harms of screening include anxiety, patient labeling, and feelings of stigmatization.The USPSTF found adequate evidence on the harms associated with the diagnostic evaluation used to guide treatment decisions (liver biopsy). These harms include bleeding, infection, and severe pain in approximately 1% of persons who had a liver biopsy and death in less than 0.2%. However, the use of liver biopsy to guide treatment decisions is declining, and noninvasive tests have sufficient accuracy to diagnose fibrosis and cirrhosis. Thus, the absolute risk to persons who currently receive a diagnosis of HCV infection and subsequent treatment is probably declining.The USPSTF found adequate evidence that antiviral therapy regimens are associated with a high rate of harms, such as fatigue, headache, flu-like symptoms, hematologic events, and rash. However, antiviral therapy is given for a defined duration, serious adverse events are uncommon, and adverse events are self-limited and typically resolve after treatment is discontinued. The USPSTF found adequate evidence that these harms of treatment are small.
USPSTF Assessment
The USPSTF concludes with moderate certainty that screening for HCV infection in adults at increased risk for infection and 1-time screening in adults in the 1945&ndash;1965 birth cohort has moderate net benefit.",None
228,Intimate Partner Violence: Screening -- Women Childbearing Age,B,1,female,14,46,"The U.S. Preventive Services Task Force (USPSTF) recommends that clinicians screen women of childbearing age for intimate partner violence (IPV), such as domestic violence, and provide or refer women who screen positive to intervention services. This recommendation applies to women who do not have signs or symptoms of abuse.",None,None,124,179,180,0,"Although all women are at potential risk for abuse, factors that elevate risk include young age, substance abuse, marital difficulties, and economic hardships.","Importance
Intimate partner violence and abuse of elderly and vulnerable adults is common in the United States but often remains undetected. Nearly 31% of women and 26% of men report experiencing some form of IPV in their lifetime. Approximately 25% of women and 14% of men have experienced the most severe types of IPV in their lifetime. These estimates likely underrepresent actual rates because of underreporting. In addition to the immediate effects of IPV, such as injury and death, there are other health consequences, many with long-term effects, including sexually transmitted diseases, pelvic inflammatory disease, and unintended pregnancy. Rates of chronic pain, neurological disorders, gastrointestinal disorders, migraine headaches, and other disabilities&nbsp;are also increased. Intimate partner violence is also associated with preterm birth, low birth weight, and decreased gestational age. Individuals experiencing IPV often develop chronic mental health conditions, such as depression, posttraumatic stress disorder, anxiety disorders, substance abuse, and suicidal behavior. For adolescent and young adults, the effects of physical and sexual assault are associated with poor self-esteem, alcohol and drug abuse, eating disorders, obesity, risky sexual behaviors, teen pregnancy, depression, anxiety, suicidality, and other conditions.Little information is available on the prevalence of abuse among noninstitutionalized elderly or vulnerable adults, although reported rates range from 2% to 25%.
Detection
For IPV, there is adequate evidence that available screening instruments can identify current and past abuse or increased risk for abuse. Several instruments used in more than 1 study were highly sensitive and specific.The USPSTF found inadequate evidence on the accuracy of screening instruments for elderly or vulnerable adults.
Benefits of Detection and Early Intervention
The USPSTF found adequate evidence that effective interventions can reduce violence, abuse, and physical or mental harms for women of reproductive age.The USPSTF found inadequate evidence that screening or early detection reduces exposure to abuse or reduces physical or mental harms or mortality for elderly and vulnerable adults.
Harms of Detection and Early Intervention
For IPV, the USPSTF found adequate evidence that the risk for harm to the individual from screening or interventions is no greater than small.For elderly and vulnerable adults, the USPSTF found inadequate evidence on the harms of screening or interventions.
USPSTF Assessment
The USPSTF concludes with moderate certainty that screening women of childbearing age for IPV has a moderate net benefit.  The USPSTF concludes that the benefits and harms of screening elderly or vulnerable adults for abuse are uncertain, and that the balance of benefits and harms cannot be determined.",None,None
314,Latent Tuberculosis Infection: Screening -- Asymptomatic adults at increased risk for infection,B,1,men and women,18,100,The USPSTF recommends screening for latent tuberculosis infection (LTBI) in populations at increased risk.,"The USPSTF found no evidence on the optimal frequency of screening for LTBI. Depending on specific risk factors, screening frequency could range from 1-time only screening among persons who are at low risk for future tuberculosis exposure to annual screening among those who are at continued risk of exposure.",Other,172,284,None,0,"increased risk for LTBI based on increased prevalence of active disease and increased risk of exposure include persons who were born in, or are former residents of, countries with increased tuberculosis prevalence and persons who live in, or have lived in, high-risk congregate settings (eg, homeless shelters and correctional facilities). Clinicians can consult their local or state health departments for more information about populations at risk in their community, because local demographic patterns may vary across the United States.",None,None,None
256,Lung Cancer: Screening -- Adults Ages 55-80 who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years,B,1,men and women,55,80,The USPSTF recommends annual screening for lung cancer with low-dose computed tomography (LDCT) in adults aged 55 to 80 years who have a 30 pack-year smoking history and currently smoke or have quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability or willingness to have curative lung surgery.&nbsp,None,Tobacco user,137,0,137,209,,210,"Age, total exposure to tobacco smoke, and years since quitting smoking are important risk factors for lung cancer and were used to determine eligibility in the National Lung Screening Trial (NLST). Other risk factors include specific occupational exposures, radon exposure, family history, and history of pulmonary fibrosis or chronic obstructive lung disease. The incidence of lung cancer is relatively low in persons younger than 50 years but increases with age, especially after age 60 years. In current and former smokers, age-specific incidence rates increase with age and cumulative exposure to tobacco smoke. Smoking cessation substantially reduces a person's risk for developing and dying of lung cancer. Among persons enrolled in the NLST, those who were at highest risk because of additional risk factors or a greater cumulative exposure to tobacco smoke experienced most of the benefit. A validated multivariate model showed that persons in the highest 60% of risk accounted for 88% of all deaths preventable by screening.","Importance
Lung cancer is the third most common cancer and the leading cause of cancer death in the United States. The most important risk factor for lung cancer is smoking, which results in approximately 85% of all U.S. lung cancer cases. Although the prevalence of smoking has decreased, approximately 37% of U.S. adults are current or former smokers. The incidence of lung cancer increases with age and occurs most commonly in persons aged 55 years or older. Increasing age and cumulative exposure to tobacco smoke are the 2 most common risk factors for lung cancer.&nbsp;Lung cancer has a poor prognosis, and nearly 90% of persons with lung cancer die of the disease. However, early-stage non&ndash;small cell lung cancer (NSCLC) has a better prognosis and can be treated with surgical resection.
Detection
Most lung cancer cases are NSCLC, and most screening programs focus on the detection and treatment of early-stage NSCLC. Although chest radiography and sputum cytologic evaluation have been used to screen for lung cancer, LDCT has greater sensitivity for detecting early-stage cancer.
Benefits of Detection and Early Treatment
Although lung cancer screening is not an alternative to smoking cessation, the USPSTF found adequate evidence that annual screening for lung cancer with LDCT in a defined population of high-risk persons can prevent a substantial number of lung cancer&ndash;related deaths. Direct evidence from a large, well-conducted, randomized, controlled trial (RCT) provides moderate certainty of the benefit of lung cancer screening with LDCT in this population. The magnitude of benefit to the person depends on that person's risk for lung cancer because those who are at highest risk are most likely to benefit. Screening cannot prevent most lung cancer&ndash;related deaths, and smoking cessation remains essential.
Harms of Detection and Early Intervention and Treatment
The harms associated with LDCT screening include false-negative and false-positive results, incidental findings, overdiagnosis, and radiation exposure. False-positive LDCT results occur in a substantial proportion of screened persons; 95% of all positive results do not lead to a diagnosis of cancer. In a high-quality screening program, further imaging can resolve most false-positive results; however, some patients may require invasive procedures.&nbsp;&nbsp; The USPSTF found insufficient evidence on the harms associated with incidental findings. Overdiagnosis of lung cancer occurs, but its precise magnitude is uncertain. A modeling study performed for the USPSTF estimated that 10% to 12% of screen-detected cancer cases are overdiagnosed&mdash;that is, they would not have been detected in the patient's lifetime without screening. Radiation harms, including cancer resulting from cumulative exposure to radiation, vary depending on the age at the start of screening; the number of scans received; and the person's exposure to other sources of radiation, particularly other medical imaging.
USPSTF Assessment
The USPSTF concludes with moderate certainty that annual screening for lung cancer with LDCT is of moderate net benefit in asymptomatic persons who are at high risk for lung cancer based on age, total cumulative exposure to tobacco smoke, and years since quitting smoking. The moderate net benefit of screening depends on limiting screening to persons who are at high risk, the accuracy of image interpretation being similar to that found in the NLST (National Lung Screening Trial), and the resolution of most false-positive results without invasive procedures."
329,Obesity in Children and Adolescents: Screening -- Children and Adolescents 6 years and older,B,1,men and women,6,17,"The USPSTF recommends that clinicians screen for obesity in children and adolescents 6 years and older and offer or refer them to comprehensive, intensive behavioral interventions to promote improvements in weight status.","Screening -&nbsp;no evidence regarding appropriate screening intervals for obesity in children and adolescents. Height and weight, which are necessary for BMI calculation, are routinely measured during health maintenance visits.
Behavioral Intervention -&nbsp;comprehensive, intensive behavioral interventions with a total of 26 contact hours or more over a period of 2 to 12 months resulted in weight loss (Table 1).3,&nbsp;4&nbsp;Behavioral interventions with a total of 52 contact hours or more demonstrated greater weight loss and some improvements in cardiovascular and metabolic risk factors. These effective, higher-intensity (&ge;26 contact hours) behavioral interventions consisted of multiple components.3,&nbsp;4&nbsp;(see clinical considerations for more information)",Other,182,294,None,0,"parental obesity, poor nutrition, low levels of physical activity, inadequate sleep, sedentary behaviors, and low family income;&nbsp;maternal diabetes, maternal smoking, gestational weight gain, and rapid infant growth. A decrease in physical activity in young children is a risk factor for obesity later in adolescence. Obesity rates continue to increase in some racial/ethnic minority populations. These racial/ethnic differences in obesity prevalence are likely a result of both genetic and nongenetic factors (e.g., socioeconomic status, intake of sugar-sweetened beverages and fast food, and having a television in the bedroom).3",None,None,None
218,Obesity: Screening for and Management of-- All Adults,B,1,men and women,18,100,"The USPSTF recommends screening all adults for obesity. Clinicians should offer or refer patients with a body mass index (BMI) of 30 kg/m2 or higher to intensive, multicomponent behavioral interventions. &nbsp; &nbsp;","The USPSTF found that the most effective interventions were comprehensive and were of high intensity (12 to 26 sessions in a year). Although the USPSTF could not determine the effectiveness of other specific intervention components, most of the higher-intensity behavioral interventions included multiple behavioral management activities, such as group sessions, individual sessions, setting weight-loss goals, improving diet or nutrition, physical activity sessions, addressing barriers to change, active use of self-monitoring, and strategizing how to maintain lifestyle changes.",None,117,162,69,166,"This recommendation applies to adults aged 18 years or older. The USPSTF uses the following terms to define categories of increased BMI: overweight is defined as a BMI of 25 to 29.9 kg/m2, and obesity is defined as a BMI of 30 kg/m2 or higher.",None,163,None
354,Osteoporosis to Prevent Fractures: Screening -- Postmenopausal women younger than 65 years at increased risk of osteoporosis,B,1,female,18,64,"The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in postmenopausal women younger than 65 years who are at increased risk of osteoporosis, as determined by a formal clinical risk assessment tool.
&nbsp;
See the&nbsp;Clinical Considerations section&nbsp;for information on risk assessment.",None,Other,195,None,None,0,"risk factors for fractures include age, low body mass index, excessive alcohol consumption, current smoking, long-term corticosteroid use, previous fractures, and history of falls within the past year. &nbsp;Clinicians should note that the presence of a given risk factor or a certain age does not represent a particular risk threshold. Although the risk of osteoporosis and osteoporotic fractures generally increases with age, the presence of multiple risk factors at a younger age may indicate that the risk-benefit profile is favorable for screening with bone measurement testing.",None,None,None
353,Osteoporosis to Prevent Fractures:Screening -- Women 65 and Older,B,1,female,65,100,The USPSTF recommends screening for osteoporosis with bone measurement testing to prevent osteoporotic fractures in women 65 years and older.,None,Other,195,None,None,0,"risk factors for fractures include age, low body mass index, excessive alcohol consumption, current smoking, long-term corticosteroid use, previous fractures, and history of falls within the past year.&nbsp;",None,None,None
327,Preeclampsia: Screening- Pregnant Women,B,1,female,11,49,The USPSTF recommends screening for preeclampsia in pregnant women with blood pressure measurements throughout pregnancy.,"Blood pressure measurements should be obtained during each prenatal care visit throughout pregnancy. If a patient has an elevated blood pressure reading, the reading should be confirmed with repeated measurements. Further diagnostic evaluation and clinical monitoring are indicated for patients with elevated blood pressure on multiple measurements.",Pregnant,180,291,292,0,"All pregnant women are at risk for preeclampsia and should be screened. Important clinical conditions associated with increased risk for preeclampsia include a history of eclampsia or preeclampsia (particularly early-onset preeclampsia), a previous adverse pregnancy outcome, maternal comorbid conditions (including type 1 or 2 diabetes prior to pregnancy, gestational diabetes, chronic hypertension, renal disease, and autoimmune diseases), and multifetal gestation.4,&nbsp;9&nbsp;Other risk factors include nulliparity, obesity, African American race, low socioeconomic status, and advanced maternal age.4,&nbsp;9
In the United States, preeclampsia is more prevalent among African American women than among white women.&nbsp;",None,None,None
80,Rh(D) Blood Typing: Screening --  Antibody Testing Unsensitized Rh (D)-Negative Pregnant Women,B,0,female,11,49,"The USPSTF recommends repeated Rh (D) antibody testing for all unsensitized Rh (D)-negative women at 24-28 weeks gestation, unless the biological father is known to be Rh (D)-negative. ",Repeat testing at 24-28 weeks gestation.,Pregnant,38,None,None,0,None,"The USPSTF found fair evidence that repeated antibody testing for unsensitized Rh (D)-negative women (unless the father is also known to be Rh [D]-negative) and intervention with Rh (D) immunoglobulin, as appropriate, provides additional benefit over a single test at the first prenatal visit in preventing maternal sensitization and improving outcomes for newborns. The benefits of repeated testing substantially outweigh any potential harms. 
The USPSTF found no new evidence addressing the role of screening, new screening tests, new treatment protocols, or potential harms associated with screening and treatment of Rh (D) incompatibility. However, there is pre-existing good evidence for the efficacy and effectiveness of blood typing, anti-Rh (D) antibody screening, and postpartum Rh (D) immunoglobulin prophylaxis. 

",None,None
280,Sexually Transmitted Infections: Behavioral Counseling -- Sexually Active Adolescents and Adults,B,1,men and women,12,100,The USPSTF recommends intensive behavioral counseling for all sexually active adolescents and for adults who are at increased risk for sexually transmitted infections (STIs).,None,Sexually Active,151,243,244,0,"All sexually active adolescents are at increased risk for STIs and should be counseled. Other risk groups that have been included in counseling studies include adults with current STIs or other infections within the past year, adults who have multiple sex partners, and adults who do not consistently use condoms. Clinicians should be aware of populations with a particularly high prevalence of STIs. African Americans have the highest STI prevalence of any racial/ethnic group, and STI prevalence is higher in American Indians, Alaska Natives, and Latinos than in white persons. Increased STI prevalence rates are also found in men who have sex with men (MSM), persons with low incomes living in urban settings, current or former inmates, military recruits, persons who exchange sex for money or drugs, persons with mental illness or a disability, current or former intravenous drug users, persons with a history of sexual abuse, and patients at public STI clinics.",None,None,None
340,"Skin Cancer Prevention: Behavioral Counseling --Young adults, adolescents, children, and parents of young children",B,1,unspecified,0,24,"The USPSTF recommends counseling young adults, adolescents, children, and parents of young children about minimizing exposure to ultraviolet (UV) radiation for persons aged 6 months to 24 years with fair skin types to reduce their risk of skin cancer.",None,Other,190,308,None,0,Fair skin types,None,None,None
319,"Statin Use for the Primary Prevention of CVD: Preventive Medicine -- Adults age 40 to 75 years with no history of CVD, 1 or more CVD risk factors, and a calculated 10-year CVD event risk of 10% or greater.",B,1,men and women,40,75,"The USPSTF recommends that adults without a history of cardiovascular disease (CVD) (ie, symptomatic coronary artery disease or ischemic stroke) use a low- to moderate-dose statin for the prevention of CVD events and mortality when all of the following criteria are met: 1) they are aged 40 to 75 years; 2) they have 1 or more CVD risk factors (ie, dyslipidemia, diabetes, hypertension, or smoking); and 3) they have a calculated 10-year risk of a cardiovascular event of 10% or greater.
Identification of dyslipidemia and calculation of 10-year CVD event risk requires universal lipids screening in adults aged 40 to 75 years.
Considerations for Implementation 
To determine whether a patient is a candidate for statin therapy, clinicians must first determine the patient&rsquo;s risk of having a future CVD event. However, clinicians&rsquo; ability to accurately identify a patient&rsquo;s true risk is imperfect, because the best currently available risk estimation tool, which uses the Pooled Cohort Equations from the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines on the assessment of cardiovascular risk,1 has been shown to overestimate actual risk in multiple external validation cohorts.2-4 The reasons for this possible overestimation are still unclear. The Pooled Cohort Equations were derived from prospective cohorts of volunteers from studies conducted in the 1990s and may not be generalizable to a more contemporary and diverse patient population seen in current clinical practice. Furthermore, no statin clinical trials enrolled patients based on a specific risk threshold calculated using a CVD risk prediction tool; rather, patients had 1 or more CVD risk factors other than age and sex as a requirement for trial enrollment.
Because the Pooled Cohort Equations lack precision, the risk estimation tool should be used as a starting point to discuss with patients their desire for lifelong statin therapy. The likelihood that a patient will benefit from statin use depends on his or her absolute baseline risk of having a future CVD event, a risk estimation that is imprecise based on the currently available risk estimation tool. Thus, clinicians should discuss with patients the potential risk of having a CVD event and the expected benefits and harms of statin use. Patients who place a higher value on the potential benefits than on the potential harms and inconvenience of taking a daily medication may choose to initiate statin use for reduction of CVD risk. The USPSTF has made several other recommendations relevant to the prevention of CVD in adults (see the &ldquo;Other Approaches to Prevention&rdquo; section).
Patient Population Under Consideration 
These recommendations apply to adults 40 years and older without a history of CVD who do not have current signs and symptoms of CVD (ie, symptomatic coronary artery disease or ischemic stroke). Some individuals in this group may have undetected, asymptomatic atherosclerotic changes; for the purposes of this recommendation statement, the USPSTF considers these persons to be candidates for primary prevention interventions. These recommendations do not apply to adults with a low-density lipoprotein cholesterol (LDL-C) level greater than 190 mg/dL (to convert LDL-C values to mmol/L, multiply by 0.0259) or known familial hypercholesterolemia; these persons are considered to have very high cholesterol levels and may require statin use.",None,Other,174,285,None,0,"Adults meeting the following criteria are at increased risk: 1) they are aged 40 to 75 years; 2) they have 1 or more CVD risk factors (ie, dyslipidemia, diabetes, hypertension, or smoking); and 3) they have a calculated 10-year risk of a cardiovascular event of 10% or greater.
Risk Factors for CVD
For the purposes of this recommendation, dyslipidemia is defined as an LDL-C level greater than 130 mg/dL or a high-density lipoprotein cholesterol (HDL-C) level less than 40 mg/dL (to convert HDL-C values to mmol/L, multiply by 0.0259). Most participants enrolled in trials of statin use for the prevention of CVD had an LDL-C level of 130 to 190 mg/dL or a diabetes diagnosis; hypertension and smoking were also common among trial participants.6 Persons with an LDL-C level greater than 190 mg/dL were usually excluded from trial participation, as it was not considered appropriate to randomly assign them to placebo. Thus, these recommendations do not pertain to persons with very high cholesterol levels (ie, LDL-C &gt;190 mg/dL) or familial hypercholesterolemia, as they were excluded from most prevention trials.",None,None,None
241,Tobacco Use: Primary Care Interventions -- Children and Adolescents,B,0,men and women,10,17,"The USPSTF recommends that primary care clinicians provide interventions, including education or brief counseling, to prevent initiation of tobacco use among school-aged children and adolescents.",None,None,131,195,196,0,None,"Importance
Tobacco use is the leading cause of preventable death in the United States. An estimated 443,000 deaths occur annually that are attributable to smoking, including nearly 161,000 deaths from cancer, 128,000 from cardiovascular diseases, and 103,000 from respiratory diseases. Smoking costs the United States approximately $96 billion each year in direct medical costs and $97 billion from productivity losses due to premature death.
Recognition of Behavior
A person's path to daily smoking and nicotine dependence can be described in 5 stages: susceptible to smoking (never smoked); initiation (trying the first cigarette); experimentation (repeatedly trying cigarettes, may show signs of addiction); established smoking (regular smoking, likely to show signs of addiction); and nicotine dependence.Children are susceptible to smoking experimentation and initiation. It can take up to 2 years to progress from early experimentation to addiction, although some children and adolescents progress more rapidly to nicotine dependence.
Effectiveness of Interventions to Change Behavior
The USPSTF found adequate evidence that behavioral counseling interventions, such as face-to-face or phone interaction with a health care provider, print materials, and computer applications, can reduce the risk of smoking initiation in school-aged children and adolescents.
Harms of Interventions to Change Behavior
The USPSTF found no evidence on the harms of behavioral interventions to prevent tobacco use; however, the magnitude of these potential harms is probably small to none.
USPSTF Assessment
The USPSTF concludes with moderate certainty that primary care&ndash;relevant behavioral interventions to prevent tobacco use in school-aged children and adolescents have a moderate net benefit.",None,None
331,Vision in Children: Screening-- 3 - 5 years,B,1,men and women,3,5,The USPSTF recommends vision screening at least once in all children aged 3 to 5 years to detect amblyopia or its risk factors.,Recommends vision screening at least once in all children aged 3 to 5 years to detect amblyopia or its risk factor.,Other,184,296,None,0,"Risk factors for amblyopia include strabismus; high, uncorrected refractive errors (eg, myopia, hyperopia, and astigmatism); anisometropia; and media opacity.1-3&nbsp;Additional risk factors associated with amblyopia, strabismus, or refractive errors include family history in a first-degree relative, prematurity, low birth weight, maternal substance abuse, maternal smoking during pregnancy, and low levels of parental education.1,&nbsp;8-13",None,None,None
273,Abdominal Aortic Aneurysm: Screening -- Women Who Have Never Smoked,D,1,female,50,100,The USPSTF recommends against routine screening for AAA in women who have never smoked.,None,None,145,231,232,0,None,"Importance
Abdominal aortic aneurysms are typically defined by an aortic diameter of 3.0 cm or larger. Population-based studies in adults older than 50 years have found that the prevalence of AAA is 3.9% to 7.2% in men and 1.0% to 1.3% in women. It is important to consider potential screening strategies for AAA because most AAAs are asymptomatic until they rupture. Although the risk for rupture varies greatly by aneurysm size, the associated risk for death is as high as 75% to 90%.
Detection
Evidence is adequate that ultrasonography is a safe and accurate screening test for AAA.
Benefits of Detection and Early Treatment
Men Ages 65 to 75 Years Who Have Ever Smoked
Four large, population-based, randomized, controlled trials (RCTs) show that invitation to one-time screening for AAA is associated with reduced AAA-specific mortality in men. This benefit begins 3 years after testing and persists up to 15 years. In addition, risk reduction for AAA rupture and emergency surgery persists up to 10 to 13 years. In the two highest-quality trials, the relative reduction in AAA-specific mortality after 13 years was 42% to 66%. In the largest trial, where prevalence of AAA was approximately 5% in the screened group, screening was associated with an absolute risk reduction in AAA death of 1.4 per 1,000 men. Abdominal aortic aneurysms are most prevalent in men who have ever smoked, occurring in approximately 6% to 7% of this population. This prevalence increases the importance of screening in these men because it maximizes the absolute benefit that could be achieved (that is, it improves the likelihood that men in this group will benefit from screening). Convincing evidence shows that one-time screening for AAA with ultrasonography results in a moderate benefit in men ages 65 to 75 years who have ever smoked.
Men Ages 65 to 75 Years Who Have Never Smoked
Screening men overall reduces AAA-specific death, rupture, and emergency surgery. However, the lower prevalence of AAA in men who have never smoked (approximately 2%) substantially reduces the absolute benefit (that is, it greatly lowers the probability that men in this group will benefit from screening). Adequate evidence shows that one-time screening for AAA with ultrasonography results in a small benefit in men ages 65 to 75 years who have never smoked.
Women Ages 65 to 75 Years Who Have Ever Smoked
Only one RCT on screening for AAA included women. It detected no difference in the rate of AAA rupture, AAA-specific mortality, or all-cause mortality between women invited for screening and the control group. However, the trial was ultimately underpowered to detect differences in health outcomes by sex; as such, the results do not rule out the possibility of a small benefit of screening in this population. Women age 70 years who have ever smoked have a relatively low prevalence of AAA (approximately 0.8% overall and about 2% for current smokers). Evidence is inadequate to conclude whether one-time screening for AAA with ultrasonography is beneficial in women ages 65 to 75 years who have ever smoked.
Women Who Have Never Smoked
The prevalence of AAA in women who have never smoked is low (0.03% to 0.60% in women ages 50 to 79 years). The evidence also shows no apparent benefit of screening for AAA in women. The USPSTF therefore concludes that adequate evidence shows that the absolute benefit of one-time screening for AAA with ultrasonography in women who have never smoked can effectively be bounded at none or almost none.
Harms of Detection and Early Treatment
In the available trials, groups invited to screening were approximately twice as likely as control groups to have any AAA surgery within 3 to 5 years, predominantly driven by an increase in elective surgeries. More than 90% of AAAs identified by screening were below the 5.5-cm threshold for immediate repair. Detecting smaller AAAs generally leads to long-term (potentially lifelong) surveillance. A person's risk for death related to elective surgery for AAA is lower than that for death related to emergency surgery for AAA rupture. However, the increase in the overall rates of detection and surgery in the screening groups still potentially represents a harm. A proportion of AAAs will never rupture because they do not advance to conditions for the rupture to appear or because a person dies of a competing cause. The exact extent of overdiagnosis and overtreatment is difficult to estimate. One study from Massachusetts General Hospital reviewed 24,000 consecutive autopsies between 1952 and 1975 and found that 75% of the 473 patients who died with an undetected or unoperated AAA had a cause of death not related to the AAA (41% of AAAs were &gt;5.1 cm in diameter). Given that even elective treatment of AAA is associated with some risk for perioperative mortality, overtreatment is an important issue to consider when deciding whether to screen for this condition. One study reported that women had a higher risk for death related to AAA surgery than men; death rates of women and men were approximately 7% versus 5% for open repair and 2% versus 1% for endovascular repair, respectively. Evidence is limited and conflicting about the effect of screening for AAA on quality of life or psychological status (for example, anxiety). Convincing evidence shows that the harms associated with one-time screening for AAA with ultrasonography are at least small in all populations and potentially higher in women because of their higher risk for operative mortality.
USPSTF Assessment
The USPSTF concludes with high certainty that screening for AAA with ultrasonography in men ages 65 to 75 years who have ever smoked has a moderate net benefit. The USPSTF concludes with moderate certainty that screening for AAA with ultrasonography in men ages 65 to 75 years who have never smoked has a small net benefit. The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of screening for AAA in women ages 65 to 75 years who have ever smoked. The USPSTF concludes with moderate certainty that the harms of screening for AAA outweigh any potential benefits in women who have never smoked.",None,None
163,Asymptomatic Bacteriuria: Screening -- Men and Non-Pregnant Women,D,1,men and women,18,100,"The USPSTF recommends against screening for asymptomatic bacteriuria in men and nonpregnant women.
",None,None,90,105,None,0,None,None,None,None
253,"BRCA-Related Cancer: Risk Assessment, Genetic Counseling, &amp; Genetic Testing -- Women Not at Increased Risk",D,1,female,18,100,The USPSTF recommends against routine genetic counseling or BRCA testing for women whose family history is not associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2 genes.,"Consideration of screening for potentially harmful BRCA mutations should begin once women have reached the age of consent (18 years). Primary care providers should periodically assess all patients for changes in family history (for example, comprehensive review at least every 5 to 10 years).",None,134,202,203,0,"Mutations in the BRCA genes cluster in families, exhibiting an autosomal dominant pattern of transmission in maternal or paternal lineage. During standard elicitation of family history information from patients, primary care providers should ask about specific types of cancer, primary cancer sites, which family members were affected, relatives with multiple types of primary cancer, and the age at diagnosis and sex of affected family members.For women who have at least 1 family member with breast, ovarian, or other types of BRCA-related cancer, primary care providers may use 1 of several brief familial risk stratification tools to determine the need for in-depth genetic counseling. Although several risk tools are available, the tools evaluated by the USPSTF include the Ontario Family History Assessment Tool (Table 1), Manchester Scoring System (Table 2), Referral Screening Tool (Table 3), Pedigree Assessment Tool (Table 4), and FHS-7 (Table 5). The Referral Screening Tool (available at www.breastcancergenescreen.org) and FHS-7 are the simplest and quickest to administer. All of these tools seem to be clinically useful predictors of which women should be referred for genetic counseling due to increased risk for potentially harmful BRCA mutations (most sensitivity estimates were &gt;85%), although some models have been evaluated in only 1 study. To determine which patients would benefit from BRCA risk assessment, primary care providers should not use general breast cancer risk assessment models (for example, the National Cancer Institute Breast Cancer Risk Assessment Tool, which is based on the Gail model) because they are not designed to determine which women should receive genetic counseling or BRCA testing. In general, these tools elicit information about factors that are associated with increased likelihood of BRCA mutations. Family history factors associated with increased likelihood of potentially harmful BRCA mutations include breast cancer diagnosis before age 50 years, bilateral breast cancer, presence of breast and ovarian cancer, presence of breast cancer in 1 or more male family members, multiple cases of breast cancer in the family, 1 or more family members with 2 primary types of BRCA-related cancer, and Ashkenazi Jewish ethnicity. The USPSTF recognizes that each risk assessment tool has limitations and found insufficient comparative evidence to recommend one tool over another. The USPSTF also found insufficient evidence to support a specific risk threshold for referral for testing.","Importance
The cancer types related to potentially harmful mutations of the BRCA genes are predominantly breast, ovarian, and fallopian tube cancer, although other types are also associated. In the general population, 12.3% of women will develop breast cancer during their lifetime and 2.74% will die of the disease, whereas 1.4% of women will develop ovarian cancer and 1.0% will die of the disease. A woman's risk for breast cancer increases to 45% to 65% by age 70 years if there are clinically significant mutations in either BRCA gene. Mutations in the BRCA1 gene increase ovarian cancer risk to 39% by age 70 years, and BRCA2 mutations increase ovarian cancer risk to 10% to 17% by age 70 years. In the general population, these mutations occur in an estimated 1 in 300 to 500 women (0.2% to 0.3%). In a meta-analysis conducted for the USPSTF, the combined prevalence of BRCA1 and BRCA2mutations was 2.1% in a general population of Ashkenazi Jewish women.
Detection of Potentially Harmful BRCA Mutations
Genetic risk assessment and BRCA mutation testing is generally a multistep process involving identification of individuals who may be at increased risk for potentially harmful mutations, followed by genetic counseling from suitably trained health care providers and genetic testing of selected high-risk individuals when indicated. Several familial risk stratification tools are clinically useful for selecting patients who should be offered genetic counseling to further determine their candidacy for possible BRCA mutation testing.
Benefits of Testing for Potentially Harmful Mutations
For women whose family history is associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2 genes, adequate evidence suggests that the benefits of testing for potentially harmful BRCA mutations are moderate. For women whose family history is not associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2genes, there is adequate evidence that the benefits of testing for potentially harmful BRCA mutations are few to none.
Harms of Detection of Potentially Harmful BRCA Mutations and Early Intervention and Treatment
Adequate evidence suggests that the overall harms of detection of and early intervention for potentially harmful BRCA mutations are small to moderate.
USPSTF Assessment
For women whose family history is associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2 genes, there is moderate certainty that the net benefit of testing for potentially harmful BRCA mutations and early intervention is moderate. For women whose family history is not associated with an increased risk for potentially harmful mutations in the BRCA1 or BRCA2 genes, there is moderate certainty that the net benefit of testing for potentially harmful BRCA mutations and early intervention ranges from minimal to potentially harmful.",None,None
147,Bacterial Vaginosis in Pregnancy: Screening -- Asymptomatic pregnant women at low risk for preterm delivery,D,1,female,11,49,The USPSTF recommends against screening for bacterial vaginosis in asymptomatic pregnant women at low risk for preterm delivery.,None,Pregnant,83,104,None,0,None,None,None,None
127,"Blood Lead Levels: Screening -- Children 1-5, Average Risk",D,0,men and women,1,5,The USPSTF recommends against routine screening for elevated blood lead levels (BLLs) in asymptomatic children aged 1 to 5 years who are at average risk.,None,None,65,100,None,0,None,None,None,None
128,Blood Lead Levels: Screening -- Pregnant Women,D,0,female,11,49,The USPSTF recommends against routine screening for elevated blood lead levels (BLLs) in asymptomatic pregnant women.,None,Pregnant,65,None,None,0,"Risk factors for increased BLLs in children and adults include minority race/ethnicity; urban residence; low income; low educational attainment; older (pre-1950) housing; recent or ongoing home renovation or remodeling; pica exposure; use of ethnic remedies, certain cosmetics, and exposure to lead-glazed pottery; occupational and paraoccupational exposures; and recent immigration. ",None,None,None
251,Breast Cancer: Preventive Medications -- Women Not at Increased Risk,D,1,female,35,100,"The USPSTF recommends against the routine use of medications, such as tamoxifen or raloxifene, for risk reduction of primary breast cancer in women who are not at increased risk for breast cancer.&nbsp;",None,Other,133,200,201,0,"Assessment of Breast Cancer Risk
If a family history of breast cancer or a personal history of breast biopsy is found during the usual patient assessment, clinicians may consider further evaluation using a breast cancer risk assessment tool. Risk assessment tools specifically for family history of breast cancer are available elsewhere (www.uspreventiveservicestaskforce.org). The National Cancer Institute has developed a Breast Cancer Risk Assessment Tool (available at www.cancer.gov/bcrisktool) that is based on the Gail model and estimates the 5-year incidence of invasive breast cancer in women on the basis of characteristics entered into a risk calculator. This tool helps identify women who may be at increased risk for the disease. Other risk assessment models have been developed by the Breast Cancer Surveillance Consortium (BCSC), Rosner and Colditz, Chlebowski, Tyrer and Cuzick, and others. Examples of risk factors elicited by risk assessment tools include patient age, race or ethnicity, age at menarche, age at first live childbirth, personal history of DCIS or LCIS, number of first-degree relatives with breast cancer, personal history of breast biopsy, body mass index, menopause status or age, breast density, estrogen and progestin use, smoking, alcohol use, physical activity, and diet. These models are not recommended for use in women with a personal history of breast cancer, a history of radiation treatment to the chest, or a possible family history of mutations in the BRCA1 or BRCA2 genes. Only a small fraction of women are at increased risk for breast cancer. Most who are at increased risk will not develop the disease, and most cases will arise in women who are not identified as being at increased risk. Risk assessment should be repeated when there is a significant change in breast cancer risk factors. There is no single cutoff for defining increased risk. Most clinical trials defined increased risk as a 5-year risk for invasive breast cancer of 1.66% or greater, as determined by the BCPT (Breast Cancer Prevention Trial). At this cutoff, however, many women would not have a net benefit from risk-reducing medications. Freedman and colleagues developed risk tables that incorporate the BCPT estimate of a woman's breast cancer risk as well as her age, race or ethnicity, and presence of uterus. On the basis of the Freedman risk&ndash;benefit tables for women aged 50 years or older (Figures 2 to 5), the USPSTF concludes that many women with an estimated 5-year breast cancer risk of 3% or greater are likely to have more benefit than harm from using tamoxifen or raloxifene, although the balance depends on age, race or ethnicity, the medication used, and whether the patient has a uterus.
Assessment of Risk for Adverse Effects
In general, women taking medications for breast cancer risk reduction are less likely to experience a VTE if they are younger and have no other predisposition to thromboembolic events. Women with a personal or family history of venous thromboembolism are at higher risk for these adverse effects. Women without a uterus are not at risk for tamoxifen-related endometrial cancer. Women with a uterus should have a baseline gynecologic examination prior to starting tamoxifen, with regular followup after the end of treatment.","Importance
Breast cancer is the most common nonskin cancer in women. An estimated 232,340 new cases will be diagnosed in 2013, and 39,620 women will die of the disease. In the United States, mortality rates are highest among African American women. Screening for breast cancer may allow for early detection but does not prevent the development of the disease.Tamoxifen and raloxifene are selective estrogen receptor modulators that have been shown in randomized, controlled trials to reduce the risk for estrogen receptor (ER)&ndash;positive breast cancer. They have been approved by the U.S. Food and Drug Administration (FDA) for this indication.
Assessment of Breast Cancer Risk Status
Important risk factors for breast cancer include increasing age, family history of breast or ovarian cancer (especially among first-degree relatives and onset before age 50 years), history of atypical hyperplasia or other nonmalignant high-risk breast lesions, previous breast biopsy, and extremely dense breast tissue. A history of these or other risk factors (see the Clinical Considerations) may prompt clinicians to conduct a formal breast cancer risk assessment.Available risk assessment models can accurately estimate the number of breast cancer cases that may arise in certain study populations, but their ability to accurately predict which women will (and will not) develop the disease is modest. Only a small fraction of women are at increased risk for breast cancer; moreover, only a subset of those women will derive benefit from risk-reducing medications.Information about the validity, feasibility, and effect of using risk assessment models to identify appropriate candidates for risk-reducing medications in primary care settings is limited.
Potential Benefits of Medications for Breast Cancer Risk Reduction
The USPSTF found adequate evidence that treatment with tamoxifen or raloxifene can significantly reduce the relative risk (RR) for invasive ER-positive breast cancer in postmenopausal women who are at increased risk for breast cancer. A systematic review of clinical trials found that tamoxifen and raloxifene reduced the incidence of invasive breast cancer by 7 to 9 events per 1000 women over 5 years and that tamoxifen reduced breast cancer incidence more than raloxifene (Table). Tamoxifen also reduces the incidence of invasive breast cancer in premenopausal women who are at increased risk for the disease. Women who are at increased risk for breast cancer are more likely to benefit from risk-reducing medications. In general, women with an estimated 5-year risk of 3% or greater are, on the basis of model estimates (Figures 2 to 5), more likely to benefit from tamoxifen or raloxifene. The USPSTF found that the benefits of tamoxifen and raloxifene for breast cancer risk reduction are no greater than small in women who are not at increased risk for the disease.In addition to breast cancer risk reduction, the USPSTF found adequate evidence that tamoxifen and raloxifene reduce the risk for nonvertebral or vertebral fractures, respectively, in postmenopausal women.
Potential Harms of Medications for Breast Cancer Risk Reduction
The USPSTF found adequate evidence that tamoxifen and raloxifene increase risk for venous thromboembolic events (VTEs) by 4 to 7 events per 1000 women over 5 years and that tamoxifen increases risk more than raloxifene (Table). The USPSTF found that potential harms from thromboembolic events are small to moderate, with increased potential for harms in older women.The USPSTF also found adequate evidence that tamoxifen but not raloxifene increases risk for endometrial cancer (4 more cases per 1000 women). Potential harms from tamoxifen-related endometrial cancer are small to moderate and depend on hysterectomy status and age. The potential risks for tamoxifen-related harms are higher in women older than 50 years and in women with a uterus. Tamoxifen may also increase the incidence of cataracts.Vasomotor symptoms (hot flashes) are a common adverse effect of both medications that is not typically classified as serious, but these symptoms may affect a patient's quality of life and willingness to use or adhere to these medications.
USPSTF Assessment
The USPSTF concludes with moderate certainty that there is a moderate net benefit from use of tamoxifen and raloxifene to reduce the incidence of invasive breast cancer in women who are at increased risk for the disease. The USPSTF concludes with moderate certainty that the potential harms of tamoxifen and raloxifene outweigh the potential benefits for breast cancer risk reduction in women who are not at increased risk for the disease.",None,None
351,Cardiovascular Disease Risk With Electrocardiography: Screening Adults at low risk of CVD events,D,1,men and women,18,100,The USPSTF recommends against screening with resting or exercise electrocardiography (ECG) to prevent cardiovascular disease (CVD) events in asymptomatic adults at low risk of CVD events.,None,None,194,317,318,0,None,None,None,None
274,Carotid Artery Stenosis:  Screening -- Adults,D,1,men and women,18,100,The USPSTF recommends against screening for asymptomatic carotid artery stenosis in the general adult population.,None,None,146,233,234,0,"The major risk factors for carotid artery stenosis include older age, male sex, hypertension, smoking, hypercholesterolemia, diabetes mellitus, and heart disease. Despite evidence on important risk factors, there are no externally validated, reliable methods to determine who is at increased risk for carotid artery stenosis or for stroke when carotid artery stenosis is present.","Importance
Stroke is a leading cause of death and disability in the United States. Although asymptomatic carotid artery stenosis is a risk factor for stroke, it causes a relatively small proportion of strokes.
Detection
The most feasible screening test for carotid artery stenosis (defined as 60% to 99% stenosis) is ultrasonography. Although adequate evidence indicates that this test has high sensitivity and specificity, in practice, ultrasonography yields many false-positive results in the general population, which has a low prevalence of carotid artery stenosis (approximately 0.5% to 1%). There are no externally validated, reliable tools that can determine who is at increased risk for carotid artery stenosis or for stroke when carotid artery stenosis is present. Adequate evidence indicates that the accuracy of screening by auscultation of the neck is poor.
Benefits of Detection and Early Intervention
There is no direct evidence on the benefits of screening for carotid artery stenosis. Adequate evidence indicates that in selected trial participants with asymptomatic carotid artery stenosis, carotid endarterectomy (CEA) performed by selected surgeons reduces the absolute incidence of all strokes or perioperative death by approximately 3.5% compared with (outdated) medical management. However, this difference is probably smaller with current optimal medical management. The magnitude of these benefits would be smaller in asymptomatic persons in the general population. For the general primary care population, the magnitude of benefit is small to none. There is no evidence that identification of asymptomatic carotid artery stenosis leads to any benefit from adding or increasing medication doses (beyond current standard medical therapy for cardiovascular disease prevention).
Harms of Detection and Early Intervention
Adequate evidence indicates that both the testing strategy for carotid artery stenosis and treatment with CEA can cause harms. Although screening with ultrasonography has few direct harms, all screening strategies, including those with or without confirmatory tests (that is, digital subtraction or magnetic resonance angiography), have imperfect sensitivity and specificity and could lead to unnecessary interventions and result in serious harms. In selected centers similar to those in the trials, CEA is associated with a 30-day stroke or mortality rate of approximately 2.4%; reported rates are as high as approximately 5% in low-volume centers and 6% in certain states. Myocardial infarctions are reported in 0.8% to 2.2% of patients after CEA. The 30-day stroke or mortality rate after carotid angioplasty and stenting (CAAS) is approximately 3.1% to 3.8%. The overall magnitude of harms of screening and subsequent treatment of asymptomatic carotid artery stenosis is small to moderate depending on patient population, surgeon, center volume, and geographic location.
USPSTF Assessment
The USPSTF concludes with moderate certainty that the harms of screening for asymptomatic carotid artery stenosis outweigh the benefits.",None,None
211,Cervical Cancer: Screening -- HPV testing in women younger than age 30 years,D,1,female,13,29,"The USPSTF recommends against screening for cervical cancer with HPV testing, alone or in combination with cytology, in women younger than age 30 years.",None,Age,113,51,153,150,None,None,None,None
208,Cervical Cancer: Screening -- Women Younger than 21,D,1,female,13,20,The USPSTF recommends against screening for cervical cancer in women younger than age 21 years.,None,Age,113,153,150,0,There is adequate evidence that screening women younger than age 21 years (regardless of sexual history) does not reduce cervical cancer incidence and mortality compared with beginning screening at age 21 years.,None,None,None
209,Cervical Cancer: Screening -- Women older than age 65 and who have had adequate prior screening,D,1,female,66,100,The USPSTF recommends against screening for&nbsp,cervical cancer in women older than age 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer.,Age,,113,150,153,51,There is adequate evidence that screening women older than age 65 years who have had adequate prior screening and are not otherwise at high risk provides little to no benefits.,None,None
210,Cervical Cancer: Screening --Women who have had a hysterectomy,D,1,female,21,100,The USPSTF recommends against screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and who do not have a history of a high-grade precancerous lesion (cervical intraepithelial neoplasia [CIN] grade 2 or 3) or cervical cancer.&nbsp,None,Age,,113,153,150,51,There is convincing evidence that continued screening after hysterectomy with removal of the cervix for indications other than a high-grade precancerous lesion or cervical cancer provides no benefits.,None,None
307,Chronic Obstructive Pulmonary Disease: Screening --Asymptomatic adults,D,1,men and women,18,100,The USPSTF recommends against screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults.,None,None,164,276,277,0,None,None,None,None
345,"Falls Prevention in Community-Dwelling Older Adults, Interventions --Adults 65 years or older",D,1,men and women,65,100,The USPSTF recommends against vitamin D supplementation to prevent falls in community-dwelling adults 65 years or older.,None,None,191,311,310,0,None,None,None,None
322,"Genital Herpes Infection: Serologic Screening --Asymptomatic adolescents and adults, including those who are pregnant",D,1,men and women,11,100,"The USPSTF recommends against routine serologic screening for genital herpes simplex virus (HSV) infection in asymptomatic adolescents and adults, including those who are pregnant.",None,None,175,286,None,0,None,None,None,None
334,Hormone Therapy in Postmenopausal Women : Preventive Medications --Postmenopausal women,D,1,female,50,100,The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal women.,None,None,186,298,None,0,This recommendation statement applies to an average-risk population. Risk factors for a specific chronic condition or individual characteristics that affect the likelihood of experiencing a specific therapy-associated adverse event may cause a woman&rsquo,s net balance of benefits and harms to differ from that of the average population.,None,None
335,Hormone Therapy in Postmenopausal Women: Preventive Medications -- Postmenopausal women who have had a hysterectomy,D,1,female,50,100,The USPSTF recommends against the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal women who have had a hysterectomy.,None,None,186,298,None,0,None,None,None,None
338,Ovarian Cancer: Screening --Asymptomatic women,D,1,female,45,100,"The USPSTF recommends against screening for ovarian cancer in asymptomatic women.
This recommendation applies to asymptomatic women who are not known to have a high-risk hereditary cancer syndrome.",None,None,189,176,306,0,None,None,None,None
83,"Pancreatic Cancer: Screening -- Adults, Asymptomatic",D,0,men and women,18,100,"The USPSTF recommends against routine screening for pancreatic cancer in asymptomatic adults using abdominal palpation, ultrasonography, or serologic markers. ",None,None,41,None,None,0,None,"The USPSTF found no evidence that screening for pancreatic cancer is effective in reducing mortality. There is a potential for significant harm due to the very low prevalence of pancreatic cancer, limited accuracy of available screening tests, the invasive nature of diagnostic tests, and the poor outcomes of treatment. As a result, the USPSTF concluded that the harms of screening for pancreatic cancer exceed any potential benefits.
",None,None
350,Prostate Cancer: Screening --Men 70 years and older,D,1,male,70,99,The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older.,None,None,193,316,314,0,None,None,None,None
204,Testicular Cancer: Screening -- Adolescent and Adult Men,D,1,male,18,100,The USPSTF recommends against screening for testicular cancer in adolescent or adult males. ,None,None,110,141,142,0,None,None,None,None
328,Thyroid Cancer: Screening -- Adults,D,1,men and women,18,100,The USPSTF recommends against screening for thyroid cancer in asymptomatic adults. (D recommendation),None,None,181,293,None,0,None,None,None,None
348,"Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication --Postmenopausal women",D,1,female,40,100,"The USPSTF recommends against daily supplementation with 400 IU or less of vitamin D and 1000 mg or less of calcium for the primary prevention of fractures in community-dwelling, postmenopausal women.",None,None,192,312,313,0,None,None,None,None
261,Vitamin Supplements for the Prevention of Cardiovascular Disease and Cancer: &beta,D,1,men and women,50,100,100,The USPSTF recommends against the use of &beta,None,139,None,None,139,214,215,None,None
270,Abdominal Aortic Aneurysm:  Screening -- Men Ages 65 to 75 Year Who Have Never Smoked,C,1,male,65,75,"The USPSTF recommends that clinicians selectively offer screening for AAA in men ages 65 to 75 years who have never smoked rather than routinely screening all men in this group. Evidence indicates that the net benefit of screening all men ages 65 to 75 years who have never smoked is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the balance of benefits and harms on the basis of evidence relevant to the patient's medical history, family history, other risk factors, and personal values.",None,None,145,231,232,0,"Despite the demonstrated benefits of screening for AAA in men overall, the lower prevalence of AAA in male never-smokers versus male ever-smokers suggests that clinicians should consider a patient's risk factors and the potential for harm before screening for AAA rather than routinely offering screening to all male never-smokers. Important risk factors for AAA include older age and a first-degree relative with an AAA; other risk factors include a history of other vascular aneurysms, coronary artery disease, cerebrovascular disease, atherosclerosis, hypercholesterolemia, obesity, and hypertension. Factors associated with a reduced risk for AAA include African American race, Hispanic ethnicity, and diabetes.","Importance
Abdominal aortic aneurysms are typically defined by an aortic diameter of 3.0 cm or larger. Population-based studies in adults older than 50 years have found that the prevalence of AAA is 3.9% to 7.2% in men and 1.0% to 1.3% in women. It is important to consider potential screening strategies for AAA because most AAAs are asymptomatic until they rupture. Although the risk for rupture varies greatly by aneurysm size, the associated risk for death is as high as 75% to 90%.
Detection
Evidence is adequate that ultrasonography is a safe and accurate screening test for AAA.
Benefits of Detection and Early Treatment
Men Ages 65 to 75 Years Who Have Ever Smoked
Four large, population-based, randomized, controlled trials (RCTs) show that invitation to one-time screening for AAA is associated with reduced AAA-specific mortality in men. This benefit begins 3 years after testing and persists up to 15 years. In addition, risk reduction for AAA rupture and emergency surgery persists up to 10 to 13 years.In the two highest-quality trials, the relative reduction in AAA-specific mortality after 13 years was 42% to 66%. In the largest trial, where prevalence of AAA was approximately 5% in the screened group, screening was associated with an absolute risk reduction in AAA death of 1.4 per 1,000 men.Abdominal aortic aneurysms are most prevalent in men who have ever smoked, occurring in approximately 6% to 7% of this population. This prevalence increases the importance of screening in these men because it maximizes the absolute benefit that could be achieved (that is, it improves the likelihood that men in this group will benefit from screening). Convincing evidence shows that one-time screening for AAA with ultrasonography results in a moderate benefit in men ages 65 to 75 years who have ever smoked.
Men Ages 65 to 75 Years Who Have Never Smoked
Screening men overall reduces AAA-specific death, rupture, and emergency surgery. However, the lower prevalence of AAA in men who have never smoked (approximately 2%)&nbsp;substantially reduces the absolute benefit (that is, it greatly lowers the probability that men in this group will benefit from screening). Adequate evidence shows that one-time screening for AAA with ultrasonography results in a small benefit in men ages 65 to 75 years who have never smoked.
Women Ages 65 to 75 Years Who Have Ever Smoked
Only one RCT on screening for AAA included women. It detected no difference in the rate of AAA rupture, AAA-specific mortality, or all-cause mortality between women invited for screening and the control group. However, the trial was ultimately underpowered to detect differences in health outcomes by sex; as such, the results do not rule out the possibility of a small benefit of screening in this population.Women age 70 years who have ever smoked have a relatively low prevalence of AAA (approximately 0.8% overall and about 2% for current smokers) (9). Evidence is inadequate to conclude whether one-time screening for AAA with ultrasonography is beneficial in women ages 65 to 75 years who have ever smoked.
Women Who Have Never Smoked
The prevalence of AAA in women who have never smoked is low (0.03% to 0.60% in women ages 50 to 79 years). The evidence also shows no apparent benefit of screening for AAA in women. The USPSTF therefore concludes that adequate evidence shows that the absolute benefit of one-time screening for AAA with ultrasonography in women who have never smoked can effectively be bounded at none or almost none.Harms of Detection and Early Treatment In the available trials, groups invited to screening were approximately twice as likely as control groups to have any AAA surgery within 3 to 5 years, predominantly driven by an increase in elective surgeries. More than 90% of AAAs identified by screening were below the 5.5-cm threshold for immediate repair. Detecting smaller AAAs generally leads to long-term (potentially lifelong) surveillance.A person's risk for death related to elective surgery for AAA is lower than that for death related to emergency surgery for AAA rupture. However, the increase in the overall rates of detection and surgery in the screening groups still potentially represents a harm. A proportion of AAAs will never rupture because they do not advance to conditions for the rupture to appear or because a person dies of a competing cause.The exact extent of overdiagnosis and overtreatment is difficult to estimate. One study from Massachusetts General Hospital reviewed 24,000 consecutive autopsies between 1952 and 1975 and found that 75% of the 473 patients who died with an undetected or unoperated AAA had a cause of death not related to the AAA (41% of AAAs were &gt;5.1 cm in diameter). Given that even elective treatment of AAA is associated with some risk for perioperative mortality, overtreatment is an important issue to consider when deciding whether to screen for this condition.One study reported that women had a higher risk for death related to AAA surgery than men; death rates of women and men were approximately 7% versus 5% for open repair and 2% versus 1% for endovascular repair, respectively. Evidence is limited and conflicting about the effect of screening for AAA on quality of life or psychological status (for example, anxiety). Convincing evidence shows that the harms associated with one-time screening for AAA with ultrasonography are at least small in all populations and potentially higher in women because of their higher risk for operative mortality.
USPSTF Assessment
The USPSTF concludes with high certainty that screening for AAA with ultrasonography in men ages 65 to 75 years who have ever smoked has a moderate net benefit.The USPSTF concludes with moderate certainty that screening for AAA with ultrasonography in men ages 65 to 75 years who have never smoked has a small net benefit.The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of screening for AAA in women ages 65 to 75 years who have ever smoked.The USPSTF concludes with moderate certainty that the harms of screening for AAA outweigh any potential benefits in women who have never smoked.",None,None
304,Aspirin Use to Prevent CVD and CRC: Preventive Medication --Adults aged 60 to 69 years with a &ge,C,1,men and women,60,69,"""The decision to initiate low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 60 to 69 years who have a 10% or greater 10-year CVD risk should be an individual one. Persons who are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years are more likely to benefit. Persons who place a higher value on the potential benefits than the potential harms may choose to initiate low-dose aspirin.""69","The decision to initiate low-dose aspirin use for the primary prevention of CVD and CRC in adults aged 60 to 69 years who have a 10% or greater 10-year CVD risk should be an individual one. Persons who are not at increased risk for bleeding, have a life expectancy of at least 10 years, and are willing to take low-dose aspirin daily for at least 10 years are more likely to benefit. Persons who place a higher value on the potential benefits than the potential harms may choose to initiate low-dose aspirin.",Other,163,274,275,0,None,"Risk assessment for CVD should include ascertainment of the following risk factors: age, sex, race/ethnicity, total cholesterol level, high-density lipoprotein cholesterol level, systolic blood pressure, hypertension treatment, diabetes, and smoking. An online version of the ACC/AHA risk calculator can be found athttp://tools.acc.org/ASCVD-Risk-Estimator/.  Risk factors for gastrointestinal (GI) bleeding with aspirin use include higher dose and longer duration of use, history of GI ulcers or upper GI pain, bleeding disorders, renal failure, severe liver disease, and thrombocytopenia. Other factors that increase risk for GI or intracranial bleeding with low-dose aspirin use include concurrent anticoagulation or nonsteroidal anti-inflammatory drug (NSAID) use, uncontrolled hypertension, male sex, and older age.4,&nbsp;5  This recommendation applies to adults who are at increased CVD risk and at average risk for CRC. Persons who are at increased CVD risk and are known to be at increased risk for CRC (for example, persons with a family or personal history of CRC or familial adenomatous polyposis)6 should consult their health care provider.",None,None
295,Breast Cancer: Screening with Mammography-- Women aged 40 to 49 years,C,1,female,40,49,"The decision to start screening mammography in women prior to age 50 years should be an individual one. Women who place a higher value on the potential benefit than the potential harms may choose to begin biennial screening between the ages of 40 and 49 years. &bull;&nbsp;&nbsp; For women who are at average risk for breast cancer, most of the benefit of mammography results from biennial screening during ages 50 to 74 years. Of all of the age groups, women aged 60 to 69 years are most likely to avoid breast cancer death through mammography screening. While screening mammography in women aged 40 to 49 years may reduce the risk for breast cancer death, the number of deaths averted is smaller than that in older women and the number of false-positive results and unnecessary biopsies is larger. The balance of benefits and harms is likely to improve as women move from their early to late 40s. &bull;&nbsp;&nbsp; In addition to false-positive results and unnecessary biopsies, all women undergoing regular screening mammography are at risk for the diagnosis and treatment of noninvasive and invasive breast cancer that would otherwise not have become a threat to their health, or even apparent, during their lifetime (known as &ldquo;overdiagnosis&rdquo;). Beginning mammography screening at a younger age and screening more frequently may increase the risk for overdiagnosis and subsequent overtreatment. &bull;&nbsp;&nbsp; Women with a parent, sibling, or child with breast cancer are at higher risk for breast cancer and thus may benefit more than average-risk women from beginning screening in their 40s. Go to the&nbsp;Clinical Considerations section&nbsp;for information on implementation of the C recommendation. *The Department of Health and Human Services, in implementing the Affordable Care Act under the standard it sets out in revised Section 2713(a)(5) of the Public Health Service Act, utilizes the 2002 recommendation on breast cancer screening of the USPSTF. &nbsp;In 2015, Congress enacted separate legislation as part of the Comprehensive Omnibus Funding law that ensured this provision remains in effect. This recommendation states: The USPSTF recommends screening mammography, with or without clinical breast examination (CBE), every 1-2 years for women aged 40 and older (B recommendation). &nbsp;We provide this information here to help primary care providers understand the implications this may have on co-payments and coverage related to screening patients for breast cancer.",See Clinical Considerations,Age,159,263,266,0,"Advancing age is the most important risk factor for breast cancer in most women, but epidemiologic data from the BCSC suggest that having a first-degree relative with breast cancer is associated with an approximately 2-fold increased risk for breast cancer in women aged 40 to 49 years.2, 9 Further, the CISNET models suggest that for women with about a 2-fold increased risk for breast cancer, starting annual digital screening at age 40 years results in a similar harm-to-benefit ratio (based on number of false-positive results or overdiagnosed cases per 1000 breast cancer deaths avoided) as beginning biennial digital screening at age 50 years in average-risk women.7, 8 This approach has not been formally tested in a clinical trial; therefore, there is no direct evidence that it would result in net benefit similar to that of women aged 50 to 74 years. However, given the increased burden of disease and potential likelihood of benefit, women aged 40 to 49 years who have a known first-degree relative (parent, child, or sibling) with breast cancer may consider initiating screening earlier than age 50 years. Many other risk factors have been associated with breast cancer in epidemiologic studies, but most of these relationships are weak or inconsistent and would not likely influence how women value the tradeoffs of the potential benefits and harms of screening. Risk calculators, such as the National Cancer Institute&rsquo;s Breast Cancer Risk Assessment Tool (available at www.cancer.gov/BCRISKTOOL<a href=""http://www.uspreventiveservicestaskforce.org/Page/Name/exit-disclaimer"" title=""This link goes offsite.
Click to read the external link disclaimer"" class=""extLink"">This link goes offsite. Click to read the external link disclaimer), have good calibration between predicted and actual outcomes in groups of women but are not accurate at predicting an individual woman&rsquo;s risk for breast cancer.10",None,None,None
310,Colorectal Cancer: Screening --Adults aged 76 to 85 years,C,1,men and women,76,85,"The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient&rsquo;s overall health and prior screening history.

Adults in this age group who have never been screened for colorectal cancer are more likely to benefit.
Screening would be most appropriate among adults who 1) are healthy enough to undergo treatment if colorectal cancer is detected and 2) do not have comorbid conditions that would significantly limit their life expectancy
","Evidence from RCTs demonstrates that annual or biennial screening with gFOBT as well as 1-time and every 3- to 5-year flexible sigmoidoscopy reduces colorectal cancer deaths.1&nbsp;The CISNET models found that several screening strategies were estimated to yield comparable life-years gained (ie, life-years gained with the noncolonoscopy strategies were within 90% of those gained with the colonoscopy strategy) among adults aged 50 to 75 years and an efficient balance of benefits and harms (see the full CISNET report for more details2,&nbsp;12). These screening strategies include 1) annual screening with FIT, 2) screening every 10 years with flexible sigmoidoscopy and annual screening with FIT, 3) screening every 10 years with colonoscopy, and 4) screening every 5 years with CT colonography. The findings for CT colonography depend on the proxy measure used for the burden of screening (number of lifetime colonoscopies or lifetime cathartic bowel preparations). Two of the 3 CISNET models found that FIT-DNA screening every 3 years (as recommended by the manufacturer) was estimated to yield life-years gained less than 90% of the colonoscopy screening strategy (84% and 87%, respectively). Another way to conceptualize these findings is to note that CISNET modeling found that FIT-DNA screening every 3 years was estimated to provide about the same amount of benefit as screening with flexible sigmoidoscopy alone every 5 years (Figure).2The&nbsp;Table&nbsp;lists the various screening tests for colorectal cancer and notes potential frequency of use as well as additional considerations for each method. The&nbsp;Figure&nbsp;presents the estimated number of life-years gained, colorectal cancer deaths averted, lifetime colonoscopies required, and resulting complications per 1,000 screened adults aged 50 to 75 years for each of the screening strategies. These estimates are derived from modeling conducted by the Cancer Intervention and Surveillance Modeling Network (CISNET) to inform this recommendation.2,&nbsp;12",Age,166,None,None,0,"For the vast majority of adults, the most important risk factor for colorectal cancer is older age. Most cases of colorectal cancer occur among adults older than 50 years; the median age at diagnosis is 68 years.3A positive family history (excluding known inherited familial syndromes) is thought to be linked to about 20% of cases of colorectal cancer.1&nbsp;About 3% to 10% of the population has a first-degree relative with colorectal cancer.7&nbsp;The USPSTF did not specifically review the evidence on screening in populations at increased risk; however, other professional organizations recommend that patients with a family history of colorectal cancer (a first-degree relative with early-onset colorectal cancer or multiple first-degree relatives with the disease) be screened more frequently starting at a younger age, and with colonoscopy.8Male sex and black race are also associated with higher colorectal cancer incidence and mortality. Black adults have the highest incidence and mortality rates compared with other racial/ethnic subgroups.3&nbsp;The reasons for these disparities are not entirely clear. Studies have documented inequalities in screening, diagnostic follow-up, and treatment; they also suggest that equal treatment generally seems to produce equal outcomes.9-11&nbsp;Accordingly, this recommendation applies to all racial/ethnic groups, with the clear acknowledgement that efforts are needed to ensure that at-risk populations receive recommended screening, follow-up, and treatment.",None,None,None
344,Falls Prevention in Community-Dwelling Older Adults: Interventions --Adults 65 years or older,C,1,men and women,65,100,The USPSTF recommends that clinicians selectively offer multifactorial interventions to prevent falls to community-dwelling adults 65 years or older who are at increased risk for falls.,None,Other,191,309,310,0,At increased risk for falls.,None,None,None
330,Healthful Diet and Physical Activity: Behavioral Counseling -- Adults without obesity who do not have known cardiovascular disease risk factors,C,1,men and women,18,100,"The USPSTF recommends that primary care professionals individualize the decision to offer or refer adults without obesity who do not have hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes to behavioral counseling to promote a healthful diet and physical activity. Existing evidence indicates a positive but small benefit of behavioral counseling for the prevention of cardiovascular disease (CVD) in this population. Persons who are interested and ready to make behavioral changes may be most likely to benefit from behavioral counseling.
&nbsp;
See the ""Useful Resources"" section for more information on how this recommendation fits into the USPSTF&rsquo;s suite of recommendations on CVD prevention.",See Clinical Considerations,Other,183,None,None,0,"common risk factors for CVD (hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes)",None,None,None
349,Prostate Cancer: Screening --men aged 55 to 69 years,C,1,male,55,69,"For men aged 55 to 69 years, the decision to undergo periodic prostate-specific antigen (PSA)&ndash;based screening for prostate cancer should be an individual one. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision.",None,None,193,316,314,0,None,None,None,None
341,Skin Cancer Prevention: Behavioral Counseling --Adults older than 24 years with fair skin types,C,1,unspecified,25,100,"The USPSTF recommends that clinicians selectively offer counseling to adults older than 24 years with fair skin types about minimizing their exposure to UV radiation to reduce risk of skin cancer. Existing evidence indicates that the net benefit of counseling all adults older than 24 years is small.&nbsp;In determining whether counseling is appropriate in individual cases, patients and clinicians should consider the presence of risk factors for skin cancer.
&nbsp;",None,Other,190,308,None,0,"Persons with fair skin types (ivory or pale skin, light eye color, red or blond hair, freckles, those who sunburn easily) are at increased risk of skin cancer and should be counseled. Other factors that further increase risk include a history of sunburns, previous use of indoor tanning beds, and a family or personal history of skin cancer. Persons with an increased number of nevi and atypical nevi are at increased risk of melanoma. Persons with a compromised immune system (eg, persons living with HIV, persons who have received an organ transplant) are at increased risk of skin cancer.",None,None,None
320,"Statin Use for the Primary Prevention of CVD: Preventive Medication--Adults aged 40 to 75 years with no history of CVD, 1 or more CVD risk factors, and a calculated 10-year CVD event risk of 7.5% to 10%",C,1,men and women,40,75,"Although statin use may be beneficial for the primary prevention of CVD events in some adults with a 10-year CVD event risk of less than 10%, the likelihood of benefit is smaller, because of a lower probability of disease and uncertainty in individual risk prediction. Clinicians may choose to offer a low- to moderate-dose statin to certain adults without a history of CVD when all of the following criteria are met: 1) they are aged 40 to 75 years; 2) they have 1 or more CVD risk factors (ie, dyslipidemia, diabetes, hypertension, or smoking); and 3) they have a calculated 10-year risk of a cardiovascular event of 7.5% to 10%.
Considerations for Implementation 
To determine whether a patient is a candidate for statin therapy, clinicians must first determine the patient&rsquo;s risk of having a future CVD event. However, clinicians&rsquo; ability to accurately identify a patient&rsquo;s true risk is imperfect, because the best currently available risk estimation tool, which uses the Pooled Cohort Equations from the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines on the assessment of cardiovascular risk,1 has been shown to overestimate actual risk in multiple external validation cohorts.2-4 The reasons for this possible overestimation are still unclear. The Pooled Cohort Equations were derived from prospective cohorts of volunteers from studies conducted in the 1990s and may not be generalizable to a more contemporary and diverse patient population seen in current clinical practice. Furthermore, no statin clinical trials enrolled patients based on a specific risk threshold calculated using a CVD risk prediction tool; rather, patients had 1 or more CVD risk factors other than age and sex as a requirement for trial enrollment.
Because the Pooled Cohort Equations lack precision, the risk estimation tool should be used as a starting point to discuss with patients their desire for lifelong statin therapy. The likelihood that a patient will benefit from statin use depends on his or her absolute baseline risk of having a future CVD event, a risk estimation that is imprecise based on the currently available risk estimation tool. Thus, clinicians should discuss with patients the potential risk of having a CVD event and the expected benefits and harms of statin use. Patients who place a higher value on the potential benefits than on the potential harms and inconvenience of taking a daily medication may choose to initiate statin use for reduction of CVD risk. The USPSTF has made several other recommendations relevant to the prevention of CVD in adults (see the &ldquo;Other Approaches to Prevention&rdquo; section).
Patient Population Under Consideration 
These recommendations apply to adults 40 years and older without a history of CVD who do not have current signs and symptoms of CVD (ie, symptomatic coronary artery disease or ischemic stroke). Some individuals in this group may have undetected, asymptomatic atherosclerotic changes; for the purposes of this recommendation statement, the USPSTF considers these persons to be candidates for primary prevention interventions. These recommendations do not apply to adults with a low-density lipoprotein cholesterol (LDL-C) level greater than 190 mg/dL (to convert LDL-C values to mmol/L, multiply by 0.0259) or known familial hypercholesterolemia; these persons are considered to have very high cholesterol levels and may require statin use.",None,Other,174,285,None,0,"Adults meeting the following criteria are at increased risk: 1) they are aged 40 to 75 years; 2) they have 1 or more CVD risk factors (ie, dyslipidemia, diabetes, hypertension, or smoking); and 3) they have a calculated 10-year risk of a cardiovascular event of 7.5% to 10%.
Risk Factors for CVD
For the purposes of this recommendation, dyslipidemia is defined as an LDL-C level greater than 130 mg/dL or a high-density lipoprotein cholesterol (HDL-C) level less than 40 mg/dL (to convert HDL-C values to mmol/L, multiply by 0.0259). Most participants enrolled in trials of statin use for the prevention of CVD had an LDL-C level of 130 to 190 mg/dL or a diabetes diagnosis; hypertension and smoking were also common among trial participants.6 Persons with an LDL-C level greater than 190 mg/dL were usually excluded from trial participation, as it was not considered appropriate to randomly assign them to placebo. Thus, these recommendations do not pertain to persons with very high cholesterol levels (ie, LDL-C &gt;190 mg/dL) or familial hypercholesterolemia, as they were excluded from most prevention trials.",None,None,None
272,Abdominal Aortic Aneurysm: Screening -- Women Ages 65 to 75 Years Who Have Ever Smoked,I,1,female,65,75,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AAA in women ages 65 to 75 years who have ever smoked.,None,Tobacco user,145,231,232,0,None,"Importance
Abdominal aortic aneurysms are typically defined by an aortic diameter of 3.0 cm or larger. Population-based studies in adults older than 50 years have found that the prevalence of AAA is 3.9% to 7.2% in men and 1.0% to 1.3% in women. It is important to consider potential screening strategies for AAA because most AAAs are asymptomatic until they rupture. Although the risk for rupture varies greatly by aneurysm size, the associated risk for death is as high as 75% to 90%.
Detection
Evidence is adequate that ultrasonography is a safe and accurate screening test for AAA.
Benefits of Detection and Early Treatment
Men Ages 65 to 75 Years Who Have Ever Smoked
Four large, population-based, randomized, controlled trials (RCTs) show that invitation to one-time screening for AAA is associated with reduced AAA-specific mortality in men. This benefit begins 3 years after testing and persists up to 15 years. In addition, risk reduction for AAA rupture and emergency surgery persists up to 10 to 13 years. In the two highest-quality trials, the relative reduction in AAA-specific mortality after 13 years was 42% to 66%. In the largest trial, where prevalence of AAA was approximately 5% in the screened group, screening was associated with an absolute risk reduction in AAA death of 1.4 per 1,000 men. Abdominal aortic aneurysms are most prevalent in men who have ever smoked, occurring in approximately 6% to 7% of this population. This prevalence increases the importance of screening in these men because it maximizes the absolute benefit that could be achieved (that is, it improves the likelihood that men in this group will benefit from screening). Convincing evidence shows that one-time screening for AAA with ultrasonography results in a moderate benefit in men ages 65 to 75 years who have ever smoked.
Men Ages 65 to 75 Years Who Have Never Smoked
Screening men overall reduces AAA-specific death, rupture, and emergency surgery. However, the lower prevalence of AAA in men who have never smoked (approximately 2%) substantially reduces the absolute benefit (that is, it greatly lowers the probability that men in this group will benefit from screening). Adequate evidence shows that one-time screening for AAA with ultrasonography results in a small benefit in men ages 65 to 75 years who have never smoked.
Women Ages 65 to 75 Years Who Have Ever Smoked
Only one RCT on screening for AAA included women. It detected no difference in the rate of AAA rupture, AAA-specific mortality, or all-cause mortality between women invited for screening and the control group. However, the trial was ultimately underpowered to detect differences in health outcomes by sex; as such, the results do not rule out the possibility of a small benefit of screening in this population. Women age 70 years who have ever smoked have a relatively low prevalence of AAA (approximately 0.8% overall and about 2% for current smokers). Evidence is inadequate to conclude whether one-time screening for AAA with ultrasonography is beneficial in women ages 65 to 75 years who have ever smoked.
Women Who Have Never Smoked
The prevalence of AAA in women who have never smoked is low (0.03% to 0.60% in women ages 50 to 79 years). The evidence also shows no apparent benefit of screening for AAA in women. The USPSTF therefore concludes that adequate evidence shows that the absolute benefit of one-time screening for AAA with ultrasonography in women who have never smoked can effectively be bounded at none or almost none.
Harms of Detection and Early Treatment
In the available trials, groups invited to screening were approximately twice as likely as control groups to have any AAA surgery within 3 to 5 years, predominantly driven by an increase in elective surgeries. More than 90% of AAAs identified by screening were below the 5.5-cm threshold for immediate repair. Detecting smaller AAAs generally leads to long-term (potentially lifelong) surveillance. A person's risk for death related to elective surgery for AAA is lower than that for death related to emergency surgery for AAA rupture. However, the increase in the overall rates of detection and surgery in the screening groups still potentially represents a harm. A proportion of AAAs will never rupture because they do not advance to conditions for the rupture to appear or because a person dies of a competing cause. The exact extent of overdiagnosis and overtreatment is difficult to estimate. One study from Massachusetts General Hospital reviewed 24,000 consecutive autopsies between 1952 and 1975 and found that 75% of the 473 patients who died with an undetected or unoperated AAA had a cause of death not related to the AAA (41% of AAAs were &gt;5.1 cm in diameter). Given that even elective treatment of AAA is associated with some risk for perioperative mortality, overtreatment is an important issue to consider when deciding whether to screen for this condition. One study reported that women had a higher risk for death related to AAA surgery than men; death rates of women and men were approximately 7% versus 5% for open repair and 2% versus 1% for endovascular repair, respectively. Evidence is limited and conflicting about the effect of screening for AAA on quality of life or psychological status (for example, anxiety). Convincing evidence shows that the harms associated with one-time screening for AAA with ultrasonography are at least small in all populations and potentially higher in women because of their higher risk for operative mortality.
USPSTF Assessment
The USPSTF concludes with high certainty that screening for AAA with ultrasonography in men ages 65 to 75 years who have ever smoked has a moderate net benefit. The USPSTF concludes with moderate certainty that screening for AAA with ultrasonography in men ages 65 to 75 years who have never smoked has a small net benefit. The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of screening for AAA in women ages 65 to 75 years who have ever smoked. The USPSTF concludes with moderate certainty that the harms of screening for AAA outweigh any potential benefits in women who have never smoked.",None,None
229,Abuse of Elderly &amp,I,1,men and women,18,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening all elderly or vulnerable adults (physically or mentally dysfunctional) for abuse and neglect.,100,None,179,124,179,0,180,None,None,"Importance
Intimate partner violence and abuse of elderly and vulnerable adults is common in the United States but often remains undetected. Nearly 31% of women and 26% of men report experiencing some form of IPV in their lifetime. Approximately 25% of women and 14% of men have experienced the most severe types of IPV in their lifetime. These estimates likely underrepresent actual rates because of underreporting. In addition to the immediate effects of IPV, such as injury and death, there are other health consequences, many with long-term effects, including sexually transmitted diseases, pelvic inflammatory disease, and unintended pregnancy. Rates of chronic pain, neurological disorders, gastrointestinal disorders, migraine headaches, and other disabilities are also increased. Intimate partner violence is also associated with preterm birth, low birth weight, and decreased gestational age. Individuals experiencing IPV often develop chronic mental health conditions, such as depression, posttraumatic stress disorder, anxiety disorders, substance abuse, and suicidal behavior. For adolescent and young adults, the effects of physical and sexual assault are associated with poor self-esteem, alcohol and drug abuse, eating disorders, obesity, risky sexual behaviors, teen pregnancy, depression, anxiety, suicidality, and other conditions.Little information is available on the prevalence of abuse among noninstitutionalized elderly or vulnerable adults, although reported rates range from 2% to 25%.
Detection
For IPV, there is adequate evidence that available screening instruments can identify current and past abuse or increased risk for abuse. Several instruments used in more than 1 study were highly sensitive and specific.The USPSTF found inadequate evidence on the accuracy of screening instruments for elderly or vulnerable adults.
Benefits of Detection and Early Intervention
The USPSTF found adequate evidence that effective interventions can reduce violence, abuse, and physical or mental harms for women of reproductive age.The USPSTF found inadequate evidence that screening or early detection reduces exposure to abuse or reduces physical or mental harms or mortality for elderly and vulnerable adults.
Harms of Detection and Early Intervention
For IPV, the USPSTF found adequate evidence that the risk for harm to the individual from screening or interventions is no greater than small.For elderly and vulnerable adults, the USPSTF found inadequate evidence on the harms of screening or interventions.
USPSTF Assessment
The USPSTF concludes with moderate certainty that screening women of childbearing age for IPV has a moderate net benefit.  The USPSTF concludes that the benefits and harms of screening elderly or vulnerable adults for abuse are uncertain, and that the balance of benefits and harms cannot be determined."
237,Alcohol Misuse: Screening and Behavioral Counseling Interventions in Primary Care -- Adolescents,I,1,men and women,12,17,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening and behavioral counseling interventions in primary care settings to reduce alcohol misuse in adolescents.&nbsp,None,,127,186,187,0,None,None,"Importance
The USPSTF uses the term &ldquo;alcohol misuse&rdquo; to define a spectrum of behaviors, including risky or hazardous alcohol use (for example, harmful alcohol use and alcohol abuse or dependence). Risky or hazardous alcohol use means drinking more than the recommended daily, weekly, or per-occasion amounts resulting in increased risk for health consequences. For example, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the U.S. Department of Agriculture define &ldquo;risky use&rdquo; as consuming more than 4 drinks on any day or 14 drinks per week for men, or more than 3 drinks on any day or 7 drinks per week for women (as well as any level of consumption under certain circumstances). &ldquo;Harmful alcohol use&rdquo; (defined by the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision) is a pattern of drinking that causes damage to physical or mental health.  &ldquo;Alcohol abuse&rdquo; (defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) is drinking that leads an individual to recurrently fail in major home, work, or school responsibilities; use alcohol in physically hazardous situations (such as while operating heavy machinery); or have alcohol-related legal or social problems. &ldquo;Alcohol dependence&rdquo; (or alcoholism) (defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) includes physical cravings and withdrawal symptoms, frequent consumption of alcohol in larger amounts than intended over longer periods, and a need for markedly increased amounts of alcohol to achieve intoxication.An estimated 30% of the U.S. population is affected by alcohol misuse, and most of these persons engage in risky use. More than 85,000 deaths per year are attributable to alcohol misuse; it is the estimated third leading cause of preventable deaths in the United States.
Detection
The USPSTF found adequate evidence that numerous screening instruments can detect alcohol misuse in adults with acceptable sensitivity and specificity.
Benefits of Detection and Behavioral Counseling Interventions
The USPSTF found adequate evidence that brief behavioral counseling interventions are effective in reducing heavy drinking episodes in adults engaging in risky or hazardous drinking. These interventions also reduce weekly alcohol consumption rates and increase adherence to recommended drinking limits. Direct evidence about the effectiveness of brief behavioral counseling interventions in pregnant women engaging in alcohol use is more limited. However, studies in the general adult population show that such interventions reduce alcohol consumption and increase adherence to recommended drinking limits among women of childbearing age.The USPSTF found insufficient evidence on the effect of screening for alcohol misuse and brief behavioral counseling interventions on outcomes in adolescents.
Harms of Detection and Behavioral Counseling Interventions
There are minimal data to assess the magnitude of harms of screening for alcohol misuse or of consequent brief behavioral counseling interventions in any population. However, no studies have identified direct evidence of harms. Thus, given the noninvasive nature of the screening process and behavioral counseling interventions, the related harms are probably small to none.
USPSTF Assessment
The USPSTF concludes with moderate certainty that there is a moderate net benefit to screening for alcohol misuse and brief behavioral counseling interventions in the primary care setting for adults aged 18 years or older.  The evidence on screening for alcohol misuse and brief behavioral counseling interventions in the primary care setting for adolescents is insufficient, and the balance of benefits and harms cannot be determined.",None
306,Aspirin Use to Prevent CVD and CRC:Preventive Medication--Adults aged 70 years or older,I,1,men and women,70,99,The current evidence is insufficient to assess the balance of benefits and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults aged 70 years or older.,None,None,163,274,275,0,None,None,None,None
305,Aspirin Use to Prevent CVD and CRC:Preventive Medication--Adults younger than 50 years,I,1,men and women,18,50,The current evidence is insufficient to assess the balance of benefits and harms of initiating aspirin use for the primary prevention of CVD and CRC in adults younger than 50 years.,None,None,163,275,274,0,None,None,None,None
302,Autism Spectrum Disorder: Screening -- Young Children (Children aged 18 to 30 months),I,1,men and women,0,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for autism spectrum disorder (ASD) in young children for whom no concerns of ASD have been raised by their parents or a clinician.,None,Age,162,269,273,272,"Although a number of potential risk factors for ASD have been identified, there is insufficient evidence to determine if certain risk factors modify the performance characteristics of ASD screening tests, such as the age at which screening is performed or other characteristics of the child or family.",None,270,271
148,Bacterial Vaginosis in Pregnancy: Screening -- Asymptomatic pregnant women at high risk for preterm delivery,I,1,female,11,49,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for bacterial vaginosis in asymptomatic pregnant women at high risk for preterm delivery.,None,Pregnant,83,104,None,0,None,None,None,None
206,Bladder Cancer: Screening -- All Adults,I,1,men and women,18,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for bladder cancer in asymptomatic adults.,None,None,112,147,148,0,"This evidence update focused on the benefits and harms of screening for bladder cancer among people without symptoms, the accuracy of screening tests done in primary care settings, and the benefits and harms of treatment. The updated evidence review did not find any new high quality evidence to adequately determine the balance of benefits and harms of screening for bladder cancer. However, bladder cancer is a common cancer and can cause considerable health problems including death. Therefore, the USPSTF determined that the evidence was insufficient to provide a recommendation for or against bladder cancer screening.  The USPSTF emphasizes the need for additional research in this area. ","Importance
Bladder cancer is the fourth most commonly diagnosed cancer in men and the ninth most commonly diagnosed cancer in women in the United States. It is the seventh-leading cause of solid cancer-related deaths. An estimated 70,980 new cases of bladder cancer were diagnosed in the United States during 2009 (52,810 cases in men and 18,170 cases in women), and approximately 14,330 people died of the disease (10,180 men and 4150 women). More than 90% of all cases of bladder cancer are classified as transitional cell carcinomas. Most newly diagnosed transitional cell carcinomas present as superficial tumors. The stages of bladder cancer include superficial (Ta or T1) and muscle-invasive tumors. Many superficial tumors (50% to 70%) will recur after treatment, with a 10% to 20% risk for the tumor to progress to the invasive stage. One fourth of all cases of bladder cancer and 20% to 40% of all invasive tumors have already metastasized to the lymph nodes at the time of diagnosis. Invasive bladder cancer is associated with a poor prognosis.
Detection
The evidence is inadequate regarding the diagnostic accuracy of potential tests (urinalysis for microscopic hematuria, urine cytology, or tests for urine biomarkers) for identifying bladder cancer in asymptomatic persons with no history of bladder cancer.
Benefits of Detection and Early Intervention
The USPSTF found inadequate evidence that screening for bladder cancer or treatment of screen-detected bladder cancer leads to improved disease-specific or overall morbidity or mortality.
Harms of Detection and Early Intervention
Screening may yield false-positive results. False-positive results may lead to anxiety, labeling, pain, and additional complications that result from diagnostic cystoscopy and biopsy (such as bladder perforation, bleeding, and infection) or imaging. The USPSTF found inadequate evidence on the harms of screening for bladder cancer. Evidence on the harms associated with early treatment, which may occur more frequently with greater detection of cases of early-stage cancer, is also inadequate.
USPSTF Assessment
The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of screening for bladder cancer in asymptomatic adults.",None,None
126,"Blood Lead Levels: Screening -- Children 1-5, Increased Risk",I,0,men and women,1,5,The USPSTF concludes that evidence is insufficient to recommend for or against routine screening for elevated blood lead levels (BLLs) in asymptomatic children aged 1 to 5 who are at increased risk.,None,Other,65,100,None,0,"Children under 5 years of age are at greater risk for elevated BLLs and lead toxicity because of increased hand-to-mouth activity, increased lead absorption from the gastrointestinal tract, and the greater vulnerability of the developing central nervous system. Risk factors for increased BLLs in children and adults include minority race/ethnicity; urban residence; low income; low educational attainment; older (pre-1950) housing; recent or ongoing home renovation or remodeling; pica exposure; use of ethnic remedies, certain cosmetics, and exposure to lead-glazed pottery; occupational and paraoccupational exposures; and recent immigration. ",None,None,None
298,Breast Cancer: Screening -- Women with dense breasts,I,1,female,18,100,"The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of adjunctive screening for breast cancer using breast ultrasonography, magnetic resonance imaging, DBT, or other methods in women identified to have dense breasts on an otherwise negative screening mammogram.",None,Other,159,263,None,0,None,None,None,None
296,Breast Cancer: Screening with Mammography-- Women aged 75 years or older,I,1,female,75,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening mammography in women aged 75 years or older.,None,Age,159,263,None,0,None,None,None,None
297,Breast Cancer: Screeningmethod with digital breast tomosynthesis(DBT)-- All women,I,1,female,18,100,The USPSTF concludes that the current evidence is insufficient to assess the benefits and harms of digital breast tomosynthesis (DBT) as a primary screening method for breast cancer.,None,None,159,263,None,0,None,None,None,None
352,Cardiovascular Disease Risk With Electrocardiography: Screening --Adults at intermediate or high risk of CVD events,I,1,men and women,18,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening with resting or exercise ECG to prevent CVD events in asymptomatic adults at intermediate or high risk of CVD events.,None,None,194,317,318,0,None,None,None,None
355,"Cardiovascular Disease, Risk Assessment With Nontraditional Risk Factors Adults",I,1,men and women,18,100,"The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of adding the ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) level, or coronary artery calcium (CAC) score to traditional risk assessment for cardiovascular disease (CVD) in asymptomatic adults to prevent CVD events.
&nbsp;
See the&nbsp;Clinical Considerations section&nbsp;for suggestions for practice regarding the I statement.",None,None,196,319,None,0,None,None,None,None
326,"Celiac Disease: Screening Asymptomatic adults, adolescents, and children",I,1,men and women,0,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for celiac disease in asymptomatic persons.,None,Other,179,290,None,0,persons with family history or other risk factors,None,None,None
238,Child Maltreatment: Primary Care Interventions  Children,I,1,men and women,0,17,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of primary care interventions to prevent child maltreatment. This recommendation applies to children who do not have signs or symptoms of maltreatment.&nbsp,None,,128,189,188,0,None,None,"Importance
In 2011, approximately 680,000 children were victims of maltreatment and approximately 1,570 children died of such treatment. Approximately 78% experienced neglect, 18% physical abuse, and 9% sexual abuse; many experienced several forms of maltreatment.
Benefits of Interventions
There is inadequate evidence that primary care interventions can prevent maltreatment among children who do not already have signs or symptoms of such treatment. Reasons for this conclusion include significant heterogeneity in study methods and interventions. There is also inconsistent and limited evidence on outcomes or how they were measured.
Harms of Detection and Early Intervention or Treatment
Although there are numerous concerns about the possible harms of interventions for child maltreatment, evidence of these harms is limited.
USPSTF Assessment
The USPSTF concludes that the evidence is limited and inconsistent, and is therefore insufficient to determine the balance of benefits and harms of interventions in primary care to prevent child maltreatment among children without signs or symptoms of maltreatment.",None
279,Chlamydia and Gonorrhea: Screening -- Sexually Active Men,I,1,male,11,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for chlamydia and gonorrhea in men.,None,Sexually Active,149,239,240,0,None,None,None,None
263,Cognitive Impairment: Screening -- Older Adults,I,1,men and women,65,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for cognitive impairment.,None,Age,141,218,219,0,None,"Importance
Dementia affects approximately 2.4 to 5.5 million Americans. Its prevalence increases with age, to 5% in persons aged 71 to 79 years, 24% in those aged 80 to 89 years, and 37% in those older than 90 years. Mild cognitive impairment (MCI) is different from dementia in that the cognitive impairment is not severe enough to interfere with instrumental activities of daily life. It is difficult to estimate the prevalence of MCI, and estimates range widely, from 3% to 42% in adults aged 65 years and older.
Detection
The USPSTF found adequate evidence that some screening tools have sufficiently high sensitivity and specificity to be clinically useful in identifying dementia.
Benefits of Detection and Early Intervention
The USPSTF found inadequate direct evidence on the benefits of screening for cognitive impairment. Evidence shows that several drug therapies and nonpharmacologic interventions have a small effect on cognitive function measures in the short term for patients with mild to moderate dementia, but the magnitude of the clinically relevant benefit is uncertain. The USPSTF found adequate evidence that interventions targeted to caregivers have a small effect on measures of caregiver burden and depression, but the magnitude of the clinically relevant benefit is uncertain. The USPSTF found no published evidence on the effect of screening on decision making or planning by patients, clinicians, or caregivers.
Harms of Detection and Early Intervention or Treatment
The USPSTF found inadequate evidence on the harms of screening for cognitive impairment and of nonpharmacologic interventions. It found adequate evidence that acetylcholinesterase inhibitors (AChEIs) are associated with adverse effects, some of which are serious, including central nervous system disturbances and arrhythmia. Gastrointestinal symptoms are also common.
USPSTF Assessment
The USPSTF concludes that the evidence on screening for cognitive impairment is lacking and that the balance of benefits and harms cannot be determined.",None,None
267,Dental Caries: Screening -- Children From Birth to Age 5 Years,I,1,men and women,0,5,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of routine screening examinations for dental caries performed by primary care clinicians in children from birth to age 5 years.,None,None,142,228,224,0,"All children are at potential risk for dental caries; those whose primary water supply is deficient in fluoride (defined as containing &lt;0.6 ppm F) are at particular risk. While there are no validated multivariate screening tools to determine which children are at higher risk for dental caries, there are a number of individual factors that elevate risk. Higher prevalence and severity of dental caries are found among minority and economically disadvantaged children. Other risk factors for caries in children include frequent sugar exposure, inappropriate bottle feeding, developmental defects of the tooth enamel, dry mouth, and a history of previous caries. Maternal and family factors can also increase children's risk. These factors include poor oral hygiene, low socioeconomic status, recent maternal caries, sibling caries, and frequent snacking. Additional factors associated with dental caries in young children include lack of access to dental care; inadequate preventive measures, such as failure to use fluoride-containing toothpastes; and lack of parental knowledge about oral health.","Importance
Dental caries is the most common chronic disease in children in the United States. According to the 1999&ndash;2004 National Health and Nutrition Examination Survey (NHANES), approximately 42% of children ages 2 to 11 years have dental caries in their primary teeth. After decreasing from the early 1970s to the mid-1990s, the prevalence of dental caries in children has been increasing, particularly in young children ages 2 to 5 years.
Recognition of Risk Status
Risk assessment tools generally evaluate risk based on factors such as demographic risk, personal and family oral health history, dietary habits, fluoride exposure, and oral hygiene practices. Information from a clinical evaluation has also been proposed, as well as qualitative or quantitative measure of oral bacterial load. The USPSTF found no studies that evaluated the accuracy of risk assessment instruments for future dental caries in the primary care setting.
Benefits of Preventive Interventions and Early Detection
Preventive Interventions
The USPSTF found adequate evidence that oral fluoride supplementation, also known as dietary fluoride supplementation, in children who have low levels of fluoride in their water and application of fluoride varnish to the primary teeth of all children can each provide moderate benefit in preventing dental caries.The USPSTF found insufficient evidence on the benefits of provider education of parents regarding oral hygiene practices to prevent dental caries in their children.
Screening
The USPSTF found no studies addressing the direct effect of routine oral screening examinations performed by primary care clinicians on improved clinical outcomes in children younger than age 5 years.
Harms of Preventive Interventions and Early Detection
Preventive Interventions
The USPSTF found adequate evidence of a link between early childhood exposure to systemic fluoride and enamel fluorosis, a visible change in the appearance of the enamel due to altered mineralization. Fluorosis can range from mild (small white spots or streaks) to severe (discoloration, pitting, or rough enamel), depending on the overall systemic fluoride exposure level over time.No studies specifically reported on the risk for fluorosis with fluoride varnish; however, compared with other topical fluoride interventions, systematic exposure to fluoride is low after varnish application. It is important to consider a child's overall systemic exposure to fluoride from multiple sources (e.g., water fluoridation, toothpaste, supplements, and/or varnish), but in the United States, enamel fluorosis presents as mild cosmetic changes in &gt;99% of cases.The USPSTF concludes that there is limited evidence about the harms associated with fluoride varnish or other preventive interventions for dental caries, but that these risks are likely small.
Screening
The USPSTF found no studies addressing the magnitude of harms of screening children from birth to age 5 years for dental caries or future risk for dental caries in the primary care setting.
USPSTF Assessment
The USPSTF concludes with moderate certainty that there is a moderate net benefit of preventing future dental caries with oral fluoride supplementation at recommended doses in children older than age 6 months who reside in communities with inadequate water fluoride.The USPSTF concludes with moderate certainty that there is a moderate net benefit of preventing future dental caries with fluoride varnish application in all children starting at the age of eruption of primary teeth to age 5 years.The USPSTF concludes that the evidence on performing routine oral screening examinations for dental caries in children from birth to age 5 years is insufficient, and the balance of benefits and harms of screening cannot be determined.",None,None
301,"Depression: Screening -- Children, aged 11 years or younger",I,1,men and women,7,11,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for MDD in children aged 11 years or younger.,None,None,161,268,267,0,None,None,None,None
262,Drug (Illicit) and Nonmedical Pharmaceutical Use: Primary Care Behavioral Interventions -- Children and Adolescents,I,1,men and women,0,17,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of primary care&ndash,based behavioral interventions to prevent or reduce illicit drug or nonmedical pharmaceutical use in children and adolescents. This recommendation applies to children and adolescents who have not already been diagnosed with a substance use disorder.,None,140,216,35,0,217,None,"Importance
According to the National Survey on Drug Use and Health (NSDUH), more than 4300 adolescents aged 12 to 17 years use drugs for the first time each day in the United States. (Note: The NSDUH collected data on use of illicit drugs and nonmedical use of prescription drugs but not over-the-counter drugs; thus, actual drug use [illicit and nonmedical use of all pharmaceuticals] rates may be greater.) Approximately 9.5% of youths aged 12 to 17 years report drug use in the past month. In addition, in 2012, 4.4% of eighth-, tenth-, and twelfth-grade students reported using over-the-counter cough or cold medicine in the past year for nonmedical reasons. Drug use is associated with many negative health, social, and economic consequences and is a significant contributor to 3 of the leading causes of death among adolescents&mdash;motor vehicle accidents, homicide, and suicide. Consequences not only arise from frequent and heavy drug use, but use increases risk-taking behaviors while intoxicated, such as driving under the influence, unsafe sexual activity, and violence. In 2011, more than 150,000 adolescents were treated in emergency departments for complications of illicit drug and nonmedical pharmaceutical use.
Benefits of Behavioral Interventions
The USPSTF found inadequate evidence about the effect of behavioral interventions to reduce drug use on health outcomes in adolescents. It also found inadequate evidence about the effect of behavioral interventions to reduce initiation of drug use in adolescents. The Task Force found no evidence about behavioral interventions for children younger than age 11 years.
Harms of Behavioral Interventions
The USPSTF found no studies about the magnitude of the harms of behavioral interventions to prevent or reduce drug use. Although the USPSTF recognizes that theoretical harms, such as the potential to increase drug initiation through a false sense of security, may exist, it concludes that the harms of behavioral interventions are probably small to none.
USPSTF Assessment
The USPSTF concludes that the evidence about primary care&ndash;based behavioral interventions to prevent or reduce illicit drug and nonmedical pharmaceutical use in children and adolescents is insufficient, and the balance of benefits and harms cannot be determined.",None
146,Drug Use - Illicit : Screening -- Adults and Pregnant Women,I,1,men and women,18,100,"The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening&nbsp;adolescents, adults, and pregnant women for illicit drug use.&nbsp;&nbsp;&nbsp;&nbsp; (This recommendation was partially updated for children and adolescents in 2014.&nbsp; For updated information on children and adolescents, see&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; http://www.uspreventiveservicestaskforce.org/uspstf/uspsnonmed.htm.)",None,None,82,116,None,0,None,None,None,None
258,Gestational Diabetes Mellitus: Screening -- Pregnant Women Before 24 Weeks of Gestation,I,1,female,15,49,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for GDM in asymptomatic pregnant women before 24 weeks of gestation.,None,Pregnant,138,212,213,0,"Several factors increase a woman's risk for developing GDM, including obesity, increased maternal age, history of GDM, family history of diabetes, and belonging to an ethnic group that has increased risk for developing type 2 diabetes mellitus (Hispanic, Native American, South or East Asian, African American, or Pacific Island descent). Factors associated with a lower risk for developing GDM include age younger than 25 to 30 years, white race, a body mass index (BMI) of 25 kg/m2 or less, no family history (that is, in a first-degree relative) of diabetes, and no history of glucose intolerance or adverse pregnancy outcomes related to GDM.","Importance
Gestational diabetes mellitus is glucose intolerance discovered during pregnancy. The prevalence of GDM in the United States is 1% to 25%, depending on patient demographics and diagnostic thresholds. Pregnant women with gestational diabetes are at increased risk for maternal and fetal complications, including preeclampsia, fetal macrosomia (which can cause shoulder dystocia and birth injury), and neonatal hypoglycemia. Women with GDM are also at increased risk for developing type 2 diabetes mellitus; approximately 15% to 60% of women develop type 2 diabetes within 5 to 15 years of delivery. Screening for GDM generally occurs after the 24th week of pregnancy. Screening before 24 weeks may identify women with glucose intolerance earlier in pregnancy.
Detection
The USPSTF found adequate evidence that primary care providers can accurately detect GDM in asymptomatic pregnant women after 24 weeks of gestation. The most commonly used screening test in the United States is the 50-g oral glucose challenge test (OGCT).Other methods of screening include the fasting plasma glucose test and screening based on risk factors. However, there is limited evidence on these alternative screening approaches. The USPSTF found inadequate evidence to compare the effectiveness of different screening tests or thresholds for a positive screen result.
Benefits of Detection and Early Treatment
The USPSTF found adequate evidence that treatment of screen-detected GDM with dietary modifications, glucose monitoring, and insulin (if needed) can significantly reduce the risk of preeclampsia, fetal macrosomia, and shoulder dystocia. When these outcomes are considered collectively, there is a moderate net benefit for both mother and infant. The benefit of treatment on long-term metabolic outcomes in women who are treated for GDM compared with those who are not treated is uncertain.The USPSTF found inadequate evidence to determine whether there are benefits to screening for GDM in women before 24 weeks of gestation.
Harms of Detection and Early Treatment
Overall, the USPSTF found adequate evidence that the magnitude of the harms of screening and treatment is small to none. Randomized, controlled trials (RCTs) demonstrated an increase in the number of prenatal visits in screen-detected women who were treated for GDM compared with screen-detected women who were not treated. There was conflicting evidence on the risk for an increase in the induction of labor associated with treatment. No significant differences were reported for cesarean delivery or neonatal intensive care unit admissions between women who were treated and women who were not treated for GDM in the overall pooled meta-analysis. Trials also demonstrated no significant differences in the incidence of small-for-gestational-age infants or episodes of neonatal hypoglycemia, but the trials were not adequately powered to detect meaningful differences in these outcomes.
USPSTF Assessment
The USPSTF concludes with moderate certainty that there is a moderate net benefit to screening for gestational diabetes after 24 weeks of gestation to reduce maternal and fetal complications (the collective outcomes of preeclampsia, macrosomia, and shoulder dystocia).The USPSTF concludes that the evidence on screening for gestational diabetes before 24 weeks of gestation is insufficient, and the balance of benefits and harms of screening cannot be determined.",None,None
240,Glaucoma: Screening -- Adults,I,1,men and women,18,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for primary open-angle glaucoma (POAG) in adults.,None,None,130,193,192,0,"Increased IOP, family history of glaucoma, older age, and African American race increase a person's risk for open-angle glaucoma. Recent evidence shows that glaucoma may be increased in Hispanics. Older African Americans have a higher prevalence of glaucoma and perhaps a more rapid disease progression; if screening reduces vision impairment, then African Americans would probably have greater absolute benefit than whites.","Importance
Open-angle glaucoma affects approximately 2.5 million Americans and is a leading cause of impaired visual function (loss of peripheral vision) and blindness.
Detection
The USPSTF found inadequate evidence on the accuracy of screening for POAG in adults. Evidence is limited by the lack of an established gold standard against which individual screening tests can be compared.
Benefits of Detection and Early Treatment
The USPSTF found no direct evidence on the benefits of screening.The USPSTF found convincing evidence that treatment of increased intraocular pressure (IOP) and early glaucoma reduces the number of persons who develop small, clinically unnoticeable visual field defects and that treatment of early asymptomatic POAG decreases the number of persons whose visual field defects worsen.However, the USPSTF found inadequate evidence that screening for or treatment of increased IOP or early asymptomatic POAG reduces the number of persons who will develop impaired vision or quality of life.
Harms of Detection and Early Treatment
The USPSTF found no direct evidence on the harms of screening. It found convincing evidence that treatment results in numerous harms, including local eye irritation from medications and risk for complications from surgery, such as early formation of cataracts. The magnitude of these harms for most persons is small. Screening is associated with a risk for false-positive and false-negative results, but the magnitude of this risk is unknown, given the considerable variability in reported test sensitivity and specificity. Screening and treatment are associated with risk for overdiagnosis and overtreatment because some evidence shows that many persons with increased IOP or early POAG have an indolent long-term course yet still receive treatment.
USPSTF Assessment
The USPSTF concludes that the evidence of effectiveness of screening for glaucoma on clinical outcomes is lacking and that the balance of benefits and harms therefore cannot be determined.",None,None
223,Hearing Loss: Screening--Older Adults,I,1,men and women,50,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for hearing loss in asymptomatic adults aged 50 years or older. This recommendation applies to asymptomatic adults aged 50 years or older. It does not apply to persons seeking evaluation for perceived hearing problems or for cognitive or affective symptoms that may be related to hearing loss. These persons should be assessed for objective hearing impairment and treated when indicated.,None,Age,120,171,170,172,"Aging is the most important risk factor for hearing loss. Presbycusis, a gradual, progressive decline in the ability to perceive high-frequency tones due to degeneration of hair cells in the ear, is the most common cause of hearing loss in older adults. However, hearing loss may result from several contributing factors. Other risk factors include a history of exposure to loud noises or ototoxic agents, including occupational exposures; previous recurring inner ear infections; genetic factors; and certain systemic diseases, such as diabetes.","Importance
Age-related sensorineural hearing loss is a common health problem among adults aged 50 years or older. Hearing loss can affect social functioning and quality of life.
Detection
Convincing evidence shows that screening tools can reliably and accurately identify adults with objective hearing loss. Clinical tests used to screen for hearing impairment include testing whether a person can hear a whispered voice, a finger rub, or a watch tick at a specific distance. Perceived hearing loss can be assessed by asking a single question (for example, &ldquo;Do you have difficulty with your hearing?&rdquo;) or with a more detailed questionnaire, such as the Hearing Handicap Inventory for the Elderly&ndash;Screening Version (HHIE-S). A handheld screening instrument consisting of an otoscope with a built-in audiometer can also be used.
Benefits of Detection and Early Treatment
Because of a paucity of directly applicable trials, evidence is inadequate to determine whether screening for hearing loss improves health outcomes in persons who are unaware of hearing loss or have perceived hearing loss but have not sought care. One good-quality study showed that hearing aids can improve self-reported hearing, communication, and social functioning for some adults with age-related hearing loss. This study nearly exclusively evaluated white male veterans with moderate hearing loss and moderate to severe perceived hearing impairment, more than one third of whom had been referred for evaluation of hearing problems; as such, these findings were of limited applicability to a hypothetical asymptomatic, screened population. The only randomized trial that directly evaluated the effect of screening for hearing impairment&mdash;rather than the effect of treatment alone&mdash;was not primarily designed nor had sufficient statistical power to detect differences in hearing-related function. The USPSTF concludes that the evidence is inadequate to assess the benefit of screening and early treatment in an unselected screening population.
Harms of Detection and Early Treatment
Because of a lack of studies, evidence to determine the magnitude of harms of screening for hearing loss in older adults is inadequate; however, given the noninvasive nature of both screening and associated diagnostic evaluation, these harms are probably small to none. Adequate evidence shows that the harms of treatment of hearing loss in older adults are small to none.
USPSTF Assessment
The USPSTF concludes that evidence is lacking, and the balance of benefits and harms of screening for hearing loss in adults aged 50 years or older cannot be determined.",None,None
254,Hypertension: Screening -- Children and Adolescents,I,1,men and women,5,17,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for primary hypertension in asymptomatic children and adolescents to prevent subsequent cardiovascular disease in childhood or adulthood.,"Several organizations recommend routine screening of blood pressure at well-child visits starting at age 3 years, based on consensus.",None,135,205,206,0,"The strongest risk factor for primary hypertension in children and adolescents is elevated body mass index. Other risk factors include low birhweight, male sex, ethnicity, and family history of hypertension.","Importance
The prevalence of hypertension in children and adolescents in the United States has been reported at 1% to 5%. Primary hypertension in children and adolescents is associated with several risk factors, the strongest of which is elevated body mass index. The prevalence of hypertension in children and adolescents has increased over the past several decades, which is probably attributable to the increase in the prevalence of childhood overweight and obesity. The prevalence of hypertension among obese children in the United States is estimated at 11%.One rationale for screening for hypertension in children and adolescents is that early identification of primary hypertension could lead to interventions to reduce blood pressure during childhood and adolescence, resulting in a reduced risk for cardiovascular events and death in adulthood.
Detection
The USPSTF found inadequate evidence about the diagnostic accuracy of screening for elevated blood pressure with sphygmomanometry in the clinical setting. The 2 fair-quality studies available used different gold standards (ambulatory blood pressure monitoring and subsequent blood pressure readings). Blood pressure screening with sphygmomanometry in the clinical setting may be reasonably sensitive for identifying children and adolescents with hypertension; however, false-positive results may occur with normalization of subsequent blood pressure measurements.
Association With Adult Hypertension and Cardiovascular Disease
The USPSTF found no direct evidence that routine blood pressure measurement accurately identifies children and adolescents who are at increased risk for cardiovascular disease in adulthood and inadequate evidence that routine blood pressure measurement accurately identifies children and adolescents who are at increased risk for adult hypertension or other intermediate measures of adult cardiovascular disease. Children and adolescents with hypertension are more likely to have hypertension as adults; however, predictive values of childhood hypertension for adult hypertension are at best modest (65%) and vary widely (19% to 65%). Most studies examining the association of hypertension and subclinical cardiovascular disease in children are cross-sectional studies and limited to children with hypertension secondary to kidney disease. Evidence about the longitudinal association between hypertension in children and adolescents and intermediate outcomes indicating cardiovascular damage in adults, such as carotid intima&ndash;media thickening or microalbuminuria, is limited and conflicting.
Benefits of Detection and Early Intervention
The USPSTF found inadequate evidence to determine whether treatment of elevated blood pressure in children or adolescents results in sustained decreases in blood pressure in childhood because studies in this area have been of short duration; trials of the efficacy of antihypertension drugs were typically 4 weeks in duration, whereas studies of lifestyle interventions ranged from 2 months to 3 years with a median duration of 7 months.The USPSTF also found inadequate evidence to determine the health outcomes associated with interventions to treat primary hypertension in childhood or adolescence.
Harms of Detection and Early Intervention
The USPSTF found inadequate evidence to assess the potential harms of screening for primary hypertension in children and adolescents. Only 1 good-quality study was identified, and it did not find any adverse effects, as assessed by school absenteeism, of detecting primary hypertension in childhood.The USPSTF found inadequate evidence to assess the potential harms of pharmacologic or nonpharmacologic treatment of elevated blood pressure in childhood or adolescence. Short-term pharmacologic treatments generally seemed to be well-tolerated, with no serious adverse events during short-term treatment periods. However, adverse event rates were often incompletely reported, and the evidence is limited by a lack of studies with follow-up longer than several weeks. Information on adverse effects of lifestyle interventions or lifestyle interventions combined with pharmacotherapy is also limited.
USPSTF Assessment
The USPSTF concludes that the evidence to support screening for primary hypertension in children and adolescents is insufficient and that the balance of benefits and harms cannot be determined.",None,None
336,Idiopathic Scoliosis: Screening--Children and adolescents aged 10 to 18 years,I,1,men and women,10,18,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for adolescent idiopathic scoliosis in children and adolescents aged 10 to 18 years.,None,None,187,299,300,0,None,None,None,None
308,Impaired Visual Acuity in Older Adults: Screening --Adults 65 years or older,I,1,men and women,65,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for impaired visual acuity in older adults.,None,None,165,132,278,0,None,None,None,None
289,Iron Deficiency Anemia: Screening -- Children ages 6 to 24 months,I,1,unspecified,0,2,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for iron deficiency anemia in children ages 6 to 24 months.,None,None,157,260,259,0,None,"Importance
The aims of iron supplementation or screening for and treatment of iron deficiency anemia in pregnant women are to improve maternal and infant health outcomes. Few data are available to estimate the current prevalence of iron deficiency anemia in pregnant women in the United States. Based on older data from 1999 to 2006, an estimated 18.6% of pregnant women have iron deficiency; of those, an estimated 16.2% have anemia.&nbsp;Rates may be higher in low-income and minority populations.
Detection and Recognition of Risk Status
The USPSTF found inadequate evidence that specifically addressed the accuracy of screening tests in asymptomatic pregnant women. The USPSTF found inadequate evidence to evaluate risk prediction tools to identify pregnant women who are at increased risk for iron deficiency anemia.
Benefits of Early Detection and Treatment
Screening
The USPSTF found inadequate evidence on screening for iron deficiency anemia in asymptomatic pregnant women. No studies evaluated the direct effects of routine screening in asymptomatic pregnant women on maternal health or birth outcomes. The USPSTF also found inadequate evidence on the treatment of iron deficiency anemia in pregnant women because none of the recent studies on treatment were generalizable to the general U.S. population. This represents a critical gap in the evidence.
Preventive Medication
Overall, the USPSTF found inadequate evidence on the effect of routine iron supplementation during pregnancy on maternal health or birth outcomes, such as maternal iron deficiency anemia, cesarean delivery, preterm delivery, infant mortality, or low birthweight. Several studies reported inconsistent findings on these health outcomes. The USPSTF found adequate evidence that routine iron supplementation during pregnancy improves intermediate maternal hematologic indexes, such as serum ferritin and hemoglobin levels. The USPSTF found adequate evidence that routine iron supplementation during pregnancy has no effects on the length of gestation and infant Apgar scores at 1 and 5 minutes.
Change in Iron Status
No studies were found that directly assessed the association between change in iron status as a result of treatment or supplementation and improvement in maternal or infant health outcomes. This represents a critical gap in the evidence.
Harms of Early Detection and Treatment
Screening
The USPSTF found inadequate evidence on the harms of routine screening for iron deficiency anemia in asymptomatic pregnant women. No studies were found that evaluated the harms of routine screening on maternal health or birth outcomes. The USPSTF found inadequate evidence on the harms of treatment of iron deficiency anemia in pregnant women; no recent studies were generalizable to the current general U.S. population.
Preventive Medication
The USPSTF found adequate evidence that the magnitude of the harms of routine iron supplementation in pregnant women is small to none. Several studies assessed the harms of iron supplementation in pregnant women. Most reported no statistically significant increase in harms. Of the harms reported, most were self-limited and transient effects of treatment, such as nausea, constipation, and diarrhea.
USPSTF Assessment

The USPSTF concludes that the evidence of the effect of routine screening for iron deficiency anemia in asymptomatic pregnant women on maternal health and birth outcomes is insufficient. Evidence is lacking, and the balance of benefits and harms cannot be determined.&nbsp;&nbsp;
The USPSTF concludes that the evidence on the effect of routine iron supplementation in pregnant women on maternal health and birth outcomes of is insufficient. Evidence is lacking, and the balance of benefits and harms cannot be determined
",None,None
290,Iron Deficiency: Supplementation -- Pregnant Women,I,1,female,11,64,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of routine iron supplementation for pregnant women to prevent adverse maternal health and birth outcomes.,None,Pregnant,156,255,254,0,"Several factors have been identified that may increase a pregnant woman&rsquo;s risk for iron deficiency anemia, including a diet lacking in iron-rich foods (for example, a vegetarian diet with inadequate sources of iron), gastrointestinal disease and/or medications that can decrease iron absorption (for example, antacids), and a short interval between pregnancies. Non-Hispanic black and Mexican American women have higher prevalence rates of iron deficiency than white women and women with parity of 2 or more. Evidence on additional risk factors, such as lower educational level and family income, has been less consistent. On the basis of a literature scan, the USPSTF found limited evidence on the use of risk prediction tools to identify pregnant women who are at increased risk for iron deficiency anemia",None,None,None
292,Iron Defiency Anemia in Pregnant Women: Screening -- Pregnant Women,I,1,female,11,64,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for iron deficiency anemia in pregnant women to prevent adverse maternal health and birth outcomes.,None,Pregnant,156,255,254,0,"Several factors have been identified that may increase a pregnant woman&rsquo;s risk for iron deficiency anemia, including a diet lacking in iron-rich foods (for example, a vegetarian diet with inadequate sources of iron), gastrointestinal disease and/or medications that can decrease iron absorption (for example, antacids), and a short interval between pregnancies. Non-Hispanic black and Mexican American women have higher prevalence rates of iron deficiency than white women and women with parity of 2 or more. Evidence on additional risk factors, such as lower educational level and family income, has been less consistent. On the basis of a literature scan, the USPSTF found limited evidence on the use of risk prediction tools to identify pregnant women who are at increased risk for iron deficiency anemia",None,None,None
313,Lipid Disorders in Children and Adolescents: Screening -- Children and Adolescents 20 years or younger,I,1,men and women,1,20,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for lipid disorders in children and adolescents 20 years or younger. (I statement),None,Age,171,None,None,0,None,None,None,None
324,Obstructive Sleep Apnea in Adults: Screening Asymptomatic adults,I,1,female,18,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for obstructive sleep apnea (OSA) in asymptomatic adults.,None,Other,177,288,None,0,"Risk factors associated with OSA include male sex, older age (40 to 70 years), postmenopausal status, higher BMI, and craniofacial and upper airway abnormalities.",None,None,None
255,Oral Cancer: Screening -- Adults,I,1,men and women,18,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for oral cancer in asymptomatic adults.,None,Tobacco user,136,207,208,0,"Tobacco and alcohol use are major risk factors for oral cancer. A total of 20% to 30% of cases of oral cancer worldwide are attributable to cigarette smoking. In the United States, up to 75% of cases of oral cancer may be attributable to tobacco and alcohol use. Additional risk factors include male sex, older age, use of betel quid, ultraviolet light exposure, infection with Candida or bacterial flora, and a compromised immune system. Sexually transmitted oral HPV infection (HPV-16) has recently been recognized as an increasingly important risk factor for oropharyngeal cancer. In the United States, the prevalence of oropharyngeal cancer due to oral HPV infection is probably as high as 80% to 95%. The prevalence of oral HPV infection is associated with age, sex, number of sexual partners, and number of cigarettes smoked per day. The effect of multifactorial risk assessment and screening for risk factors on oral cancer morbidity and mortality is unknown.","Importance
Oral cavity cancer (or oral cancer) and pharyngeal cancer include cancer of the lip, oral cavity, and pharynx (nasopharynx, oropharynx, and laryngopharynx). Ninety percent of all cases of oral cavity and pharyngeal cancer are classified as squamous-cell carcinoma. An estimated 41,380 new cases of and 7890 deaths from cancer of the oral cavity and pharynx will occur in 2013. At the time of diagnosis, more than 50% of persons with oral and pharyngeal cancer have regional or distant metastases. Screening for oral cancer may be helpful if potentially malignant disorders can be identified earlier and treated successfully.Oral and oropharyngeal cancer have different causes. Oral cavity cancer is predominantly caused by tobacco and alcohol use. Oropharyngeal cancer, another subset of neck and head cancer, includes human papillomavirus (HPV) as an important risk factor. The incidence and mortality rate of oral cancer has been decreasing in the United States presumably because of reduced tobacco and alcohol use. However, HPV-related oropharyngeal cancer is increasing in incidence. Oropharyngeal cancer includes lesions of the tonsil, oropharynx, and base of the tongue. The epidemiology of HPV-related oropharyngeal cancer is evolving and could have important implications for identifying high-risk populations that might benefit from screening.
Detection
The USPSTF found inadequate evidence that the oral screening examination accurately detects oral cancer.
Benefits of Detection and Early Treatment
The USPSTF found inadequate evidence that screening for oral cancer and treatment of screen-detected oral cancer improves morbidity or mortality.
Harms of Detection and Early Treatment
The USPSTF found inadequate evidence on the harms of screening. No study reported on harms from the screening test or from false-positive or false-negative results. Potential diagnostic harms are primarily related to the harms of biopsy for suspected oral cancer or its potential precursors. Harms of treatment for screen-detected oral cancer and its potentially malignant precursors (leukoplakia and erythroplakia) may result from complications of surgery (first-line treatment), radiation, and chemotherapy. The natural history of screen-detected oral cancer or potentially malignant disorders is unclear; thus, the magnitude of overdiagnosis due to screening is unknown.
USPSTF Assessment
The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of screening for oral cancer in asymptomatic adults by primary care providers.",None,None
356,PAD and CVD Risk Assessment With the Ankle-Brachial Index Adults,I,1,men and women,18,100,"The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for peripheral artery disease (PAD) and cardiovascular disease (CVD) risk with the ankle-brachial index (ABI) in asymptomatic adults.
&nbsp;
See the&nbsp;Clinical Considerations section&nbsp;for suggestions for practice regarding the I statement.",None,Other,197,321,320,0,"In addition to older age, major risk factors for PAD include diabetes, current smoking, high blood pressure, high cholesterol levels, obesity, and physical inactivity, with current smoking and diabetes showing the strongest association.6&nbsp;",None,None,None
325,"Periodic Screening With the Pelvic Examination: ScreeningAsymptomatic, nonpregnant adult women who are not at increased risk for any specific gynecologic condition",I,1,female,18,100,"The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of performing screening pelvic examinations in asymptomatic women for the early detection and treatment of a range of gynecologic conditions.
&nbsp;This statement does not apply to specific disorders for which the USPSTF already recommends screening (ie, screening for cervical cancer with a Papanicolaou [&ldquo;Pap&rdquo;] smear, screening for gonorrhea and chlamydia). See the&nbsp;Table&nbsp;for more information.",None,Sex,178,289,None,0,None,None,None,None
342,Skin Cancer Prevention: Behavioral Counseling Adults,I,1,unspecified,18,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of counseling adults about skin self-examination to prevent skin cancer.,None,None,190,308,None,0,None,None,None,None
312,Skin Cancer: Screening --Asymptomatic adults,I,1,men and women,18,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for skin cancer in adults.,None,Other,170,282,283,0,"Skin cancer of any type occurs more commonly in men than in women and among persons with a fair complexion, persons who use indoor tanning beds, and persons with a history of sunburns or previous skin cancer. Specific risk factors for melanoma include having a dysplastic nevus (atypical mole), having multiple (ie, &ge;100) nevi, and having a family history of melanoma.3,&nbsp;4&nbsp;Like most types of cancer, the risk of melanoma increases with age; the median age at diagnosis is 63 years, and the median age at death is 69 years.1",None,None,None
288,Speech and Language Delay and Disorders: Screening -- Children Age 5 and Younger,I,1,men and women,0,5,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for speech and language delay and disorders in children aged 5 years or younger.,None,None,155,252,253,0,"Based on a review of 31 cohort studies, several risk factors have been reported to be associated with speech and language delay and disorders, including male sex, family history of speech and language impairment, low parental education level, and perinatal risk factors (e.g., prematurity, low birth weight, and birth difficulties).",None,None,None
321,Statin Use for the Primary Prevention of CVD: Preventive Medication -- Adults 76 years and older with no history of CVD,I,1,men and women,76,100,"The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of initiating statin use for the primary prevention of CVD events and mortality in adults 76 years and older without a history of heart attack or stroke.
Considerations for Implementation 
To determine whether a patient is a candidate for statin therapy, clinicians must first determine the patient&rsquo;s risk of having a future CVD event. However, clinicians&rsquo; ability to accurately identify a patient&rsquo;s true risk is imperfect, because the best currently available risk estimation tool, which uses the Pooled Cohort Equations from the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines on the assessment of cardiovascular risk,1 has been shown to overestimate actual risk in multiple external validation cohorts.2-4 The reasons for this possible overestimation are still unclear. The Pooled Cohort Equations were derived from prospective cohorts of volunteers from studies conducted in the 1990s and may not be generalizable to a more contemporary and diverse patient population seen in current clinical practice. Furthermore, no statin clinical trials enrolled patients based on a specific risk threshold calculated using a CVD risk prediction tool; rather, patients had 1 or more CVD risk factors other than age and sex as a requirement for trial enrollment.
Because the Pooled Cohort Equations lack precision, the risk estimation tool should be used as a starting point to discuss with patients their desire for lifelong statin therapy. The likelihood that a patient will benefit from statin use depends on his or her absolute baseline risk of having a future CVD event, a risk estimation that is imprecise based on the currently available risk estimation tool. Thus, clinicians should discuss with patients the potential risk of having a CVD event and the expected benefits and harms of statin use. Patients who place a higher value on the potential benefits than on the potential harms and inconvenience of taking a daily medication may choose to initiate statin use for reduction of CVD risk. The USPSTF has made several other recommendations relevant to the prevention of CVD in adults (see the &ldquo;Other Approaches to Prevention&rdquo; section).
Patient Population Under Consideration 
These recommendations apply to adults 40 years and older without a history of CVD who do not have current signs and symptoms of CVD (ie, symptomatic coronary artery disease or ischemic stroke). Some individuals in this group may have undetected, asymptomatic atherosclerotic changes; for the purposes of this recommendation statement, the USPSTF considers these persons to be candidates for primary prevention interventions. These recommendations do not apply to adults with a low-density lipoprotein cholesterol (LDL-C) level greater than 190 mg/dL (to convert LDL-C values to mmol/L, multiply by 0.0259) or known familial hypercholesterolemia; these persons are considered to have very high cholesterol levels and may require statin use.",None,Other,174,285,None,0,"Risk Factors for CVD
For the purposes of this recommendation, dyslipidemia is defined as an LDL-C level greater than 130 mg/dL or a high-density lipoprotein cholesterol (HDL-C) level less than 40 mg/dL (to convert HDL-C values to mmol/L, multiply by 0.0259). Most participants enrolled in trials of statin use for the prevention of CVD had an LDL-C level of 130 to 190 mg/dL or a diabetes diagnosis; hypertension and smoking were also common among trial participants.6 Persons with an LDL-C level greater than 190 mg/dL were usually excluded from trial participation, as it was not considered appropriate to randomly assign them to placebo. Thus, these recommendations do not pertain to persons with very high cholesterol levels (ie, LDL-C &gt;190 mg/dL) or familial hypercholesterolemia, as they were excluded from most prevention trials.",None,None,None
264,"Suicide Risk:Screening -- Adolescents, Adults, and Older Adults",I,1,men and women,12,100,"The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for suicide risk in adolescents, adults, and older adults in primary care.",None,None,143,222,221,0,None,None,None,None
291,"Thyroid Dysfunction: Screening -- Nonpregnant, Asymptomatic Adults",I,1,men and women,18,100,"The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for thyroid dysfunction in nonpregnant, asymptomatic adults.",The optimal screening interval for thyroid dysfunction (if one exists) is unknown.,None,150,256,257,0,"The most common cause of hypothyroidism in the United States is chronic autoimmune (Hashimoto) thyroiditis. Risk factors for an elevated TSH level include female sex, advancing age, white race, type 1 diabetes, Down syndrome, family history of thyroid disease, goiter, previous hyperthyroidism (possibly due in part to ablation therapy leading to iatrogenic thyroid dysfunction), and external-beam radiation in the head and neck area. Common causes of hyperthyroidism include Graves disease, Hashimoto thyroiditis, and functional thyroid nodules. Risk factors for a low TSH level include female sex; advancing age; black race; low iodine intake; personal or family history of thyroid disease; and ingestion of iodine-containing drugs, such as amiodarone. The USPSTF found no direct evidence that treatment of thyroid dysfunction based on risk level alters final health outcomes.",None,None,None
287,"Tobacco Smoking Cessation: Electronic Nicotine Delivery systems (ENDS) -- All adults, including pregnant women",I,1,men and women,18,100,"The USPSTF concludes that the current evidence is insufficient to recommend electronic nicotine delivery systems (ENDS) for tobacco cessation in adults, including pregnant women. The USPSTF recommends that clinicians direct patients who smoke tobacco to other cessation interventions with established effectiveness and safety (previously stated).",None,Tobacco user,153,248,247,246,"According to the 2012&ndash;2013 National Adult Tobacco Survey, smoking prevalence is higher in the following groups: men; adults aged 25 to 44 years; persons with a race or ethnicity category of &ldquo;other, non-Hispanic&rdquo;; persons with a GED (vs. graduate-level education); persons with an annual household income of less than $20,000; and persons who are lesbian, gay, bisexual, or transgender.&nbsp;Higher rates of smoking have been found in persons with mental health conditions.",None,249,None
286,Tobacco Smoking Cessation: Pharmacotherapy Interventions -- Pregnant Women,I,1,female,11,64,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of pharmacotherapy interventions for tobacco cessation in pregnant women.,None,Pregnant,153,248,247,246,"According to the 2012&ndash;2013 National Adult Tobacco Survey, smoking prevalence is higher in the following groups: men; adults aged 25 to 44 years; persons with a race or ethnicity category of &ldquo;other, non-Hispanic&rdquo;; persons with a GED (vs. graduate-level education); persons with an annual household income of less than $20,000; and persons who are lesbian, gay, bisexual, or transgender.&nbsp;Higher rates of smoking have been found in persons with mental health conditions.",None,249,None
332,Vision in Children: Screening -- younger than 3 years,I,1,men and women,0,2,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of vision screening in children younger than 3 years.,None,None,184,None,None,0,None,None,None,None
285,"Vitamin D Deficiency: Screening -- Community-dwelling, Nonpregnant, Asymptomatic Adults",I,1,men and women,18,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for vitamin D deficiency in asymptomatic adults.,None,None,154,250,251,0,"Although there is not enough evidence to support screening for vitamin D deficiency, some evidence suggests factors that may increase risk for vitamin D deficiency. Persons with low vitamin D intake, decreased vitamin D absorption, and little or no sun exposure (for example, due to the winter season, high latitude, or physical sun avoidance) may be at increased risk for vitamin D deficiency.&nbsp;Obesity and darker skin pigmentation may also be associated with low levels of total serum 25-(OH)D, but whether these factors reflect vitamin D deficiency or increase the risk for adverse clinical outcomes is unclear. Obesity may allow for greater sequestration of vitamin D into adipose tissue; however, this vitamin D may still be bioavailable.&nbsp;Increased skin pigmentation reduces the skin's ability to produce vitamin D in response to UVB exposure. Prevalence rates of low total serum 25-(OH)D are 2 to 9 times higher in African Americans and 2 to 3 times higher in Hispanics than in white persons,&nbsp;yet the risk for fractures in African Americans is half that in white persons.&nbsp;Other factors, such as body composition and calcium economy, have been proposed to explain this paradox;&nbsp;however, a recent study suggests that although total serum 25-(OH)D levels in African Americans may be low, the concentration of bioavailable 25-(OH)D may not be.&nbsp;Some evidence suggests that older age and female sex may also be associated with increased risk for vitamin D deficiency; however, these findings are inconsistent.",None,None,None
346,"Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication -Men and premenopausal women",I,1,men and women,18,100,"The USPSTF concludes that the current evidence is insufficient to assess the balance of the benefits and harms of vitamin D and calcium supplementation, alone or combined, for the primary prevention of fractures in men and premenopausal women.",None,None,192,312,313,0,None,None,None,None
347,"Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication Postmenopausal women",I,1,female,40,100,"The USPSTF concludes that the current evidence is insufficient to assess the balance of the benefits and harms of daily supplementation with doses greater than 400 IU of vitamin D and greater than 1000 mg of calcium for the primary prevention of fractures in community-dwelling, postmenopausal women.",None,None,192,312,313,0,None,None,None,None
259,Vitamin Supplements for the Prevention of Cardiovascular Disease and Cancer: Multivitamins,I,1,men and women,50,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the use of multivitamins for the prevention of cardiovascular disease or cancer.,None,None,139,214,215,0,None,"Importance
Use of dietary supplements is common in the U.S. adult population. Forty-nine percent of adults used at least 1 dietary supplement between 2007 and 2010, and 32% reported using a multivitamin&ndash;multimineral supplement. Supplement use is more common among women and older adults than men and younger adults. Most dietary supplements are used to improve or maintain overall health. The substantial effect of cardiovascular disease and cancer on health status and mortality in the United States has been well-described, and many supplements are promoted to prevent these conditions.
Benefits of Vitamin Supplementation
The USPSTF found inadequate evidence on the benefits of supplementation with multivitamins to reduce the risk for cardiovascular disease or cancer. The USPSTF found inadequate evidence on the benefits of supplementation with individual vitamins or minerals or functional pairs in healthy populations without known nutritional deficiencies to reduce the risk for cardiovascular disease or cancer. The USPSTF found adequate evidence that supplementation with &beta;-carotene or vitamin E in healthy populations without known nutritional deficiencies does not reduce the risk for cardiovascular disease or cancer.
Harms of Vitamin Supplementation
The USPSTF found inadequate evidence on the harms of supplementation with multivitamins and most single vitamins or minerals or functional pairs. The USPSTF found adequate evidence that supplementation with &beta;-carotene increases the risk for lung cancer in persons who are at increased risk for this condition. The USPSTF found adequate evidence that supplementation with vitamin E has few or no substantial harms.
USPSTF Assessment
The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of supplementation with multivitamins for the prevention of cardiovascular disease or cancer. The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of supplementation with single or paired nutrients (except &beta;-carotene or vitamin E) for the prevention of cardiovascular disease or cancer. The USPSTF concludes with moderate certainty that there is no net benefit of supplementation with vitamin E or &beta;-carotene for the prevention of cardiovascular disease or cancer.",None,None
260,Vitamin Supplements for the Prevention of Cardiovascular Disease and Cancer: Single- or Paired-nutrients,I,1,men and women,50,100,The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the use of single- or paired-nutrient supplements (except &beta,-carotene and vitamin E) for the prevention of cardiovascular disease or cancer.,,139,214,214,0,None,None,"Importance
Use of dietary supplements is common in the U.S. adult population. Forty-nine percent of adults used at least 1 dietary supplement between 2007 and 2010, and 32% reported using a multivitamin&ndash;multimineral supplement. Supplement use is more common among women and older adults than men and younger adults (2). Most dietary supplements are used to improve or maintain overall health. The substantial effect of cardiovascular disease and cancer on health status and mortality in the United States has been well-described, and many supplements are promoted to prevent these conditions.
Benefits of Vitamin Supplementation
The USPSTF found inadequate evidence on the benefits of supplementation with multivitamins to reduce the risk for cardiovascular disease or cancer. The USPSTF found inadequate evidence on the benefits of supplementation with individual vitamins or minerals or functional pairs in healthy populations without known nutritional deficiencies to reduce the risk for cardiovascular disease or cancer. The USPSTF found adequate evidence that supplementation with &beta;-carotene or vitamin E in healthy populations without known nutritional deficiencies does not reduce the risk for cardiovascular disease or cancer.
Harms of Vitamin Supplementation
The USPSTF found inadequate evidence on the harms of supplementation with multivitamins and most single vitamins or minerals or functional pairs. The USPSTF found adequate evidence that supplementation with &beta;-carotene increases the risk for lung cancer in persons who are at increased risk for this condition. The USPSTF found adequate evidence that supplementation with vitamin E has few or no substantial harms.
USPSTF Assessment
The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of supplementation with multivitamins for the prevention of cardiovascular disease or cancer. The USPSTF concludes that the evidence is insufficient to determine the balance of benefits and harms of supplementation with single or paired nutrients (except &beta;-carotene or vitamin E) for the prevention of cardiovascular disease or cancer. The USPSTF concludes with moderate certainty that there is no net benefit of supplementation with vitamin E or &beta;-carotene for the prevention of cardiovascular disease or cancer.",None
